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Zusammenfassung 
Bei den meisten Patienten mit akut- und chronisch-entzündlichen Erkrankungen des zentralen 
Nervensystems (CNS) können expandierte Antikörperspezies, sogenannte oligoklonale Banden 
(OCB), in Liquor cerebrospinalis (CSF) nachgewiesen werden. OCBs werden intrathekal 
produziert und stellen ein wichtiges diagnostisches Kriterium dar. Bei Infektionen des CNS, wie 
beispielsweise Neuroborreliose, ist bekannt, dass OCB Antikörper gegen den Erreger gerichtet 
sind. Bei Enzephalitiden mit unklarer Ursache, und insbesondere bei Multiple Sklerose (MS), der 
häufigsten entzündlichen CNS-Erkrankung, sind die Zielantigene der OCB Antikörper unbekannt.  
Ziel dieser Studie war die Identifizierung von Antigenen von OCB Antikörper aus CSF von 
Patienten mit neurologischen Erkrankungen. Die OCB Antikörper wurden bereits in früheren 
Arbeiten aus CSF isoliert und charakterisiert. Sie stammten aus vier MS Patienten und einem 
Patienten mit -Aminobuttersäure-A Rezeptor (GABAAR-) Enzephalitis.  
In früheren Arbeiten wurden unfraktionierte CSF-Proben oder Antikörper aus Einzelzellen 
verwendet, um Antigene zu identifizieren. Diese Studien ermöglichten aber keine Zuordnung der 
Antigene zu einer definierten OCB. Kürzlich wurde in der AG Dornmair eine Methode etabliert, 
die die Zuordnung schwerer und leichter Ketten bei definierten OCB Antikörpern aus CSF erlaubt. 
Dies ermöglicht es nun Antigene definierter OCBs zu bestimmen. Hier wurden sechs OCB-
basierte Antikörper als IgG1-Moleküle rekombinant hergestellt und mittels Proteinmicroarrays auf 
Reaktivität gegen Proteine untersucht. Drei der identifizierten Kandidatenantigene wurden durch 
Immunpräzipitation und „enzyme-linked immunosorbent assays“ unabhängig validiert. Diese drei 
Antigene sind intrazelluläre Proteine deren Expression nicht auf das CNS beschränkt ist. 
Reaktivität der OCBs gegen ubiquitäre, intrazelluläre Strukturen, könnte auf eine nicht-pathogene 
Rolle der OCBs in der MS hindeuten. OCBs könnten als Reaktion auf die vermehrte Bildung von 
Zelltrümmern in der Frühphase der Erkrankung gebildet werden und deren Beseitigung durch 
Opsonisierung beschleunigen. 
Die GABAAR-Enzephalitis ist eine besonders schwere, akute Enzephalitis mit unklarer Etiologie. 
Ein monoklonal expandierter Antikörper aus CSF eines GABAAR-Enzephalitis Patienten wurde 
als IgG1-Molekül exprimiert und seine Spezifität für die extrazelluläre Domäne des GABAAR 
nachgewiesen. Unter der Annahme, dass die GABAAR-Enzephalitis als paraneoplastisches 
neurologisches Syndrom im Zusammenhang mit einer Tumorerkrankung zu sehen ist, wurde 
dieser Antikörper mittels Proteinmicroarrays auf Reaktivität gegen weitere Proteine untersucht. 
Es wurden mehrere Zink-bindende Proteine, die Mehrzahl mit „LIM-Domäne“, identifiziert. Es ist 
bekannt, dass diese Proteine tumor-reaktive Immunantworten auslösen können. Die Erkennung 
des LIM-Proteins „cystein-rich protein 2“ (CSRP2) wurde durch Immunpräzipitation unabhängig 
validiert. Da sowohl GABAAR, als auch CSRP2 über Zink-Bindestellen verfügen, könnten diese 
die Grundlage für eine Kreuzreaktivität auf molekularer Ebene bilden.   
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Summary 
Expanded antibody species can be detected in cerebrospinal fluid (CSF) samples in most 
patients with acute or chronic inflammatory conditions of the central nervous system (CNS). 
These so-called oligoclonal bands (OCB) are produced intrathecally and provide an important 
diagnostic tool. In infectious conditions, such as neuroborreliosis, OCBs recognize the causing 
agent. In idiopathic encephalitides, and in particular multiple sclerosis (MS), the most common 
inflammatory disease of the CNS, target antigens are not known.  
The aim of this study was to identify target structures of distinct OCB antibodies derived from 
CSF of patients with neurologic disorders. The OCB antibodies had been identified and 
characterized in previous studies. They were derived from four MS patients and one patient with 
-aminobutyric acid-A receptor (GABAAR)-encephalitis. 
In previous studies, target antigens were identified using unfractionated CSF samples or single 
cell derived antibodies. In these studies, target antigens could not be assigned to a distinct OCB. 
Recently, a new method was established, which identifies matching heavy and light chains of 
expanded antibody species in CSF. This now allows for the search for target antigens of distinct 
OCBs. Here, six OCB-derived antibodies were expressed as IgG1-molecules and screened for 
reactivity to protein antigens on microarrays. Three target antigens were validated independently 
using immunoprecipitation and enzyme-linked immunosorbent assays. All three antigens are 
intracellular proteins expressed in most tissues of the human body, indicating that OCB 
antibodies may recognize ubiquitous, intracellular proteins. Although more OCB-antigens need to 
be analyzed, these results suggest that OCB-antibodies may be raised in response to cell debris 
caused by primary immune reactions and may take part in debris removal by opsonizing cellular 
debris.  
GABAAR-encephalitis is a rare and severe form of acute encephalitis of unknown etiology. A 
monoclonally expanded antibody species from CSF of a GABAAR-encephalitis patient was 
recombinantly expressed and found to recognize the extracellular domain of the GABAAR 1-
subunit. GABAAR-encephalitis may have a paraneoplastic background, i.e. it may be associated 
with malignancies. To identify a potential link to a paraneoplastic syndrome, the GABAAR 1-
subunit specific antibody was tested for reactivity to potential tumor antigens on microarrays. A 
number of zinc-binding proteins, most of them LIM-domain proteins, were identified as targets. 
Reactivity with “cysteine-rich protein 2” (CSRP2) was validated by immunoprecipitation. LIM-
proteins are involved in transcriptional regulation and other members of this family of proteins are 
strongly associated with malignancies. Since GABAAR and CSRP2 contain zinc-binding motifs, 
this structure may provide a potential molecular basis for the cross-reactivity of the antibody to 
both proteins.  
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1 Introduction  
Since the first description of immunoglobulins (Ig) in the late 19th century [1], enormous progress 
was made in understanding their role in the human immune system. Generally, antibodies 
recognize foreign structures, induce immunologic processes, and thereby prevent harmful actions 
by a foreign invader. The complex mechanism producing a highly diverse repertoire, which allows 
the recognition of virtually every invader, was revealed and greatly advanced research in the field 
of immunology. In contrast to the protective function of antibodies, autoimmunity occurs as an 
adverse effect of effective host defense. In an aberrant immune response, antibodies may target 
self-structures and cause a variety of diseases. Despite the broad knowledge that has 
accumulated on antibodies over time, their role and function in distinct diseases remain puzzling.  
1.1 Immunoglobulins  
Antibodies may display a highly diverse and versatile repertoire of specificities, which is needed 
for efficient recognition and clearance of foreign invaders. The antibody repertoire is created by 
random recombination of gene segments, somatic hypermutation (SHM) and class switch 
recombination during B-cell development. These processes enable the immune system to 
increase the specificity of the antibody to the foreign invader and clear the infection more 
efficiently. Fully differentiated B-cells (plasma cells) produce large amounts of antigen-specific 
antibodies and build up memory to effectively clear a second infection (memory B-cell).  
1.1.1 B-cell Maturation and BCR Rearrangement  
B-cell precursors arise from hematopoetic progenitors in the bone marrow, where the formation of 
the B-cell receptor (BCR) is initiated. Pro-B-cells start to rearrange the heavy (H-) chain gene 
locus, as schematically depicted in Figure 1-1. 
 
Figure 1-1: Schematic illustration of V(D)J-recombination and somatic hypermutation.  
V(D)J-recombination is exemplarily depicted for the H-chain locus. At first, a single randomly selected D- segment 
is joined to one J- segment (middle row) in an AID dependent mechanism, followed by selection and joining of an 
upstream V-segment (bottom row). The gene segments are joined imprecisely (A). Upon completion of the V(D)J-
recombination of the H-chain locus, one V- and one J-segment on either of the two L-chain loci is selected and 
joined (not depicted). In germinal centers, Ig-coding DNA-sequences undergo somatic hypermutation that 
introduces single amino acid exchanges (horizontal black bars) in the V-region of H- and L-chains (B). The 
illustration is adapted from [2]. 
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The H-chain gene locus codes for three gene segments: variable (V), diversity (D) and junction 
(J). Each segment is made up of numerous copies of V-, D, and J-genes. In a first step, a 
randomly selected D-gene is connected to any J-gene of the H-chain locus, which is 
subsequently combined with a V-gene. Cells in the pre-B state rearrange the light (L-) chain locus 
in the same manner. Random addition or deletion of nucleotides at the combination sites further 
diversifies the receptor repertoire. Upon successful rearrangement of H- and L-chain locus, the 
immature B-cell expresses membrane-bound BCR that is capable of binding an antigen.  
Such immature B-cells leave the bone marrow and encounter their antigen in the periphery. Upon 
antigen encounter, mature B-cells migrate to secondary lymphatic tissues, such as lymph nodes 
or the spleen, where they form germinal centers (GC) and undergo affinity maturation [3]. Within 
these structures, B-cells up-regulate the protein “activation-induced cytidine deaminase” (AID) 
that introduces point mutations in the Ig-coding DNA-sequences. These somatic hypermutations 
(SHM) result in increased affinity for the antigen and further diversification of the receptor 
repertoire [4]. The affinity maturation process is active until the antigen is cleared from the 
system. The random selection process in cooperation with imprecise joining and somatic 
hypermutation creates a highly diverse receptor repertoire that may form more than 1018 different 
specificities. A schematic overview of the development of B-cells is given in Figure 1-2. 
 
Figure 1-2: Schematic illustration of B-cell maturation.  
B-cell precursors start their maturation process in the bone marrow. Upon successful V(D)J-rearrangement of the 
H- and L-chain, immature B-cells leave the bone marrow and eventually recognize an antigen in the periphery. 
Antigen-experienced B-cells (mature B-cells) migrate to germinal centers (GC) where they are in close contact 
with T-cells (green) and antigen-presenting cells (APC, yellow). Up-regulation of AID, that introduces point 
mutations in the variable region of the BCR, fine-tunes the receptor specificity. B-cells that display increased 
antigen specificities are positively selected, leave the GC, and proliferate. The progeny differentiate into plasma 
cells that produce large amounts of antibodies and memory B-cells that ensure immunologic memory. The 
illustration is modified from [5]. 
 
B-cells expressing high-affinity receptors are positively selected in the GC, proliferate, and 
differentiate into plasmablasts and finally plasma cells that produce large amounts of soluble Ig. 
Some cells give rise to antigen-specific memory B-cells that circulate the system after infection 
clearance to promptly elicit a specific immune response in case of re-infection.  
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Fully differentiated plasma cells usually undergo AID-mediated class switch recombination that 
allows production of five different Ig-subclasses, each of them adapted to a distinct task. 
Antibodies can be secreted in forms of IgM, IgD, IgG, IgA and IgE, with IgG being the subclass 
with highest prevalence in human serum [6] and CSF [7].  
1.1.2 Antibody Structure and Function 
IgG makes up the majority of circulating antibodies. The basic structure of all Ig-molecules is a Y-
shaped heterodimer consisting of two identical H- and two identical L-chains (Figure 1-3). 
Structurally, antibodies consist of Ig-domains, a common protein fold that consists of antiparallel 
β-sheets forming one β-barrel per domain. H-chains possess four Ig-domains and L-chains 
possess two Ig-domains. The heterodimeric molecule is stabilized by disulfide bridges in the 
constant regions between H- and L- chain and in the hinge region between the two H-chains. 
Once the chains are split by treatment with a reducing agent, the molecular weight (MW) of H-
chains is approximately 50 kDa and the one of L-chains is about 25 kDa, generating a fully 
assembled IgG-molecule with a MW of 150 kDa.  
 
Figure 1-3: Schematic structure of an IgG-molecule.  
The molecule consists of two identical H- (blue) and two identical L-chains (magenta) that are interconnected by 
disulfide bridges in the constant (CH1 and CL) and hinge regions. Antigens are bound via the antigen binding site, 
made up of the N-terminus of one H- and one L-chain. CH2 and CH3-domains of the H-chains form the Fc-
fragment that controls the antibody effector function. The complete L-chain and the two N-terminal Ig-domains of 
the H-chains form the Fab-fragment (A). The ribbon diagram of an antibody illustrates the folding of antiparallel β-
sheets into β-barrels in each of the Ig-domains. The loops of the variable region contain the CDRs that interact 
with the antigen. The illustration of PDB 1IGY is modified from [8] (B). Single-chain Fv-fragments consist of the 
variable regions of H- and L-chain that are linked via a polypeptide linker (C). The ribbon diagram of x-ray 
diffraction analysis of a scFv-molecule illustrates the retained structural characteristics of the Ig-domains in the 
artificial antibody-fragment. The illustration of PDB 4H0G is modified from [9] (D). 
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An antibody-molecule combines two fundamental functions that are reflected by its structure: 
First, specific antigen recognition via the variable region and second, mediation of effector 
functions by the constant region. Both chains carry a highly variable region that confers specificity 
to the Ig-molecule and is subject to affinity-maturation as described above. The N-terminal Ig-
domain constitutes the variable region and consists of three complementary determining regions 
(CDR). CDRs 1 and 2 are encoded by the V-gene segment, the CDR3 in contrast is the site of 
joining of V(D)J-segments (Figure 1-1). The CDR-loops interconnect the β-sheets of the 
framework regions. These loops engage prominent positions in the molecule and interact directly 
with the target antigen. The complete antigen binding site is constituted by the variable regions of 
one H- and one L-chain; however, the fraction which is actually involved in antigen recognition 
varies. The surface area available for antigen recognition is approximately 1000 square Ångström 
[10] (Figure 1-3D).  
Both H- and L-chains have constant regions that consist of three Ig-domains (CH1-3) in case of 
the H-chain and a single one in L-chains (CL). In H-chains, the Ig-domains of the constant region 
are interconnected by a hinge region that confers flexibility to the molecule. This way a single 
IgG-antibody may complex two antigens in varying distances and angles. The constant regions, 
especially those of H-chains, mediate the effector functions of antibodies. The different antibody 
subclasses are specifically recognized by receptors on effector cells or activate specific, non-
cellular downstream mechanisms like the complement cascade. Proteolytic cleavage of IgG-
molecules by papain was found to separate these functions creating two distinct fragments: one 
carrying the antigen binding site, named Fab-fragment and one consisting of the H-chain constant 
domains CH2 and CH3, named Fc. 
Naturally produced antibodies always have both Fab and Fc-fragment and at least two identical 
binding sites. In some instances, the constant regions are abandoned due to specific 
experimental requirements or to reduce the molecule’s size. Commonly used truncated antibody 
formats are Fab-fragments and single chain variable fragments (scFv). A schematic illustration of 
an IgG-molecule and an exemplary ribbon diagram depicting the folded structure as well as the 
Fab- and scFv-counterparts are shown in Figure 1-3. Both synthetic molecules possess the full 
variable region, that confers antigen-specificity, but the Fab-fragment lacks the Fc-fragment 
whereas the scFv lacks the constant regions entirely. Classically, Fab-fragments are heterodimers 
of the full length L-chain and a truncated H-chain stabilized by one disulfide bridge, with each of 
the chains being approximately 25 kDa in size. In contrast, scFv-molecules consist of a single 
chain that carries the variable regions of the H- and L-chains connected by a flexible linker of 5-
15 small amino acids (AA), like glycine or serine, generating a 28 kDa protein. Both antibody-
fragments carry a single antigen binding site and are capable of antigen recognition. However, 
higher avidity stabilizes antigen-antibody-interactions and therefore full antibodies are generally 
better suited to study interactions with low to medium affinities. 
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The discrimination of antibody subclasses is based on their different constant regions. They are 
specialized to the requirements of different inflammatory conditions and thus elicit distinct effector 
functions. The pentameric structure of IgM is well suited to recognize repetitive patterns because 
the high avidity compensates for lower affinity before SHM. IgG-antibodies have usually 
undergone somatic hypermutation, thus have higher affinities and are better suited to quickly 
reach the inflammatory site due to the smaller size. The major effector functions elicited by IgG-
molecules are neutralization, antibody-dependent cell-mediated cytotoxicity (ADCC) and 
complement activation (Figure 1-4). Antibodies that encounter their antigen prevent interaction of 
the foreign molecule with host cells by charging its surface epitopes. Following this neutralization 
step, the immune system aims at clearing the foreign molecule. Clearance may be achieved by 
the complement system that is activated by antibody-antigen-complexes via the classical 
pathway. The membrane attack complex forms the final stage of the amplification cascade and 
initiates the lysis of the target microbe. Antibodies cross-linking membrane-bound molecules on 
pathogen-infected host cells recruit effector cells like natural killer cells and macrophages that 
then lyse the antibody-coated cell. The process of antibodies coating a molecule to initiate 
clearance is called opsonization.  
 
Figure 1-4: Effector functions of antibodies.  
Antibodies neutralize soluble antigens and prevent toxic effects or their entry into host cells. Cross-linking of an 
antigen by multiple IgG-molecules activates the complement cascade leading to the formation of the membrane 
attack complex that eliminates the foreign invader. Antibodies that recognize an antigen on the surface of a 
pathogen-infected cell can recruit effector cells that bind the Fc-fragment of the antibodies and induce apoptosis in 
the infected cell (antibody-dependent cell-mediated cytotoxicity, ADCC). The illustration is modified from [11]. 
 
1.1.3 Specificity of Antibodies 
Although the B-cell maturation process aims at creating antigen-specific antibodies, cross-
reactivity is frequently encountered. Classically, polyreactivity of antibodies is defined as reactivity 
of a monoclonal antibody to DNA, lipopolysaccharide and insulin [12]. This reactivity profile is 
commonly associated with germline or near-germline configuration of Ig-chains [13]. Clearly, 
reactivity to multiple antigens (multireactivity) is not restricted to the above mentioned antigen 
classes and recognition of two or more related or unrelated protein antigens by a single antibody 
is a common finding [14]. Such multispecificity is an accepted phenomenon in the naïve antibody 
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repertoire. These multi- and autoreactive receptors are kept in check during the maturation 
process of B-cells, limiting harmful autoreactivity [12]. It is conceivable that multireactivity of 
antibodies in the healthy system helps the rapid neutralization of infectious agents at the site of 
entry besides a variety of other potential functions [14].  
In addition to the well-accepted multireactivity in (near-) germline antibodies, affinity-matured, 
supposedly antigen-specific, antibodies were found to be multireactive as well. To this end, 
broadly neutralizing antibodies to an HIV-1 envelope protein in HIV-infected individuals were 
found to simultaneously recognize cardiolipin with comparable affinity [15]. Furthermore, 
autoantibodies derived from autoimmune hepatitis [16], rheumatoid arthritis [17] and systemic 
lupus erythematousus (SLE) patients [18] show signs of multireactivity as well. 
Closely related molecules and similar secondary structures can cause cross-reactivity of an 
antibody. However, the examples mentioned above identified an unrelated molecule as “cross-
reactive antigen”. In Figure 1-5, different mechanisms to explain the specific recognition of 
unrelated antigens by a monoclonal antibody are depicted. Those are rigid adaptation, induced fit 
and differential ligand positioning. A prominent example illustrating the fact that only a fraction of 
the binding pocket is actually involved in antigen binding is the murine 8-18C5 antibody specific 
for myelin oligodendrocyte glycoprotein (MOG). Introducing an alternative L-chain to this antibody 
leaves the MOG-reactivity unchanged, demonstrating that the interaction mostly relies on the 
variable region of the H-chain [19]. The relatively large area of the antigen binding site enables 
specific recognition of multiple distinct antigens, related and unrelated epitopes, by a single 
antibody (see Figure 1-3).  
 
Figure 1-5: Schematic illustration of three potential mechanisms of polyreactivity.  
Structurally different antigens (orange) are bound by the same, rigid binding site (depicted in form of Fab-
fragments). The rigid adaptation theory predicts different residues or areas within the binding pocket to combine 
with distinct antigen surfaces without major conformational changes (A). The induced fit-mechanism is based on 
the conformationally flexible binding pocket that adapts to structurally distinct antigens upon encounter (B). The 
third option predicts differential positioning of antigens. The antigen binding site carries multiple specific and 
spatially distinct regions that can interact with unrelated antigens (C). The illustration is adapted from [20]. 
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The rigid adaptation theory views the binding site as a whole that accommodates structurally 
distinct antigens using different subsites within the binding pocket without major conformational 
changes [21]. On the contrary, the induced fit theory is based on the conformational flexibility of 
antibodies [22]. The hinge region has long been appreciated to arrange for simultaneous binding 
of two epitopes with varying distances from each other, but more recently, it becomes apparent 
that the variable regions may also undergo more or less subtle conformational changes during 
antigen recognition [23]. 
This flexibility may enhance antigen specificity by an induced-fit mechanism, but also could 
further increase the receptor repertoire diversity as it may allow specific binding to multiple 
structures [24, 25]. Differential positioning theory assumes pre-defined subsites within an antigen 
binding pocket that allows specific recognition of distinct, structurally unrelated antigens [26]. 
At least for naturally occurring multireactive antibodies from the naïve repertoire, it was shown 
that these antibodies can bind to late apoptotic cells, activate complement and thereby enhance 
phagocytosis by macrophages [27]. Thus, multireactive antibodies may assist efficient clearing of 
cell debris produced by mechanical stress, infectious insults or other processes [28]. 
1.2 Autoimmunity and Autoantibodies 
B-cell maturation involves mechanisms that are prone to create self-reactive receptors and 
antibodies. The random process that creates the highly diverse receptor repertoire concomitantly 
causes the formation of auto-reactive receptors. The immune system has evolved various 
strategies to restrain these cells: First, early B-cells with self-reactive receptors [12] may 
rearrange the L-chain sequence (receptor editing) [29], second, cells may be entirely deleted from 
the repertoire, i.e., undergo apoptosis [30], or third, may lose the capacity to respond to their 
antigens (anergy) [31]. The presence of autoreactive antibodies in the healthy human system is 
well known and may even have a beneficial role as part of first line defense mechanisms or 
through immunoregulatory functions [14, 32].  
However, autoreactivity may also occur during affinity-maturation in an appropriate immune 
response to a disease-related agent [33] or a malignancy [34]. In susceptible individuals, 
appropriate regulation of these self-reactive clones may fail, initiating an immune response 
against the host with production of vast amounts of auto-antibodies. A number of autoimmune 
diseases manifest themselves by prominent autoantibody production such as anti-nuclear 
antibodies found in SLE and Sjörgen’s syndrome, anti-thyroid antibodies in Hashimoto thyroiditis, 
rheumatoid factor in rheumatoid arthritis and antibodies targeting Aquaporin-4 in neuromyelitis 
optica (NMO, [35]). In contrast, anti-tumor immunity may raise antibodies directly targeted at 
autoantigens. Anti-tumor responses that elicit neurological deficits are termed paraneoplastic 
neurologic syndromes. In this case, tumors are thought to ectopically express neuronal antigens 
[36, 37] that become the target of the immune response that may also attack CNS-tissue [38].  
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In many cases, the etiology of autoimmune diseases is not very well understood. Often, an 
interplay between genetic and environmental factors is assumed to trigger the onset of the 
disease that is then perpetuated by autoreactivity in a dysregulated immune system [39]. 
Autoimmune diseases can manifest themselves in a variety of ways. In total, around 80 different 
autoimmune conditions are known so far that affect approximately 4.5 % of the world’s population 
[40] and for some conditions increasing prevalence rates have been reported [41]. The most 
common autoimmune disease of the central nervous system (CNS) is MS with 2-2.5 million 
people affected worldwide.  
1.2.1 Pathogenesis of Multiple Sclerosis 
MS is a presumably autoimmune-mediated disorder of the CNS. Focal inflammation in different 
CNS-regions is a hallmark of the disease. Within such lesions, the myelin sheath surrounding 
neurons is destructed. Symptoms and disease course of the disorder vary widely between 
affected individuals. MS patients often experience relapsing-remitting forms of the disease in 
early stages. These are characterized by the occurrence of new symptoms that ameliorate over 
time. In later stages, the disease course may become secondary-progressive, in which persisting 
impairment accumulates [42].  
The precise mechanisms that cause this heterogeneous chronic inflammatory disorder of the 
CNS remain elusive. MS-pathology is currently viewed as myelin destruction due to autoimmune 
processes in susceptible individuals. For a long time, MS was considered a CD4+ T-cell mediated 
disease. This is supported by a strong genetic association of MS with the HLA class II variant 
DRB1*1501 [43]. Also, the rodent model for MS “experimental autoimmune encephalomyelitis” 
(EAE) is driven by myelin-specific T-cells [44].  
The fact that the concordance between monozygotic twins is relatively low has drawn attention to 
environmental factors [45]. External influences, like smoking [46], may cause sustained activation 
of the immune system and possibly trigger autoimmunity. The concentration of vitamin D has also 
been associated with modified disease risk [47]. Another factor may be microbial infections. 
Similar to smoking, infection with Epstein-Barr virus represents a persistent immune activator and 
is tightly associated with MS incidence [48]. 
Another matter of debate is whether the triggers originate in the CNS-compartment or the 
periphery. First, an immune response targeted at a CNS-specific antigen may occur in the 
periphery and migrate into the CNS. Second, the initiating event may take place inside the CNS 
and could recruit other immune cells in a secondary event. Whether the triggers are cryptic self-
molecules, foreign molecules that cause autoreactivity by molecular mimicry, or the general 
highly inflammatory setting, which may dysregulate the immune system, remains unclear as well 
[49]. Molecular mimicry as basis of a misdirected immune response has been shown to be 
involved in the pathogenesis of Gullaine-Barré-Syndrom that is commonly associated with a 
preceding Campylobacter jejuni infection [50].  
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In recent years, multiple findings have drawn the attention to B-cells and antibodies in the 
disorder and argue for a more complex pathogenesis than previously thought [51]. For instance, 
transgenic mice with MOG-specific T-cells were found to recruit MOG-specific B-cells and trigger 
anti-MOG antibody production. These antibodies were pathogenic and the mice spontaneously 
developed a relapsing-remitting disease course resembling the most common form of MS [52]. 
Anti-CD20 antibodies rapidly deplete B-cells from the system and were found to be of 
considerable therapeutic value, although they spare CD20-negative pro-B-cells and antibody-
producing plasmablasts/plasma cells. B-cell depletion has proven effective in reduction of 
relapses, illustrating the wide effects on the disease performed by B-cells. Besides secreting 
antibodies, they modulate the immune response by secreting cytokines [53] and serving as 
antigen-presenting cell (APC, [54]). Precisely because the role of antibodies in the disease 
course remains enigmatic, it is important to characterize them in depth.  
Importantly, human serum contains large amounts of antibodies of various specificities. These 
polyclonal antibodies are also, although in low concentrations, present in human CSF. Yet, MS 
patients often have additional expanded antibody species of distinct biochemical properties, 
named oligoclonal bands (OCB). Understanding the role of OCB-antibodies may be one step 
towards unraveling the processes triggering disease onset and progression.  
1.2.2 Expanded Antibodies in CSF of MS Patients 
Clonally expanded antibody species in CSF are a hallmark and diagnostic marker of MS. CSF is 
a clear fluid that surrounds the brain and spinal cord and is an ultrafiltrate of blood. The fluid 
environment protects the brain from concussions and is an important route to transport molecules 
[55]. Although CSF is directly derived from blood, the protein content is very low and smaller 
proteins are over-represented due to the ultrafiltration process that is sensitive to the proteins’ 
MW [56]. Only 0.2 % of the IgG-concentration of blood are present in healthy human CSF and 
immune responses are generally absent from the CNS, thus intrathecal antibody production 
suggests a pathogenic process [57]. The specific expansion allows differentiation of distinct 
antibody species from the polyclonal background of antibodies by isoelectric focusing (IEF), so 
that OCBs can be demonstrated as distinct bands (Figure 1-6). OCBs were first visualized by IEF 
in the 1940s [58-60]. The detection of OCBs in CSF is not specific for any single condition, but 
rather a hint to an inflammatory condition in the CNS. Although there is a strong association with 
pathogenic conditions, OCBs may appear in healthy individuals as well. Expanded antibody 
species forming OCBs in CSF are observed in infectious disorders such as neuroborreliosis, 
neurosyphilis or HIV encephalitis and are also found in autoimmune conditions like SLE, 
Sjörgen’s syndrome, besides MS [61]. In contrast to antibodies, which react to foreign invaders in 
inflammatory settings, OCBs in autoimmune diseases, especially in MS, remain enigmatic 
because their antigens are still unknown.  
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Figure 1-6: Clinical IEF and anti-IgG immunofixation of CSF and serum. 
The left panel shows the IEF-analysis of CSF (upper) and serum (lower) of an MS patient. Multiple strong bands 
superimpose the polyclonal background of antibodies in the CSF sample of the MS patient (red arrows). In 
contrast, the serum of the same patient does not exhibit oligoclonal banding, but only a polyclonal background. 
On the right side, the same analysis with CSF and serum of a healthy donor shows polyclonal antibody 
background in both samples. IEF analysis was done by the Institute of Clinical Chemistry, Klinikum Großhadern, 
LMU München.  
 
Infectious conditions, and other immunologic challenges, induce the secretion of vast amounts of 
antibodies once antigen-specific cells have undergone affinity maturation. Hence, a small number 
of individual, positively selected clones will mass-produce a highly restricted antibody repertoire 
that targets the infectious agent and can be detected as OCB. It is very well conceivable, and has 
been demonstrated for a number of disease conditions, that these OCB antibodies recognize the 
infectious agent [62-65]. Upon clearance of the infectious cause, antigen-specific antibodies are 
no longer needed in vast amounts thus their production is downregulated and OCBs disappear 
eventually. In contrast to neuroinflammatory conditions that elicit OCB production, the expanded 
antibodies in MS do not vanish, but persist basically unchanged for years even under most 
treatments [66]. 
MS is the most prominent autoimmune disorder associated with OCBs. The vast majority, around 
95 %, of all patients display OCBs [67] and at least a fraction of these antibodies is produced 
intrathecally, in the CNS [68]. Furthermore, B-cells present in CSF of MS patients are closely 
related arguing for an ongoing B-cell maturation and proliferation inside the CNS [69]. These 
findings point to the persistence of a recurring antigenic stimulus that perpetuates the immune 
response and antibody production. As mentioned above, a supposedly persistent stimulus could 
arise from microbial infections, environmental factors or recurring production of cell debris, but 
has not been identified so far.  
Classically, OCBs are formed by affinity-matured, class-switched IgG-molecules, further 
supporting an underlying antigen-driven process. On a functional level, IgG-molecules are 
capable of complement activation. IgG and complement deposits were detected in acute 
demyelinating lesions of autopsy brain material of MS patients [70], implicating a role of OCB-
antibodies in disease. The effectiveness of plasma exchange in a subset of MS patients also 
points to an impact of antibodies on disease progression [71]. So far, it is not well understood 
what the role of OCB-antibodies in MS is, likewise their specificity remains to be elucidated. It is 
unclear whether antibodies are being produced in an irrelevant bystander activation mechanism 
due to the highly inflammatory status of the CNS [72] or play an active role in the disease. Thus, 
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identification of the target structures of OCB antibodies may hold clues on the pathogenesis of 
the disease.  
1.2.3 Target Antigens of OCB-antibodies 
Based on EAE-models, antibodies to myelin components like myelin oligodendrocyte glycoprotein 
(MOG), myelin basic protein (MBP) or proteolipid protein (PLP) are considered prime candidates 
due to their prominent localization in the myelin sheath. Besides myelin antigens, other 
oligodendroglial molecules were described, such as oligodendrocyte-specific protein [73], 
transketolase [74] or transaldolase [75]. Direct targeting of oligodendrocytes may explain the 
vanishing reconstruction of the myelin sheath with disease duration [76]. Similarly, neuronal and 
axonal structures seem to be targets of autoantibodies in MS. Neurofascin, located at the node of 
Ranvier, where the myelin sheath is intermittent, might be a target that enables direct axonal 
damage [77]. Neurofilament is released from axons upon an insult and is targeted by 
autoantibodies [78], but this is also observed in other CNS-diseases [79, 80]. A major advance in 
MS research was the identification of Aquaporin-4 on astrocytes as targets of antibodies [35] in a 
subset of patients that are now diagnosed with NMO [81].  
Furthermore, ubiquitous proteins, expressed in virtually all cells, were found to be targeted by 
antibodies in CSF and/or serum of MS patients. These include heat shock proteins [82], 
heterogeneous nuclear ribonucleoprotein [83] or components of the proteasome [84]. 
Furthermore, non-protein ubiquitous target structures were identified as targets of antibodies from 
CSF of MS patients including DNA [85] and lipids [86, 87].  
In line with a proposed infectious trigger of the disease, a variety of viral components have been 
described to be recognized by antibodies from MS samples [88]. The most prominent association 
is the “MRZ-reaction”, describing the reactivity of around 89 % of CSF-samples from MS patients 
with measles (M), rubella (R), and varicella zoster (Z) virus particles [89]. Furthermore, virtually all 
MS patients show seroreactivity to human herpes viruses, particularly Epstein-Barr-Virus [90].  
1.2.3.1 Antigen Identification Strategies 
Though incomplete, the above examples of target antigens compile a highly diverse set of 
molecules with heterogeneous structural and functional features. A detailed analysis revealed 
more than 30 antigens [91]. The individual entities of the large conglomerate of different target 
structures are widely accepted, but a common pattern was not identified so far. Thus, the 
antigens could not shed light on disease etiology [91]. Generally, the relevance of the 
autoantigens described above remains unclear due to the missing link between the individual 
antigens. On the one hand this finding may suggest antibodies have only marginal impact on MS 
pathology [92, 93], on the other hand this may, at least in part, reflect the heterogeneity of the 
disease itself [70].  
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The different methods used to identify target antigens further complicate the interpretation. Two 
fundamental approaches are in use. First, unfractionated CSF samples are directly applied in 
antigen searches [94, 95]. Second, antibodies are reconstructed from single plasma cells and 
recombinant antibodies used for antigen identification [96, 97]. In both cases, it remains unclear if 
detected signals derive from an expanded antibody species or the polyclonal background. 
Further, an antigen-specificity may not be attributed to a distinct oligoclonal band. CSF contains 
serum derived antibodies [57]. These are not produced in the CNS-compartment and form the 
polyclonal background of antibodies. Due to the low overall IgG-concentration of CSF [57], weak 
signals are expected. Thus, using the first approach, signals from OCB-antibodies may be 
superimposed by signals from irrelevant polyclonal antibodies. The second approach requires 
selection of single CSF B-cells from which matching IgG H- and L-chains are cloned allowing for 
production of recombinant antibodies. Besides the expanded B-cell clones that produce OCB-
antibodies, irrelevant B-cells are found in CSF that may produce non-expanded antibodies. Thus, 
it is not clear whether the selected antibody represents an OCB or not. Such antibodies may also 
contribute to the polyclonal background and thus will not advance the search of antigens to OCB-
antibodies [98]. This uncertainty applies to all antigens mentioned above.  
An exception to these considerations constitutes the CSF-sample of patient MS2. This patient 
sample is characterized by a persisting single expanded antibody species as shown by clinical 
isoelectric focusing depicted in Figure 1-7 [99]. In such a sample, the serum derived polyclonal 
background of antibodies is present but the clonal expansion is very limited. Accordingly, next 
generation sequencing and Ig-proteome analysis of this sample confirmed a monoclonal 
expansion.  
 
 
Figure 1-7: Clinical IEF and immunoblotting of CSF and serum samples from patient MS2. 
CSF and serum samples at two different time points are shown. A single band was detected in the CSF samples 
at both time points but in neither of the serum samples. Samples and IEF analysis were provided by W. 
Kristoferitsch, Vienna. The illustration is modified from [99]. 
 
As persisting OCBs are found in most patients, it is assumed that they may hold clues to unravel 
disease etiology. Thus, it is important to study distinct OCB-antibodies in the absence of other 
OCB-antibodies and polyclonal background. Limited diversity facilitates the characterization of 
relevant antibodies and their target antigens. In addition, samples taken at early time points 
during disease onset could prove particularly helpful for the identification of initiating factors or 
processes in pathogenesis. 
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1.2.3.2 Identifying expanded Antibody Species forming distinct OCBs in CSF 
To overcome the shortcomings of previous antigen identification strategies, a new method to 
identify, characterize and clone distinct OCB-antibodies from CSF was established by B. 
Obermeier [100]. The overall workflow is illustrated in Figure 1-8. This method allows the 
correlation of expanded H- and L-chains that form a distinct OCB in a patient sample and thereby 
enables in depth analysis of its antigen specificity.  
CSF from MS patients is separated into its cellular and soluble components and both fractions 
are analyzed individually. In a first step, IgG-molecules are collected by protein G affinity-
chromatography and deglycosylated to reduce sample complexity. The antibodies are then 
separated based on their isoelectric point by IEF followed by classical polyacrylamide gel 
electrophoresis (PAGE) separation. All experimental procedures are run under strictly non-
reducing conditions to preserve disulphide bridges between the individual chains and thereby 
ensure the parallel purification of matching H- and L-chains. Staining with Coomassie brilliant 
blue reveals a number of distinct spots that each represent IgG H2L2 complexes. Such spots are 
selected for subsequent mass spectrometric analysis.  
 
 
Figure 1-8: Workflow to identify matching H- 
and L-chains of OCB-antibodies from CSF.  
The method is based on parallel analysis of the 
IgG-transcriptome of CNS-resident B-cells and 
the IgG-proteome of the CSF sample. IgG-
molecules are isolated by protein G affinity 
chromatography and deglycosylated (#1). The 
antibody population is separated according to 
the isoelectric point of the molecules by IEF that 
yields bands with concentrated biochemically 
highly similar antibody species. In a second 
dimension, the antibodies are separated based 
on their MW by SDS-PAGE (#2). This separates 
free H- and L-chains and incomplete 
heterodimers from the full length IgG molecules 
of interest. These are isolated from the gel, 
analyzed by mass spectrometry (#3). The IgG-
repertoire is analyzed in parallel. mRNA is 
obtained and transcribed into cDNA followed by 
nested PCR on IgG H- and L-chains (#4). The 
IgG-transcriptome is determined by either 
Sanger sequencing or next generation 
sequencing (#5) and peptide fragments are 
aligned to the full length sequences of H- and L-
chains from the transcriptome (#6). This will 
yield full length sequences of matching H- and 
L-chains from an OCB-forming antibody (#7). 
The antibody is then recombinantly produced 
(#8) and applied in antigen search experiments. 
The illustration is adapted from [101]. 
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Mass spectrometry allows the identification of a number of peptides from the expanded H- and L-
chains. As in almost all mass-spectrometric experiments, the sequence coverage is not complete, 
i.e. full length sequences are not revealed. Therefore, the IgG-transcriptome of B-cells present in 
the CSF sample is analyzed in parallel. Following two rounds of nested PCR on IgG H- and L-
chains, products are either sequenced by Sanger sequencing or by next generation sequencing. 
Both methods reveal full length sequences of the entire IgG H- and L-chain repertoire in CSF of a 
patient. The peptides detected by mass spectrometry are then aligned to the full length 
sequences from transcriptome analysis and this allows the definite identification of an expanded 
antibody species. The alignments are highly patient-specific due to somatic hypermutations and 
CDRs. The matching H- and L-chain are then recombinantly expressed in human embryonic 
kidney (HEK293E) cells. The substantial amounts of antibody obtained by recombinant 
expression enable the search for antigen structures of distinct OCB-derived antibodies. 
In contrast to earlier efforts to identify target antigens of OCB-antibodies, this method ensures 
that the studied antibodies represent a truly expanded antibody species from a patient. Using this 
method, B. Obermeier identified five distinct OCB-derived antibodies applicable for antigen 
searches. OCB-derived antibodies were expressed as Fab-fragments at first and used in initial 
antigen search experiments [100, 102], which however did not yield consistent results. 
Additionally, an MS-OCB-derived antibody was studied here with regard to its antigen specificity 
that represented a monoclonal antibody expansion in an MS patient [99]. 
 
 
1.3 Pathogenesis of GABAAR-encephalitis 
In contrast to the chronic inflammation of the CNS observed in MS, acute forms of encephalitis 
exist. Viral and bacterial encephalitides are most commonly encountered, but autoimmune 
conditions can also cause acute inflammation of the CNS [103].  
Such autoimmune encephalitides have come into focus in recent years. A number of neurologic 
syndromes are associated with antibodies, mainly of the IgG-isotype. They target neuronal cell 
surface and synaptic proteins, and the list of encephalitogenic antibodies continually expands 
[104]. Those antibodies in serum and CSF may target the N-methyl-D-aspartate receptor 
(NMDAR, [36]), -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR, [105]), 
-aminobutyric acid-B receptor (GABABR, [106]) and receptor associated proteins such as the 
leucine-rich glioma inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) 
[107]. In all cases, the condition is probably caused by an autoimmune reaction and some of 
these syndromes may be associated with malignancies [108]. In such paraneoplastic syndromes, 
symptoms arise from the host’s immune response to a malignancy anywhere in the body [109].  
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A prominent example of a paraneoplastic syndrome is NMDAR-encephalitis, which seems to be 
triggered by ovarian teratoma expressing neuronal antigens including NMDAR [36]. The precise 
molecular mechanisms of paraneoplastic syndromes however remain unclear [110].  
Most recently, GABAAR-encephalitis was identified as a new form of autoimmune encephalitis. 
This severe form of encephalitis causes seizures and refractory status epilepticus. Antibodies 
from CSF and serum of GABAAR-encephalitis patients recognize synaptic GABAAR and were 
found to substantially downregulate the number of receptors on the cell surface [111]. Similarly, a 
loss of GABAAR surface expression was observed in status epilepticus of other causes [112]. 
GABAAR is a ligand-gated ion channel that exerts inhibitory effects on neurotransmission. In most 
cases, binding of the neurotransmitter γ-aminobutyric acid (GABA) triggers a net influx of chloride 
into neurons by opening the chloride selective channel via a conformational switch mechanism 
[113]. The hyperpolarization raises the threshold for excitatory signals and thereby inhibits action 
potentials.  
 
Figure 1-9: Ribbon-diagram of a GABAAR β3 homopentamer.  
The fully assembled GABAAR β3 consist of five identical subunits anchored to the plasma membrane. Correctly 
arranged subunits form a channel that selectively allows chloride-ions to pass once the receptor is activated. (A 
and B). Each subunit is anchored to the plasmamembrane with 4 transmembrane helices (cyan), consisting of the 
200-250 N-terminal AA. The extracellular domain mainly consists of β-sheets (magenta) (C). This illustration of 
PDB 4COF is modified from [114]. 
 
The receptor may form a pentameric structure using a variety of subunits from the pool of six α-, 
three β-, γ- and ρ-, and single δ-, ε-, θ-, and π-subunits [115]. Mostly, heteropentamers are 
formed that contain two α- and two β-subunits along with one other subunit [116]. GABAAR is 
mainly found in the neuropil and cerebral cortex in the central neurvous system and the subunit 
composition crucially influences function [117]. Figure 1-9 depicts the GABAAR β3-
homopentamer crystal structure as a model for heteropentameric equivalents. The extracellular 
domain of the receptor consists of the 200-250 N-terminal AA of each of the subunits. The 
subunits are anchored into the membrane via four α-helical transmembrane domains with an 
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intracellular loop between the third and fourth helix [118]. Besides its natural ligand GABA, 
GABAAR may be regulated by a number of other substances including general anaestetics and 
drugs to treat epilepsy, insomnia and anxiety [119]. Among other endogenous modulators, 
GABAAR was also found to be regulated by zinc ions [120]. 
The number of patients with GABAAR-encephalitis is small and so far a mainly non-
paraneoplastic autoimmune cause is assumed [111]; however a fraction of these patients was 
found to present with thymoma [121, 122].  
1.3.1 Identification of systemic Antigens of a GABAAR-encephalitis related Antibody 
GABAAR-encephalitis was described as a novel form of autoimmune non-paraneoplastic 
encephalitis in a series of essentially six patients [111]. By definition, paraneoplastic syndromes 
are associated with any kind of malignancy, however it was found that in the majority of cases 
neurologic symptoms occur prior to cancer diagnosis [123, 124]. In some cases the underlying 
malignancies are small or possibly undetectable [34], thus the apparent absence of a malignancy 
does not exclude a possible paraneoplastic syndrome. This led to investigate potential cross-
reactivity of an antibody targeting the GABAAR 1-subunit with other proteins, which might 
possibly be related to malignancy. The antibody used for these experiments was identified from 
the IgG repertoire of B-cells found in CSF of one of the index patients (Ip2) described by Petit-
Pedrol et al. [111]. Using next generation sequencing, a single expanded antibody species was 
detected in this sample (E. Beltrán, unpublished data). This expanded antibody provided the 
basis for the search of a potential systemic antigen in GABAAR-encephalitis that might possibly 
have initiated an immune response to GABAAR in a cross-reactive or paraneoplastic manner.  
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1.4 Objective 
The aim of this study was to elucidate target antigens of expanded antibody species found in CSF 
of patients with CNS-disorders. The knowledge of target structures should help to understand the 
role of these antibodies in the pathogenesis of MS and GABAA-receptor encephalitis.  
So far, the involvement and role of OCB-antibodies in MS remains enigmatic. The major aim of 
this study was the identification of antigens of distinct OCBs, because knowledge of the targets of 
OCBs is likely to offer insights into their function in this disease. The recently established MS-
OCB-derived recombinant antibodies are a particularly valuable tool to identify antigenic 
structures of expanded antibody species as they are the first antibodies which are unambiguously 
derived from distinct OCBs in CSF of MS patients. Identification of antigens of different distinct 
OCBs might disclose similarities and a common pattern may provide hints to a potential role of 
OCB antibodies in MS. Besides understanding the role of antibodies in MS, identification of 
antigens targeted at disease-onset may help to elucidate early processes leading to manifestation 
of the disease. In particular, the monoclonally expanded antibody found in CSF of patient MS2 at 
the time of first clinical signs of disease could identify target structures that play a role early in 
disease.  
Previous antigen searches were carried out with OCB-derived Fab-fragments but did not yield 
consistent results. Thus, OCB-derived full length antibodies were produced that form more stable 
antigen-antibody-complexes due to higher avidity and therefore may facilitate antigen 
identification. Protein microarrays were screened to identify candidate antigens, which 
subsequently were validated using independent methods such as immunoprecipitation, enzyme-
linked immunosorbent assays and fluorescence microscopy.  
In GABAA-receptor encephalitis, the target structure in the CNS was known. Based on the 
assumption that GABAA-receptor encephalitis might relate to paraneoplastic mechanisms, the 
aim was to identify a target antigen that possibly raised an anti-tumor immune response in the 
periphery. The monoclonally expanded antibody found in patient CSF that strongly reacted to the 
1-subunit of the GABAA-receptor, is used here to investigate this possibility. The reactivity of the 
recombinantly expressed antibody rAb-Ip2 to the GABAAR subunit was confirmed by enzyme-
linked immunosorbent assay.  
Using similar methods as mentioned above, rAb-Ip2 was tested for reactivity to proteins to identify 
potential cross-reactive antigens that may form the basis for a paraneoplastic neurologic 
syndrome in the patient.   
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2 Materials and Methods 
2.1 Materials 
All chemicals were purchased from Merck (Darmstadt), Sigma-Aldrich (Taufkirchen) or Qiagen 
(Hilden). Consumables were obtained from Biozym (Oldendorf), Eppendorf (Hamburg), Corning 
Incorporated (New York, USA), Millipore (Schwalbach) and Nunc (Langenselbold). Manufacturers 
other than those stated above are mentioned in the respective sections. 
2.1.1 Patient Material 
Patient material MS1 used in this study was provided by the Institute of Clinical 
Neuroimmunology, LMU Munich (T. Kümpfel). The sample was taken at first diagnosis. All other 
samples from different neurological conditions were provided by the Clinic of Neurology, 
University of Ulm (M. Senel). Informed consent was obtained from all patients. The study was 
approved by the Institutional Review Boards of the Ludwig-Maximilians-University Munich and the 
University of Ulm. Table 2-1 summarizes the demographic data and basic CSF findings of patient 
material used in this study. 
Table 2-1: Demographic Data on Samples used for antigen-reactivity Screening in larger Patient Cohorts.  
The cohort included patients with multiple sclerosis (MS), other inflammatory disorders (OID), neuroborreliosis 
(NB), cranial nerve palsies (CNP) and non-inflammatory neurologic disorders (NIND). The first column shows the 
number of cases per disease entity and distribution of sexes. The following columns show the mean age at 
sampling, mean cell count and IgG-content of the CSF samples, mean IgG-content of the serum samples and the 
range of each parameter within one group. The last column gives the percentage of OCB-positive patients.  
 
N (Male/ 
Female) 
Age  
(Years) 
CSF cell #  
(/μl) 
CSF IgG 
(mg/l) 
Serum IgG 
(g/l) 
OCB  
(%) 
 
MS 
20  
(8/12) 
44  
(30-48) 
2  
(1-3) 
39.3  
(35.5-49) 
10.9  
(9.75-11.7) 
16 of 20 
(80.0) 
 
OID 
7  
(4/3) 
53  
(39-72) 
1360  
(107-3000) 
317  
(210-1370) 
6.7  
(5-14.5) 
1 of 7  
(14.3) 
 
NB 
13  
(9/4) 
41 
(25-64) 
103  
(57-190) 
167  
(132-313) 
10  
(9.1-11.3) 
12 of 13 
(92.3) 
 
CNP 
8  
(5/8) 
54  
(45-67) 
2  
(1-2) 
30.8  
(25.3-49.7) 
10.9  
(9.4-12.2) 
0 of 8  
(0) 
 
NIND 
17  
(11/6) 
55  
(49-67) 
1  
(0-1) 
21.9  
(15.9-25.3) 
10.5  
(8.27-11.5) 
0 of 17  
(0) 
 
2.1.2 General Equipment 
Table 2-2: List of General Equipment in use 
Purpose Device Source 
Autoclave Varioklav Classic 500 H+P Labortechnik, Oberschleißheim, 
Germany 
Bunsen burner Fireboy eco Integra Bioscience, Fernwald, Germany 
CD-spectrometer J-715 Jasco, Gross-Umstadt, Germany 
Cell count Neubauer improved 
counting chamber 
Carl Roth, Karlsruhe, Germany 
Centrifugation Benchtop centrifuge 5417 R Eppendorf, Hamburg, Germany 
Sorvall RC-5C Plus Thermo Fisher Scientific, Waltham, MA, 
USA 
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Purpose Device Source 
Centrifugation 
(cont.) 
Megafuge1.0 R Heraeus, Hanau, Germany 
Ultracentrifuge Optima L90K Beckman Coulter, Brea, CA, USA 
Gelelectrophoresis Electro blotting chamber In-house workshop 
XCell SureLock™ Mini-Cell Invitrogen, Darmstadt, Germany 
Agarose gels In-house workshop 
ELISA reader Victor 2 1420 multilabel 
counter 
Perkin Elmer, Waltham, MA, USA 
Flow cytometry FACSverse Becton Dickinson, Heidelberg, Germany 
FPLC-System LCC 501 Plus Amersham Farmacia (GE Healthcare), 
Solingen, Germany UV-detector Uvicord SD 
Incubation HT Multitron Standard Infors HT, Basel, Switzerland 
Thermotron Thermo Fisher Scientific Heratherm 
Gel 
documentation 
Molecular imager Gel doc™ 
XR Bio-Rad, München, Germany 
QuantityOne Basic Software 
Perfection 4990 Photo Epson, Meerbusch, Germany 
Heating Thermomixer comfort 5436 Eppendorf 
Waterbath MA6 Lauda, Lauda-Königshofen, Germany 
Ice machine Scotsman AF30 Scotsman, Suffolk, UK 
Mass 
spectrometry 
Proteomics Analyzer 4700 
or 4800 MALDI-TOF/TOF 
AB Sciex, Darmstadt, Germany 
Microarray 
Scanning 
GenePix 4000B Axon Instruments, Union City, CA, USA 
Microscopy AxioVert 200M Carl Zeiss, Jena, Germany 
Wilovert® Will, Wetzlar, Germany 
Microwave - Privileg, Stuttgart, Germany 
Mixing Vortex Genie 2 Scientific Industries, New York, NJ, USA 
Concentration 
determination 
NanoDrop® ND-1000 
Spectrophotometer 
PeqLab, Erlangen, Germany 
PCR GeneAMP® PCR system 
9600 Perkin Elmer 
T personal Thermocycler Biometra, Göttingen, Germany 
pH-meter pH521 Bruno Kummer, Freiburg, Germany 
 Pipetboy acu Integra Bioscience 
Gilson Pipetman® P Gilson, Middleton, WI, USA 
Power supply EPS 400/500 Amersham Farmacia  EPS 2A200 
Rotors JA-10 Beckman Coulter JA25.50 
70Ti Beckman Coulter 
Shaker Duomax 1030 Heidolph Instruments, Schwabach, 
Germany Unimax 2010 
Sonification Sonifier 450 Branson, Geneva, Switzerland 
Sterile workbench Lamin Air® Heraeus 
Stirring Ikamag RCT magnetic stirrer IKA, Staufen, Germany 
UV-
transillumination 
UV-Transilluminator 312 nm Bachofer Laborgeräte, Reutlingen, 
Germany 
Water purification Milli-Q Advantage Millipore, Schwalbach , Germany 
Weighing Analytical balance 2001 MP2 Sartorius, Göttingen, Germany Precision balance L2200P 
Western blot 
detection  
OPTIMAX® Protec, Oberstenfeld, Germany 
GE Imager 4000 GE Healthcare,  
Odyssey Fc LI-COR, Bad Homburg, Germany 
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2.1.3 General Buffers and Reagents 
Table 2-3: List of generally used Buffers 
Name  Composition Use 
PBS pH 7.4  150 mM NaCl  
8.4 mM Na2HPO4  
1.9 mM NaH2PO4 x H2O  
Protein biochemistry  
PBS-T  1x PBS 0.05 % (w/v), Tween-20  Washing buffer  
SDS 
Running 
buffer  
Tris-Glycine 
0.1 % (w/v) SDS,  
0.02 M tris,  
0.2 M glycine 
run Tris-Glycin SDS-PAGE 
SDS 
Running 
buffer  
Bis-Tris 
50 mM MOPS,  
50 mM tris base,  
0.1 % SDS,  
1 mM EDTA 
run Bis-Tris SDS-PAGE 
reducing 
SDS sample 
buffer (3x) 
0.15 M tris-HCl pH6.8, 
7.5 % (w/v) SDS,  
45 % (w/v) glycerol,  
0.01 % (w/v) bromphenol blue,  
6 % (v/v) β-mercaptoethanol 
reducing SDS-PAGE 
non-reducing 
SDS sample 
buffer (5x) 
0.2 M tris-HCl pH6.8,  
7.5 % (w/v) SDS,  
20 % (w/v) glycerol,  
0.02 % (w/v) bromphenol blue 
non-reducing SDS-PAGE 
anode buffer 50 mM boric acid 
20 % methanol 
in H2O, pH9 
Western blotting 
cathode 
buffer 
50 mM boric acid 
5 % methanol 
in H2O, pH9 
Western blotting 
ECL A 0.25 % (w/v) luminol 
in 1 M tris pH8.6 
membrane development 
ECL B 0.11 % (w/v) para-hydroxycoumaric 
acid 
in DMSO 
membrane development 
trypan blue 
(0.1 %) 
0.4 % trypan blue solution  
1:4 in 1x PBS 
cell counting 
LB-medium 1 % (w/v) NaCl 
0,5 % (w/v) Bacto™ Yeast Extract  
1 % (w/v) Bacto™ Tryptone, pH 7 
bacterial cultures 
DNA sample 
buffer (6x)  
50 % (v/v) glycerol, 
0,02 % (w/v) bromphenol blue, 
0,02 % (w/v) xylene cyanole, 
10 mM tris-HCl, pH7.5 
agarose gels 
TBE-buffer 
(10x) 
0.89 M tris,  
0.89 M boric acid,  
0.02 M EDTA, pH 8 
agarose gels 
 
Table 2-4: List of generally used Reagents 
Name  Use Source 
Nucleic acids 
10 mM dNTPs PCR reaction 
Invitrogen 
10x PCR buffer Roche Diagnostics, Mannheim, Germany 
Taq polymerase 
TMB substrate (1x) ELISA detection eBioscience 
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2.1.4 Restriction Enzymes 
Table 2-5: List of Restriction Enzymes in use 
Name Manufacturer 
BamHI, BssHII, KasI, NcoI, NdeI, SacII, SalI, 
MscI, Bsu36I 
New England Biolabs 
 
2.1.5 Primer 
Primers were synthesized by Metabion (Martinsried) and delivered in 100 µM stock solutions. 
M13 sequencing primers were obtained from Invitrogen. AA exchanges introduced by the primer 
are printed in bold, restriction sites are underlined (Table 2-6 to Table 2-9).  
Table 2-6: List of Primers for cloning FAM84Awt and FAM84A-mutants 
Primer Sequence 
FAM84Awt BssHII for 5’-CACAGGCGCGCGATGTGACATCCAGATGGGCAACCAACTGGACC-3’ 
FAM84AwtBamHI 
V5/His6 rev 
5’-
AGGGATCCTTAGTGGTGGTGGTGGTGGTGTTGTGAATCTAGTCCTAGTAG
TGGATTTGGTATTGGTTTTCCCTCCTTATCGTCCACGAGG-3’ 
FAM84A NdeI for  5’-CACCCATATGGGCAACCAACTG-3’ 
FAM188VA MscI rev  5’-ggAGGTGGCCACAGGCATTCTGCACCACCAGTTCGGCCGCCAGG-3’ 
FAM190EA MscI rev 5’-taAGGTGGCCACAGGCATTCTGCACCACCAGTGCGGC-3’ 
FAM191LA MscI rev  5’-AGGTGGCCACAGGCATTCTGCACCACCGCTTCGG-3’ 
FAM84 MscI for  5’-AATGCCTGTGGCCACCTGG-3’ 
FAM Bsu36I-for 5’-aACGCCTCAGGCAGACTGAG-3’ 
FAM323EA Bsu36I rev 5’-
TCTGCCTGAGGCGTCGATCCGCCGCTTCTCGCGGATCAGATCTGCCAGGC
-3’ 
FAM324DA Bsu36I rev 5’-
TCTGCCTGAGGCGTCGATCCGCCGCTTCTCGCGGATCAGAGCTTCCAGGC
-3’ 
FAM327RA Bsu36I rev 5’-TCTGCCTGAGGCGTCGATCCGCCGCTTCTCGGCGATC-3’ 
FAM328EA Bsu36I rev 5’-TCTGCCTGAGGCGTCGATCCGCCGCTTCGCGCGG-3’ 
FAM331RA Bsu36I rev 5’-TCTGCCTGAGGCGTCGATCGCCCGC-3’ 
 
Table 2-7: Primers for cloning AKAP17A  
Primer Sequence 
AKAP17A SacII for 5’-GGCTCCGCGGTGGGTCCTGTCCATGGCAGCGGCTACCATC-3’ 
AKAP17A  
BamHI/His6 rev 
5’-
CAAGGATCCTTAATGGTGATGGTGATGGTGTCGGGAACGACAGACGAGC-
3’ 
AKAP17A 
BamHI/V5/His6 rev 
5’-
CTAGGATCCTTAATGGTGATGGTGATGGTGGGTGCTGTCCAGGCCCAGCA
GAGGATTAGGGATGGGCTTGCCTCGGGAACGACAGACGAGCGCTACAC-3’ 
 
Table 2-8: Primers for cloning GABAα1ex 
Primer Sequence 
GABAα1ex NcoI for 5’-GAGCCATGGGGCAGCCGTCATTACAAGATGAAC-3’ 
GABAα1ex 
BamHI/V5/His6/BglII 
rev 
5’-
AAGAGATCTTTAATGGTGATGGTGATGGTGGGTGCTGTCCAGGCCCAGCA
GAGGATTAGGGATGGGCTTGCCTCCTCCGGATCCGCCAATCTTTCTCTTC
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AAGTG-3’ 
Table 2-9: List of sequencing primers in use 
Primer Sequence 
pTT5 forward 5´-CTTTCTCTCCACAGGTGTC-3´ 
pTT5 reverse 5´-CCTTCCGAGTGAGAGACAC-3´ 
M13 forward 5´-GTAAAACGACGGCGTC-3´ 
M13 reverse 5´-GAGGAAACAGCTATGAC-3´ 
T7 promotor 5´-TAATACGACTCACTATAGGG-3´ 
T7 terminator 5´-GCTAGTTATTGCTCAGCGG-3´ 
 
2.1.6 Vectors 
Table 2-10: List of Vectors  
Name Resistance gene Size Description Source 
pET19b ampR,  5.7 kb expression vector Novagene 
pET33b(+) kanR 5.4 kb expression vector Novagene 
pCR®2.1-TOPO® ampR, kanR 3.9 kb TOPO-TA cloning Invitrogen 
pQE30 ampR 3.4 kb expression vector Qiagen 
pTT5  ampR 4.4 kb expression vector Yves Durocher,  
NRC Biotechnology 
Research Institute 
 
2.1.7 Bacterial Strains 
Table 2-11: List of Bacterial Strains 
Name Genotype Source 
E. coli TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 deoR recA1 
endA1araΔ139 Δ(ara, leu) 7697  
galU galK λ- rpsL(StrR) nupG 
One Shot® TOP 10  
Chemically Competent 
Cells  
(Invitrogen) 
E. coli BL21-StarTM-DE3 F- ompT hsdSB (rB-mB-) gal dcm  
rne131(DE3) 
Invitrogen 
 
2.1.8 Cell Line 
Table 2-12: Cell Line in Use 
Name Description Source 
HEK293E Large 
Scale Transient 
Expression System 
human embryonic kidney cell line, 
G418-resistence 
D. Jenne  
(Yves Durocher NRC 
Biotechnology Research Institute) 
 
2.1.9 Antibodies 
Table 2-13: List of Primary Antibodies 
Name reactivity use dilution 
used  
conjugate host source 
α-V5-HRP V5-tag WB, 
ELISA 
1:5 000- 
1:10 000 
HRP mouse LifeTechnologies 
α-V5 V5-tag ELISA  --- rabbit  Millipore 
α-His6-
HRP 
His6-tag WB, 
ELISA 
1:1 000 
1:2 000 
HRP mouse SigmaAldrich 
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mono α-
DDK 
DDK-tag WB 1:2 000 --- mouse Origene 
poly α-
AKAP17A 
human 
AKAP17A 
IP, 
WB 
1:2 000 --- rabbit MyBioSource 
mono α-
AKAP17A 
human 
AKAP17A 
IP, 
WB 
1:1 000 --- mouse Biorad 
poly α-
FAM84A 
human 
FAM84A 
IP, 
WB, 
ELISA 
1:2 000 --- rabbit ThermoScientific 
mono α-
FAM84A 
human 
FAM84A 
IP, 
WB, 
ELISA 
1:1 000 --- mouse abcam 
poly α-
MKNK1 
human MKNK1 ELISA 1:1 000 --- rabbit ThermoScientific 
mono α-
MKNK1 
human MKNK1 ELISA 1:1 000 --- mouse abcam 
poly α-
GABAAR 
human 
GABAAR α1-
subunit 
ELISA 1:175  rabbit  abcam 
 
Table 2-14: List of Secondary Antibodies  
Name Reactivity Use Dilution 
used 
Conjugate Host Scource 
α-mouse 
HRP  
Mouse IgG heavy 
+ light chain 
WB 1:5 000 HRP Rabbit LifeTechnologies 
α-rabbit 
HRP  
rabbit IgG heavy 
+ light chain 
WB 1:10 000 HRP Donkey abcam 
α-rabbit 
IgG Fc 
HRP 
Rabbit IgG Fc ELISA 1:50 000 HRP goat AbD Serotec 
α-human 
IgG-HRP  
human IgG Fc 
region 
WB, 
ELISA 
1:1 000 HRP Mouse Invitrogen 
α-human 
IgG HRP 
human IgG heavy 
+ light chain 
WB, 
ELISA 
1: 10 000 HRP goat Invitrogen 
 
2.1.10 Proteins 
Table 2-15: List of commercially obtained Proteins 
Short 
name 
Full name UniProt # ~ MW 
[kDa] 
Scource Manufacturer 
MKNK1 MAP kinase-interacting kinase 1 Q9BUB5-1 51  HEK Origene 
FAM20B Family with sequence similarity 20 B O75063 44  CHO R&D Systems 
CHD2 Chromodomain helicase DNA binding protein 2 O14647 81  
Wheat 
germ Abnova 
MAPK7 Mitogen-activated protein kinase 7 Q13164 88  HEK Origene 
CRIP2 Cystein-rich protein 2 P52943 22  HEK Origene 
CSRP2 Cysteine- and glycine-rich protein 2 P16527 21  HEK Origene 
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2.2 Molecular Cloning and Microbiological Methods 
Molecular cloning techniques in cooperation with microbiological methods allow rapid production 
and amplification of desired DNA-constructs. The following sections describe the individual steps 
that are necessary to construct expression vectors that allow the production of large amounts of 
recombinant target proteins.  
2.2.1 Polymerase Chain Reaction (PCR)  
Amplification of certain DNA-sequence and their modification are basic applications of the PCR-
technique. When preparing expression vectors, this method is used to introduce restriction sites 
to the gene of interest, to introduce mutations at a specific site or to determine if the desired 
sequence is present. The basic parameters and reaction mix setup is listed in detail in Table 
2-16. Elongation times were adjusted to the target sequence, 1 min elongation time is allowed per 
1 000 bp fragment length.  
Table 2-16: Basic PCR Reaction Mix and Parameters 
basic reaction mix  basic PCR parameters 
1X PCR buffer (Roche) Function Temperature Time 
200 µM dNTP-Mix  initial denaturation 94 °C 3 min 
0.5 µM forward primer  denaturation 94 °C 1 min 
0.5 µM reverse primer  hybridization 55 °C 1 min 
5 U Taq DNA-polymerase  elongation 72 °C 1.5 min 
100 ng DNA matrix  final elongation 72 °C 10 min 
ad 50 µl dH2O   4 °C ∞ 
 
2.2.1.1 Bacterial Colony Screening 
Material from single colonies of freshly transformed bacteria was directly used to screen for the 
gene of interest. The PCR-mix was set up in 20 µl reaction volume and colony material 
transferred to the reaction tube. The reaction was carried out over 25 cycles with 55 °C annealing 
temperature using 1 U of Taq polymerase.  
2.2.1.2 In vitro PCR-Mutagenesis  
To analyze binding characteristics of antibody-antigen-complexes, in vitro PCR mutagenesis was 
applied to introduce single AA exchanges at specific sites in the candidate antigen nucleotide 
sequence. Primers were complementary to the target sequence with few desired nucleotide 
exchanges that induce AA mutations. Additionally, these primers contain restriction sites that 
allow easy integration of the PCR-product into the target vector. Constructs obtained by PCR 
mutagenesis are described in detail in section 2.2.11.  
  
25-40 
cycles 
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2.2.2 Isolation of Plasmid-DNA 
Plasmid DNA was recovered from bacterial cultures using either the QIAprep Spin Miniprep Kit or 
the QIAGEN Plasmid Maxi kit, depending on the culture volume. Purification was done according 
to the manufacturer’s instructions, with elution volumes of 35 µl or 200 µl elution buffer 
respectively.  
DNA-fragments were purified from PCR mixes and agarose gels using the QIAquick Kit or 
QIAgen MinElute and were eluted in 12 µl or 30 µl of elution buffer respectively. 
2.2.3 Agarose Gelelectrophoresis 
DNA-fragments were separated based on their size using agarose gel electrophoresis. Agarose 
gels were casted at concentrations of 1-2 % agarose in TBE buffer, to allow optimal separation of 
the specific fragments. Samples in sample buffer and DNA standard are loaded to the gel and the 
electric field is applied at 90 V. Addition of 0.5 µg/ml final concentration of ethidium bromide to the 
TBE-buffer enables detection of DNA-bands with UV-light at 312 nm wavelength. In case of 
preparative agarose gels, the DNA-bands of interest were cut out of the gel and purified using the 
QIAquick Kit as described in section 2.2.2. 
2.2.4 DNA Digestion using Endonucleases 
Restriction enzymes recognize specific nucleotide sequences and cut these by a particular 
pattern. This yields DNA-fragments with compatible ends which are exploited when ligating insert 
and vector. The restriction enzymes used in this study are listed in Table 2-5. All restriction 
digests were carried out in the buffer recommended by the manufacturer, using the appropriate 
amount of enzyme units. Mostly, double digests were possible, however, in case of contiguous 
recognition sites or incompatible digestion buffers sequential digests were carried out. If so, the 
first restriction enzyme was heat inactivated or the buffer exchanged using the MinElute PCR 
Purification Kit prior to the second digestion step. Digestions were carried out overnight at the 
optimal temperature of the restriction enzyme in use.  
2.2.5 DNA Ligation 
Prior to ligation of insert and vector, the vector was dephosphorylated to prevent its self-ligation. 
Up to 1 µg of vector DNA was dephosphorylated using rAPid alkaline phosphatase (Roche) in a 
reaction volume of 20 µl for 15 min at 37 °C. The phosphatase was inactivated by incubation for 
2 min at 75 °C before proceeding to ligation.  
T4 DNA-ligase (Invitrogen) was used to ligate vector- and insert-DNA. 100 ng of open, 
dephosphorylated vector and 4-times molar excess of insert were incubated in 20 µl reaction 
volume overnight at 16 °C. Ligated vector-insert-constructs were transformed to chemically 
competent E. coli bacteria as described in section 2.2.12.  
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2.2.6 TOPO-TA Cloning 
The TOPO-TA cloning kit allows direct integration of a PCR product into the pCR®2.1-TOPO® 
vector (LifeTechnologies). Amplification of DNA using Taq polymerase yields PCR products 
containing 3’ adenine overhangs which allow hybridization of the fragment to the thymidine 
overhang of the linearized vector of the cloning kit. DNA-fragments were cloned into the vector as 
described by the manufacturer and subsequently transformed into chemically competent 
OneShot® TOP10 E. coli (section 2.2.12).  
2.2.7 DNA Quantification 
DNA-concentration was determined using either absorbance of UV light at 260 nm wavelength or 
by comparison with standard amounts of ethidium bromide stained bands in agarose gels. UV-
absorbance was measured using the ND1000 spectrophotometer according to the manufacturer’s 
instructions. DNA bands in agarose gels were stained during the separation process by including 
ethidium bromide in the running buffer as described in section 2.2.3. 
2.2.8 DNA Sequencing 
To confirm the identity of a sequence, samples were sent for Sanger-sequencing at the “LMU 
Genetics Sequencing Service”. Primers used for sequencing reactions are listed in Table 2-7. 
Results were analyzed and edited using “Chromas Lite Version 2.01“. 
2.2.9 Cloning of full length recombinant Antibodies 
To recombinantly express proteins in a eukaryotic system, the pTT5 vector was chosen as it is 
well suited for production of secreted proteins by the HEK293E system [125]. Plasmids are 
propagated in the cells via their EBV latency origin of replication (oriP) thereby increasing the 
total number of plasmids throughout the expression period. Furthermore, the human 
cytomegalovirus promotor (pCMV) encoded on the plasmid, in cooperation with the trans-
activating adenoviral protein E1a that is constitutively expressed in the HEK293E cells, ensures 
high expression rates of recombinant proteins [126]. 
Table 2-17 lists the patient-derived recombinantly produced antibodies used in the present study, 
deviant original naming and their source.  
Table 2-17: List of recombinantly produced Antibodies from Patient CSF.  
The first column gives the name of the antibody used throughout this work, followed by the according 
nomenclature in the original publication and the source.  
antibody original nomenclature  source 
rOCB-MS3-s1 Fab-1039-s1 
Obermeier [100] 
rOCB-MS1-s8 Fab-HM-63-s8 
rOCB-MS1-s9 Fab-HM-63-s9 
rOCB-MS4 Fab-NS-52 
rOCB-MS1-s2 Fab-HM-63-s2 
r8-18C5 8-18C5 Obermeier [100], Linington [127] 
rOCB-MS2-s5 Fab7/AB7 Brändle [99] 
rAb-Ip2 --- E. Beltrán (unpublished data) 
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Cloning of a full length IgG1-molecule from OCB-derived antibody H- and L-chains was described 
in detail in the preceding master’s thesis [99]. The construct obtained from this prior study was 
subsequently used to transform all previously cloned Fab-fragments of OCB-derived antibodies 
[100] into full length antibody constructs with IgG1 backbone. Additionally, the humanized Fab-
fragment [100] of the mouse myelin oligodendrocyte glycoprotein (MOG)–specific antibody 8-
18C5 [127] was cloned into a full length construct. The Ab-Ip2 was cloned into the full length 
pTT5-construct accordingly.  
The heavy chain variable regions of the five previously existing OCB-derived Fab-fragments were 
cut out of the existing Fab-encoding pTT5 H-chain vectors by SalI and SacII. The original full 
length rOCB-MS2-s5 H-chain vector was linearized using the same restriction enzymes and 
variable regions were ligated into the open vector. The light chain constructs remained 
unchanged (Figure 2-1). 
 
 
Figure 2-1: Schematic of the cloning strategy used to obtain full length antibody constructs.  
The pTT5/MS2-s5-construct encodes the full length H-chain of rOCB-MS2-s5. The vector was opened using SacII 
and SalI restriction sites. H-chain variable regions (VH) of MS-derived antibodies rAb-MS1-s2, -MS1-s8, -MS1-s9, 
-MS3-s1, -MS4 and the MOG-specific r8-18C5 were cut from Fab-coding vectors using the same sites. VH of rAb-
Ip2 was obtained by PCR (A). The pTT5-constructs coding for L-chains remained unchanged in case of MS-
derived antibodies and r8-18C5. The L-chain variable region (V) of rAb-Ip2 was obtained by PCR and inserted 
into the pTT5/-vector via BssHII and BamHI restriction sites. 
 
The sequences of the variable regions of the H- and L-chains of an expanded antibody from CSF 
of a GABAAR-encephalitis patient were extended by SacII and SalI restriction sites (H-chain, 
Figure 2-1A) and BssHII and KasI (L-chain, Figure 2-1B) respectively. PCR-products were then 
introduced in the full length pTT5 H- or L-chain-vector using these restriction sites (in cooperation 
with E. Beltrán). All antibodies were cloned in two variants, with and without C-terminal V5-tag. 
The V5-tag was a useful tool to detect reactivity in protein microarray experiments, whereas some 
validation assays required the absence of this tag. The amino acid sequences of all recombinant 
antibodies are included in the appendix.  
2.2.10 Cloning of single chain variable Fragment (scFv) 
For rOCB-MS2-s5, recombinant expression in HEK293E cells was not possible as previously 
described in the master’s thesis. Alternatively, this OCB-derived antibody was produced in E. coli 
using the pET19-vector system. The vector carries the T7 promotor and terminator sequence, 
which allows for recombinant production in bacterial strains expressing T7 RNA polymerase. The 
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intrinsic His6-tag, enteropeptidase coding sequence and Proteinkinase A recognition site of the 
vector were not employed here. C-terminal V5- and His6-tags were introduced by PCR. 
 
 
 
Figure 2-2: Schematic illustration of the scFv- MS2-
s5-construct. 
The N-terminal VH region was linked to the V region 
by a triple glycine linker. The His6- and V5-tags form 
the C-terminus of the construct. The gene-construct 
was purchased from GeneArt and inserted into the 
pET19-vector via the NcoI and BamHI restriction sites. 
 
rOCB-MS2-s5 was cloned as single chain variable fragment (scFv). Recombinant expression of 
proteins often creates protein aggregates that need to be refolded in order to be active. However, 
refolding large multi-domain proteins is complicated, thus a minimized format of the antibody was 
constructed. This construct contains the variable regions of H- (N-terminal) and L- (C-terminal) 
chain, connected by a flexible triple glycine linker (GGGGS). These small molecules are easily 
refolded and thereby better suited for prokaryotic expression [128]. The scFv-construct was C-
terminally tagged with V5 and His6. The construct was obtained from GeneArt® 
(LifeTechnologies) and inserted in the pET19 expression vector via NcoI and BamHI restriction 
sites. The amino acid sequence of scFv-MS2-s5 is included in the appendix. 
2.2.11 Cloning of Candidate Antigens 
Candidate antigens were cloned for recombinant expression to obtain large amounts of protein to 
independently validate antibody-antigen recognition. Apart from AKAP17A, candidate antigens 
were expressed in E. coli. All constructs were C-terminally His6-and V5-tagged. In addition, an 
AKAP17A-construct without V5-tag was used.  
2.2.11.1 FAM84A 
The FAM84A-gene (UniProt: Q96KN4-1) was codon-optimized and synthesized with BssHI and 
BamHI restriction sites by GeneArt® (LifeTechnologies). The construct was cloned into the pTT5 
vector and used for eukaryotic expression. Additionally, the NdeI restriction site was introduced at 
the 3’-end by PCR that allows for directed insertion of the FAM84A-gene into the pET33b(+)-
vector via NdeI and BamHI. Both constructs were C-terminally tagged with V5 and His6-tags.  
Additionally, single alanine exchanges were introduced into the FAM84A-gene by PCR 
mutagenesis. Alanine is the second smallest AA and does not feature distinguished 
characteristics and therefore does in most cases not influence the overall properties of the 
protein, particularly its folding behavior. Mutations to be inserted were located at two distinct sites 
of the gene and therefore demanded for two individual cloning strategies. To mutate AA188, 
AA190 and AA191 to alanine, the existing NdeI and MscI restriction sites were used. To 
exchange AA263, AA264, AA267, AA268 and AA271 with alanine, the MscI restriction site was 
used and a Bsu36I motif, which was newly introduced. Reverse primers contained nucleotide 
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mismatches that encoded the individual AA-exchange and the MscI or Bsu36I site respectively. 
All primers used to obtain the wild type and mutant sequences are listed in Table 2-6.  
 
 
Figure 2-3: Cloning Strategy for FAM84A Mutagenesis.  
Mutations at AA188, 190 and 191 were introduced via PCR with the FAM84A-NdeI for Primer and FAM84A-MscI 
rev Primers coding for the respective AA exchange (A). To introduce mutations at AA 263, 263, 267, 268, and 
271, a two-step strategy was applied. AA exchanges were introduced in a first PCR on the FAM84A wild type (wt) 
sequence using FAM84A-MscI for primers and FAM84A-Bsu36I rev primers that carry the nucleotide mismatches 
for the mutations. A second PCR using FAM84A-Bsu36I for and FAM84A-BamHI rev primers introduced the 
Bsu36I restriction site. The two PCR products were digested with Bsu36I and then ligated. The ligation product 
was used as template for a third PCR with FAM84A-MscI for and FAM84A-BamHI rev primers. The resulting PCR 
products carrying single AA exchanges were digested with MscI and BamHI and replaced the wt FAM84A 3’ end. 
 
2.2.11.2 AKAP17A 
AKAP17A (UniProt: Q02040-3) had previously been cloned [102] into the pQE30 vector via 
BamHI and SalI for prokaryotic expression. For expression in the HEK293E system, AKAP17A 
was equipped with a signal peptide, SacII und BamHI restriction sites and inserted into the pTT5-
vector. Furthermore, AKAP17A was cloned in two variants with and without C-terminal V5-tag. 
Primer sequences are listed in Table 2-7.  
2.2.11.3 GABAARα1ex 
In this study, the soluble extracellular domain of the GABAAR α1-subunit (GABAARα1ex) was 
used. The nucleotide triplets coding for extracellularly localized AAs of the α1-subunit of the 
GABAA-receptor (UniProt: P14867-1) were deduced. The sequence stretch entailing AA28-251 of 
the full length protein was selected for recombinant expression.  
The transmembrane domain was replaced by C-terminal V5- and His6-tags using PCR 
mutagenesis. The protein-coding sequence was further modified to carry a 5‘ NcoI restriction site 
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that allows directional insertion of the construct into the pET33b(+)-vector via NcoI and BamHI 
restriction sites. The pET33b(+)-system allows prokaryotic expression. Primers to introduce 
specific restriction sites and tags in the GABAARα1ex-sequence are listed in Table 2-8.  
2.2.12 Transformation of chemically competent E. coli 
Chemically competent E. coli strains OneShot® TOP10 and BL21 strain were transformed with 
protein-coding vectors by heat shock. Both bacterial strains were thawed on ice and incubated 
with 1-2 µl of plasmid for 30 min on ice. Subsequently, bacteria were heat shocked for 30 s at 
42 °C and then quickly cooled. 250 µl of S.O.C. medium (Invitrogen) were added and bacteria 
incubated with horizontal shaking for 1 h at 37 °C. Cells were either plated on agar plates or 
directly used for pool expressions.  
The TOP10 strain was used to propagate new constructs. This strain is characterized by high 
transformation efficiencies and suitability for replication of high-copy plasmids. This strain was 
also used to produce vast amounts of pTT5-vector constructs for eukaryotic expression (section 
2.2.2). To recombinantly express proteins in E. coli, the BL21 strain was used, which has been 
specifically constructed for high protein expression rates.  
2.3 Recombinant Protein Expression 
Studying the specificity and reactivity spectrum of antibodies requires large amounts of IgG-
molecules and their candidate antigens. Recombinant production of these molecules is one way 
to meet this requirement. The two main expression systems employed in this study were 
HEK293E and E. coli strain BL21.  
2.3.1 Eukaryotic Protein Expression in HEK293EBNA Cells 
HEK293EBNA cells have been specifically developed for large scale recombinant protein 
expression and secretion. This cell line is derived from human embryonic kidney cells, grows in 
suspension and has been adapted to serum-free medium. It is stably transfected with the pCEP5-
vector and transiently transfected with pTT5-vector constructs for recombinant expression. The 
pTT5-vector is described in more detail in section 2.2.9. The “HEK293E Large Scale Transient 
Expression System“ and the original pTT5 vector construct are patented by Y. Durocher (NRC 
Biotechnology Research Institute, Ottawa, Ontario, CA) and provided by courtesy of D. Jenne 
(license holder, MPI of Neurobiology/Helmholtz Zentrum Munich, Germany). 
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2.3.1.1 Cell Culture Maintenance 
Suspension cultures of HEK293E cells are kept in polycarbonate conical flask with vented caps 
(Corning) and incubated at 37 °C, 8 % CO2, 70 % humidity and 90 rpm in a Multitron shaker. 
FreeStyle™ 293 Expression Medium was supplemented with 0.1 % Pluronic F68 non-ionic 
surfactant to reduce foam formation and thereby shear forces. Addition of geneticin to a final 
concentration of 25 µg/ml ensured that only cells that carry plasmids survive. Cell concentrations 
of 0.1-3 x 106 cells per ml ensure optimal growth and survival. Cell numbers were determined 
using Neubauer counting chambers, according to the manufacturer’s instructions. Trypan blue 
allowed distinction of live and dead cells. Cells approximately doubled within 24 h and were used 
up to passage 25-30. 
2.3.1.2 Transfection and Expression 
One hour prior to transfection, the cell suspension was diluted to a final concentration of 
1 x 106 cells/ml. Production scale for all constructs was 500 ml. For all transfections, the culture 
volume determined the total amount of transfected DNA. 1 µg DNA per 1 ml cell suspension was 
used. In case of antibody transfections, the same amount of H- and L-chain coding pTT5-
plasmids was transfected. Plasmids and the transfection reagent polyethylene imine (PEI, 
0.2 µg/ml final concentration) were each independently diluted in 0.01 % volume cell suspension 
OptiPro™ SFM (Invitrogen). PEI was then carefully added to the plasmid solution and incubated 
at RT for 30 min to allow formation of DNA-PEI-complexes that can be endocytosed by cells. The 
DNA-PEI-complexes are dropwise added to the cell suspension which is then further incubated 
with standard parameters. To ensure optimal expression of the recombinant protein, medium was 
supplemented with tryptic protein hydrolysates at 0.5 % final concentration at 3-24 h post 
transfection.Harvest and Purification 
HEK293E productions were harvested 120 h after transfection by centrifugation of the cell 
suspension for 5 min at 300 g and 4 °C. The target proteins were either directly purified from cell 
culture supernatants (rAbs) or cell pellets (AKAP17A) were stored at -20 °C. 
a) Full Antibodies and Fab-Fragments 
Full length antibodies and Fab-fragments were secreted by the HEK293E-system and purified 
from the culture supernatant. The C-terminal His6-tag of antibodies and Fabs enables purification 
of recombinant protein by immobilized metal ion affinity chromatography (IMAC).  
After harvest, the culture supernatant is further cleared by centrifugation at 24 000 g and 4 °C for 
30 min. The supernatant is adjusted to 10 mM imidazole, 1x PBS, pH 7.5 and a final 
concentration of 100 µM phenylmethanesulfonyl fluoride (PMSF) was added. Ni-NTA-Agarose 
(Qiagen) was packed to a final volume of 1/100 initial volume cell suspension and equilibrated 
with 10 mM Imidazole in PBS. The adjusted culture supernatant was loaded onto the column at 
1.5 ml/min flow rate. The column was then connected to the “Amersham Pharmacia Biotech” 
FPLC-system that is controlled by the LCC-501 Plus and attached to the UV-detector (Uvicord 
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SD) that allows tracking of washing and elution steps at 277 nm wavelength. Loaded columns 
were washed with 10 CV of 20 mM imidazole in PBS. Elution of proteins is achieved by 
increasing the imidazole concentration to 200 mM. The eluate was collected in one ml fractions 
and stored at 4 °C until further processing. Fab-fragments used in this study had previously been 
produced and purified by J. Bruder according to this protocol [102]. 
b) AKAP17A 
AKAP17A was retained inside HEK293E cells. Thus, after harvesting the cell suspension, the 
supernatant is discarded and the cell pellet stored at -20 °C. Cell pellets were thawed and lysed 
directly prior to further experiments and described in the according sections.  
2.3.2 Prokaryotic Protein Expression in E. coli BL21 
In case of failure of expression in HEK293E, the E. coli BL21 prokaryotic expression system was 
used. The BL21 strain carries the T7 RNA polymerase, controlled by the lac-promotor and is 
thereby suited to express recombinant protein under the T7 promotor at high levels after induction 
with isopropyl-thio-β-galactoside (IPTG). Generally, prokaryotes perform distinct posttranslational 
modifications (PTM) that differ markedly from mammalian PTM-patterns. A major difference is the 
inability of E. coli to introduce glycosylations, thus prokaryotic expression was not the system of 
choice to recombinantly produce candidate antigens. However, a major advantage of this system 
is high production rates and easy handling. As the chosen system is not suited for secretion, 
products were purified from the cytoplasm.  
2.3.2.1 Transformation and Expression 
scFv-MS2-s5/pET19b, FAM84A/pET33b(+) and GABAARα1ex/pET33b(+) constructs were 
transformed into BL21 bacteria by heat shock (section 2.2.12). Single clones were picked and 
grown in kanamycin (50 µg/ml) supplemented LB-medium at 37 °C overnight. FAM84A-
transformed bacteria were further supplemented with 1 % (w/v) glucose during overnight culture. 
Overnight cultures were centrifuged for 10 min at 3 000 g and resuspended in the original volume 
of non-supplemented LB-medium. In case of the scFv, the washed overnight cultures were further 
diluted 1:20 and 1:10 in pure LB medium respectively. To induce protein expression, 2 mM final 
concentration of IPTG was added once the bacteria had reached an optical density (OD) of 0.4. 
FAM84A-expressing bacteria were allowed to grow for 1.5 h in pure LB medium prior to induction. 
Induced bacterial cultures were incubated for 4 h at 37 °C before cells were harvested by 
centrifugation at 4 °C for 20 min at 3 000 g. Pellets were instantly frozen after harvest and stored 
at -20 °C until used for protein purification.  
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2.3.2.2 Harvest and Purification  
Recombinant production in E. coli strains mainly yields two forms of the desired product: natively 
folded protein and clusters of protein aggregates, so called inclusion bodies (IB). To account for 
the different aggregate conditions that the target proteins will adopt, the purification strategy is 
different as described in the following sections.  
a) Inclusion body Purification of scFv-MS2-s5 and GABAARα1ex 
The IB purification protocol used here is adapted from Palmer and Wingfield [129] all steps are 
carried out at 4 °C if not stated otherwise. 
IBs of scFv-MS2-s5 or GABAα1ex were purified from BL21 bacteria. Per gram bacterial pellet, 
8 ml of 100 mM Tris-Cl, pH7.0 with protease inhibitor tablet (Roche) were added and 
resuspended. Lysozyme was added to a final concentration of 200 µg/ml and incubated at RT for 
20 min. Samples were sonified for 5 min with stirring and then centrifuged for 30 min at 18 000 g 
(Eppendorf, 5417R). The supernatant is discarded and the pellet thoroughly washed with 4 ml of 
100 mM Tris, pH7.0 with 2 M urea and 2 % Triton X-100 per gram initial weight. The suspension 
was centrifuged at 18 000 g for 16 min, the supernatant discarded and the washing procedure 
was repeated twice. In a final washing step, the pellet was washed with 4 ml of 100 mM Tris, 
pH7.0. IBs are extracted by resuspending the pellet in 2 ml of 8 M guanidine hydrochloride with 
5 mM EDTA in 50 mM Tris, pH7.0 per gram initial weight. To ensure complete solution of 
aggregates, the IB preparation is rotated for 1 h at RT prior to final centrifugationn at 18 000 g for 
3 h. Purification yielded 1-5 mg scFv-MS2-s5 and about 20 mg GABAα1ex per gram bacterial 
pellet. Solubilized IBs were either directly refolded as described in section 2.3.3 or stored at 4 °C.  
b) Native Protein Purification of FAM84A from E. coli Cytosol 
FAM84A was expressed in a natively folded state by E. coli BL21. To recover the folded target 
protein, bacteria were lysed and the released protein purified by IMAC. 
Bacterial pellets (section 2.3.2) was thawed on ice and resuspended in 10 ml lysis buffer 
(300 mM sodium chloride, 50 mM sodium phosphate, 10 mM imidazole, 0.1 % Tween-20, pH8.0 
and protease inhibitor tablet) per gram initial wet weight. Lysozyme at a final concentration of 
1 mg/ml was added and incubated on ice for 30 min. To ensure complete lysis of cells, the 
suspension was sonified for 2 min on ice. Cell debris was removed by centrifuging at 4 °C for 
10 min at 10 000 g and subsequently for 60 min at 150 000 g. Ni-NTA agarose is equilibrated with 
lysis buffer without Tween-20 and packed into a column to form a CV of 1/10 of the lysis volume. 
The supernatant is loaded onto the column with a flow rate of 1.5 ml/min. As described in section 
2.3.1.3, the column is connected to the FPLC system and washed with 8 CV lysis buffer, 
containing 20 mM imidazole, and then with 2 CV lysis buffer containing 50 mM imidazole. 
Recombinant protein is eluted from the column by an imidazole gradient from 50-270 mM 
imidazole in 40 ml. Eluted protein was collected in 2 ml fractions and further subjected to 
ultrafiltration and dialysis as described in section 2.3.4.  
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2.3.3 Protein Refolding 
scFv-MS2-s5 and GABAα1ex were produced as IB in E. coli BL21 and therefore not natively 
folded. For further experiments, natively folded protein is required, especially with regard to the 
scFv-fragment, as antibody-antigen-recognition may be conformation dependent. By means of 
rapid dilution, many unfolded proteins fold in their native conformation by rapidly removing the 
denaturing agent. Yields may vary depending on the efficiency of the refolding reaction. The scFv-
MS2-s5 IB preparation in 8 M guanindine-chloride solution (section 2.3.2.2) was rapidly diluted by 
dropwise infusing it into 100-fold sample volume of PBS at RT while stirring. The highly diluted 
protein solution was stirred for 1 h after rapid dilution and then left at 4 °C overnight without 
stirring. The GABAα1ex preparation was treated accordingly, but diluted 1:1 000 in PBS. The final 
concentration was 15 µg/ml. scFv-MS2-s5 was further concentrated by ultrafiltration and dialyzed 
as described in section 2.3.4. The final concentration was 70 µg/ml. To determine their secondary 
structure, all refolded proteins were analyzed by CD-spectroscopy as described in section 2.4.3. 
Refolded proteins were directly employed in ELISA assays. 
2.3.4 Ultrafiltration 
To concentrate proteins, either from elution fractions or after refolding, Amicon® centrifugal filters 
(Merck) were used. The exclusion size was adapted to the MW of the target protein. For good 
recovery, the exclusion size is generally chosen to be 20 % smaller than the protein of interest. 
Therefore Amicons with MW cutoff of 30 kDa, 10 kDa and 3 kDa were used according to the 
manufacturer’s instructions.  
To finalize protein purification, the retentate is dialyzed twice against PBS overnight at 4 °C. The 
finalized products were stored at 4 °C.  
2.4 General Protein Analysis 
Prior to the application of in-house productions of candidate antigens and antibodies in 
experiments, careful assessment of biochemical characteristics is warranted to ensure the 
identity and quality of the product in use.  
2.4.1 Protein Determination 
Determination of total protein concentration of a sample is most useful when handling pure 
preparations of proteins. In this case, the total protein concentration approximates the 
concentration of the protein of interest. Protein purification procedures described in sections 
2.3.1.3 and 2.3.2.2 yield pure recombinant protein preparations and therefore allow the use of the 
two methods of protein determination described below.  
2.4.1.1 Lowry’s method 
Determination of total protein concentrations by “Lowry’s method” is most widely used. In this 
study modifications of the original protocol by Peterson were applied. In a first step, copper ions 
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(Cu(II)) form complexes with peptide bonds of the protein in an alkaline environment. 
Subsequently, Folin-Ciocalteu phenol reagent is reduced, resulting in a purple color [130]. 
Unknown samples or BSA standard dilutions were mixed with the same volume of cupric tartrate 
reagent (0.8 M sodium hydroxide, 10 % SDS, 2 % cupric sulfate, 4 % sodium tartrate, 20 % 
sodium carbonate) and incubated for 10 min at RT. Then, half the initial sample volume of Folin-
Ciocalteu phenol reagent is added and further incubated at RT for 30 min. Resulting absorbance 
is measured using the Victor2 1420 Multilabel Counter (Perkin Elmer) at 650 nm. Using the 
calibration curve that is calculated from BSA standard dilutions (20–140 µg/ml), the concentration 
of the unknown samples was determined. 
2.4.1.2 UV-Absorbance 
The absorbance of aromatic AA at 280 nm wavelength can be used to determine the total protein 
concentration of a sample. In this case, the extinction coefficient that takes into account the AA-
composition of the protein of interest is factored into the calculation. All measurements were done 
using the ND1000 spectrophotometer.  
2.4.2 Sodiumdodecylsulfate polyacrylamide Gelelectrophoresis (SDS-PAGE)  
SDS-PAGE is the method of choice to analytically separate different proteins of a sample based 
on their MW [131].  
Gels may be run under reducing or non-reducing conditions. Reducing conditions are generally 
preferred as this will yield more defined protein bands. To this end, samples were complemented 
with reducing loading dye, including 2 % β-mercaptoethanol, and heated to 95 °C for 5 min before 
loaded to the gel. When analyzing the integrity of full length antibodies, however, using non-
reducing conditions is inevitable as this treatment preserves disulfide bonds that interconnect H- 
and L-chains. Irrespective of reducing or non-reducing conditions, loading buffer was added to 
samples before loading them to either Tris-Glycine gels (4-20 %, Invitrogen) or Bis-Tris gels 
(12 %, Invitrogen). All gels were run with the appropriate running buffer for 90 min at 130 V. 
2.4.2.1 Coomassie Staining 
To visualize total protein of SDS-PAGE separated samples, Coomassie Brilliant Blue was used. 
This allows detection of minimal protein amounts of approximately 500 ng. Gels were soaked with 
Coomassie solution (0.1 % (w/v) Coomassie Brilliant Blue R-250, 40 % methanol, 10 % acetic 
acid) for 20-30 min, followed by destaining (50 % methanol, 7 % acetic acid) to remove excess 
Coomassie and to achieve the desired staining intensity. By washing with 5 % acetic acid 
overnight, unspecific background staining is reduced and the gel returns to its original size.  
2.4.2.2 Silver Staining 
Weak protein bands, representing protein amounts in low ng ranges, can be detected using silver 
staining protocols. To retain the option to later analyze protein bands by mass spectrometry, the 
Shevchenko protocol for silver staining was applied [132].  
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Proteins are fixed by soaking the gel with fixing solution (50 % methanol, 5 % acetic acid in water) 
for 10 min. Fixing solution is washed off and sensitizing solution (0.02 % (w/v) sodium thiosulfate 
in water) is added and incubated with gentle shaking for 1 min before it is washed off with water. 
Repeating this step for a total of three-times will allow for a more sensitive staining. 
Subsequently, staining solution (0.1 % (w/v) silver nitrate in water, pre-chilled) is added and 
incubated for 20 min at 4 °C with gentle shaking. The gel was washed with water twice before 
adding developing solution (0.04 % formaldehyde, 2 % (w/v) sodium carbonate in water). Gels 
were incubated with developing solution until the desired staining intensity was reached, 
refreshing the solution in case of discoloring. To end the reaction, stop solution (5 % acetic acid in 
water) was added.  
2.4.3 Circular Dichroism Spectroscopy 
The secondary structure of proteins can be studied using circular dichroism spectroscopy. This 
method takes advantage of differential optical activity of the chiral Cα-atom in the peptide 
backbone and distinct structural features of a folded protein. The Cα-atoms of AA in α-helices and 
β-sheets have different extinction coefficients. Experimentally, the absorption of circular polarized 
light of different wavelengths is measured. The difference between the absorbance of right-
handed circularly polarized and left-handed circularly polarized light is calculated and determines 
the molar ellipticity θ at a certain wavelength. Plotting the ellipticity values and according 
wavelengths yields a spectrum that may be translated into structural features of the protein. CD-
measurements were done with Elisabeth Weyher-Stingl and Reinhard Mentele using the J-715 
spectrometer at the “Microchemistry Core Facility” of the MPI for biochemistry. Spectra were 
taken at wavelengths between 195 and 250 nm at RT and read at 50 nm/min acquisition speed. 
All spectra were acquired in multiple runs and averaged for analysis. PBS or the according 
sample buffer was used as blank value that was subtracted prior to data analysis. Protein 
concentrations of 0.1 - 0.2 mg/ml were used for measurements. Using the “Spectra Manager 
CDPro Analysis” program, the experimental measurements were compared to a set of 56 
reference proteins (Contin SMP56) and the proportions of secondary structures deduced from 
these [133].  
2.4.4 Mass Spectrometry 
To confirm the identity of recombinantly produced proteins, mass spectrometry was applied as 
this method is suited to rapidly identify proteins based on characteristic peptides. In this study, 
proteins were digested by trypsin and applied to matrix-assisted laser/desorption/ionization 
(MALDI) mass spectrometry.  
Mass spectrometric measurements were done in cooperation with Reinhard Mentele and Monica 
Zobawa (MPI for Biochemistry, Department for Proteinanalytics, Prof. Lottspeich, Martinsried, 
Germany). Mass spectra were acquired using either the „4700 Proteomics MALDI-TOF/TOF 
Analyzer“ or “4800 Proteomics MALDI-TOF/TOF Analyzer”. Mass spectra were analyzed using 
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“Data Explorer“ software (Applied Biosystems, Darmstadt, Germany) and generated peak list run 
through the NCBI protein database.  
2.4.5 Secondary Structure Predictions 
To evaluate CD-spectroscopy data on proteins that had not previously been studied by X-ray 
diffraction or nuclear magnet resonance spectroscopy, predictions on the secondary structure of 
the specific proteins were consulted. Predictions were based on the “psipred” propgram [134] that 
distinguishes between α- helices, β-sheets and disordered regions. The “Spectra Manager CDPro 
Analysis” program used to analyze CD-spectra differentiates each of the three structure 
categories α-helix, β-sheet and disorders into two subclasses which were summed up to compare 
to the prediction results. 
2.4.6 Sequence Alignment 
Some candidate antigens were compared with respect to AA-sequence homology. The Clustal 
Omega program [135] is a multiple sequence alignment tool that is used to determine the overall 
similarity of multiple protein sequences. The program was run using default settings and results 
were fed to the ESPript 3.0 program [136] that was used to prepare alignment illustrations. 
For pairwise global sequence alignments the EMBOSS Needle tool, based on the Needlemann-
Wunsch-algorithm, was used to identify the best overall alignment for two sequences. The 
EMBOSS water tool uses the Smith-Waterman-algorithm to find the best local alignment and to 
identify homologous regions within small stretches of two sequences [137].  
2.4.7 Helical Wheel Projections 
The arrangement of AAs in an α-helix is illustrated in a wheel projection. The wheel depicts a full 
turn every 3.6 AAs and provides a way to easily identify the residues that face the same direction 
of a helix. Helical wheel projections of AA-sequences of candidate antigens were generated by 
the projection program created by Don Armstrong and Raphael Zidovetzki using default settings. 
Version: Id: wheel.pl,v 1.4 2009-10-20 21:23:36 don Exp.  
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2.5 Immunological Methods 
Identification and validation of candidate antigens was based on immunological methods. These 
allow specific detection of target molecules in low concentrations ranging from pico- to nanogram. 
If not stated otherwise, the antibody concentrations applied to the individual assays are listed in 
Table 2-13 and Table 2-14. 
2.5.1 Flow Cytometry 
The general functionality of recombinantly produced OCB-derived antibodies was tested using 
flow cytometry. This method allows detecting fluorescence-labeled antibodies that recognize their 
antigen on the cell surface. Thus, a previously established TE671-cell line (provided by K. 
Dornmair, [138]), which expresses the extracellular domain (AA30 –150) of MOG, was used to 
verify the binding reactivity of r8-18C5 to its antigen. 
105 cells were incubated with 10 µg/ml of r8-18C5 or rOCB-MS3-s1 as isotype control for 30 min 
on ice. The original mouse 8-18C5 antibody served as positive control. The positive control 
antibody along with its isotype control X40 was run in parallel using the above parameters. All 
dilutions and washing steps were in PBS with 2 % BSA. Cells were centrifuged in between 
washing steps for 5 min at 300 g and 4 °C. After three washing steps, secondary AlexaFluor647-
coupled goat-anti-human IgG H+L-chain antibody was diluted 1:150 and incubated for 30 min on 
ice. In case of the original 8-18C5 antibody, secondary AlexaFluor647-coupled goat-anti-mouse 
IgG H+L-chain was used. Following three final washes, cells were taken up in 150 µl of PBS with 
propidiumiodide at a final concentration of 2 µg/ml. 104 cells of each condition were analyzed 
using the FACSverse and data was analyzed with “FlowJo”© software V10 (Tree Star, Ashland, 
OR, USA). 
2.5.2 Protein Microarray 
To screen OCB-antibodies for reactivity to proteins, “ProtoArrays®” (v5.0 Human Protein 
Microarrays, Invitrogen, PAH0525101, Lots HA20259 and HA20302) were used. Each array 
consists of 48 subarrays, made up of 22 columns by 22 rows that contain more than 9 000 
proteins. Most proteins originate from the “Invitrogen human Ultimate ORF™ collection”. 
Additionally, the tested proteins are enriched for kinases and proteins that have been related to 
various disease processes, including 20 established antigens of autoimmune diseases. All 
proteins were purified from an insect cell system, printed in duplicates on nitrocellulose-coated 
glass slides and screened simultaneously for reactivity with one of the rAbs. All rAbs, along with 
the humanized, MOG-specific r8-18C5 [127], were assayed in their full length format with V5-tag. 
Arrays were treated according to the manufacturer’s statement and all procedures were carried 
out at 4 °C , arrays were gently agitated during incubation times. 
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Figure 2-4: Schematic Illustration of the Protein Microarray Workflow.  
The glass slide with ~9400 spotted proteins is incubated with recombinant antibodies that are detected with an 
AlexaFluor647-coupled anti-V5 secondary antibody. Arrays were washed and dried before fluorescence signals 
were detected. The illustration is modified from [102] 
 
Arrays were blocked using blocking buffer (LifeTechnologies, PA055) with synthetic block 
(LifeTechnologies, PA017) for 1 h. Recombinant OCB-antibodies were added at a concentration 
of 10 µg/ml in wash buffer (synthetic block in PBS, 0,05 % Tween-20) and incubated for 90 min. 
As only limited amounts of the rOCB-MS2-s5 were available, the antibody concentration was 
reduced to 5 µg/ml in this case. Arrays were washed five times for 5 min before the secondary α-
V5 antibody conjugated with Alexa647 (LifeTechnologies, 45-1098) was added at 1 µg/ml 
concentration in wash buffer and incubated for 90 min. The washing procedure was repeated, the 
array dried by centrifuging at 200 g for 2 min and stored in the dark at 4 °C until analyzed with the 
Microarray Scanner GenePix 4000B (Axon Instruments) at 635 nm wavelength using different 
photomultiplier (PMT) settings. Signals were analyzed using the PPI option of the “Protoarray™ 
Prospector 5.2.1” program (LifeTechnologies) as described earlier by J. Bruder [102]. For quality 
control, the mean signal of internal negative controls and the overall mean array signal were 
determined. Besides the internal array controls, one array was probed with only the secondary 
antibody and used as negative control, the array probed with r8-18C5 served as isotype control. 
To analyze the r8-18C5 probed array, rOCB-MS3-s1 was chosen as isotype control. The specific 
background signal measured at every spot was subtracted from the signal prior to analysis. 
Signals were considered that were 3x enriched compared to both the signal intensity of the 
negative control as well as the one of the isotype control (r8-18C5 or rOCB-MS3-s1) and 5x 
enriched compared to the background signal. In case of rOCB-MS2-s5, only signals that were 
also recognized by the Prospector software as “hits” were selected. “Hits” are defined by the 
program as proteins with Z-score above 3, CIP-value below 1*10-4 and Z-factor above 0.05 with a 
coefficient of variation below 0.5. This additional selection was necessary to account for the 
increased number of candidate antigens caused by unspecific reactivity due to lower 
concentration and purity of rOCB-MS2-s5. Proteins were only considered as candidate antigens 
when duplicate signals were detected. For analysis, data acquired using PMT700 was used and 
all hits were visually confirmed.  
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Results from protein microarrays were confirmed with independent techniques to verify the 
reactivity found in the screening approach. From the pool of candidate antigens (f ≥ 3) only 
proteins with enrichment factors above 100 were selected for further experiments. Those 
methods included immunoprecipitation, Western blotting, and ELISA and are described in detail 
in the following sections. Further, candidate antigens used in these validation experiments were 
produced in organisms other than insect cells, to confirm that array reactivity was not directed at 
insect cell specific modifications. Such validation experiments were carried out for selected 
antigen candidates, the selection of these candidates is described in the results (section 3.3.1).  
2.5.3 Immunoprecipitation  
One of the methods used here to verify the binding of the OCB-derived antibodies to candidate 
antigens was immunoprecipitation. Two general approaches were applied for precipitation. First 
antibody-antigen-complexes were allowed to form in solution and were subsequently incubated 
with the bead matrix that binds IgG-molecules. Second, antibodies were coupled to the bead 
matrix and the samples were then added. Thus, the complexes form directly at the matrix.  
2.5.3.1 Immunoprecipitation of HEK-derived MKNK1 
MKNK1 purified from HEK-cells (amsbio) was used to validate the reactivity of rOCB-MS2-s5 by 
immunoprecipitation.  
Tosyl-activated magnetic beads (Thermo Fisher Scientific) were coupled with rscFv-MS2-s5, 
control Fab-fragments rFab-MS3-s1, rFab8-18C5 and positive control antibody ab56425 (abcam) 
to MKNK1. Tosyl-activated beads covalently bind primary amine or sulphydryl groups and were 
therefore best suited for this experiment. 20 µg of antibodies were coupled to 1 mg of beads 
according to the manufacturer’s recommendations. Beads were then blocked in 1 % BSA in PBS-
T for 1 h at RT. 0.7 µg of MKNK1 were added and incubated for 30 min at RT. Beads were 
washed three times with 1 % BSA in PBS-T and twice with PBS-T. Bound antigens were eluted 
with 60 µl reducing SDS-PAGE loading buffer at RT for 10 min and analyzed by Western blotting. 
2.5.3.2 Immunoprecipitation of HEK-derived FAM84A 
FAM84A was validated as candidate antigen of rOCB-MS1-s8 by immunoprecipitation. To this 
end, purified HEK-derived protein FAM84A (amsbio) was used.  
Protein G Dynabeads (LifeTechnologies) were washed in PBS and then incubated with 1 % BSA 
in PBS-T rotating for 1 h at RT. Simultaneously, 2 µg of purified HEK-derived FAM84A were 
individually incubated with 25 µg of each of the antibodies rOCB-MS3-s1, rOCB-MS1-s2, rOCB-
MS1-s8 and r8-18C5. ab58330 served as positive control. Following 30 min of incubation with 
rotation at RT, 3 mg of blocked Protein G beads were resuspended in each of the individual tubes 
and incubated for another 10 min at RT with agitation. Beads were washed five times with PBS-T 
and complexes eluted from the matrix by incubation with 60 µl reducing SDS-PAGE loading 
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buffer for 10 min at 95 °C. The eluate was analyzed using Western blotting as described in 
section 2.5.4.  
2.5.3.3 Immunoprecipitation of HEK293-derived AKAP17A 
AKAP17A was precipitated from crude HEK293E cell lysate, validating the Protoarray findings 
with rOCB-MS1-s2. HEK293E cells were transfected with the AKAP17A/pTT5 construct without 
V5-tag, grown and harvested as described in section 2.3.1 and stored at -20 °C until lysis.  
Protein G Dynabeads were covalently coupled with individual antibodies using the amine cross-
linker bis(sulfosuccinimidyl)suberate (BS3, Pierce). Coupling was carried out according to the 
manufacturer’s instructions. In short, an excess of recombinantly produced OCB-antibodies and 
beads were mixed and incubated for 1 h. Antibody attached to Protein G is covalently coupled by 
adding 5 mM BS3 in 20 mM Na2HPO4, 150 mM NaCl, pH8.6 and rotating for 30 min. The cross-
linking reaction is repeated once with fresh BS3 reagent and then stopped by adding 5 % (v/v) 
quenching buffer (1 M Tris pH 7.5) and further rotating incubation for 15 min. Coupled Dynabeads 
were stored in PBS at 4 °C until deployed in immunoprecipitation.  
Cells were thawed, resuspended in lysis buffer (300 mM NaCl, 150 mM NaH2PO4 in 1x PBS pH 
7.5) and sonified for 5 min on ice. The lysate was cleared from cell debris by centrifuging for 
10 min at 3 400 g, 4 °C and 10 min at 12 000 g, 4 °C. The supernatant was immediately 
subjected to immunoprecipitation using Protein G Dynabeads with covalently coupled antibodies. 
Prior to the immunoprecipitation, pre-coupled and fresh Dynabeads were blocked using synthetic 
buffer (Life Technologies) in PBS for 1 h. Pre-blocked, uncoupled Protein G Dynabeads were 
incubated with the lysate for 15 min to minimize background resulting from unspecific interactions 
with the bead matrix. Pre-cleared lysate was then incubated with Protein G Dynabeads pre-
coupled with recombinant OCB-antibodies rOCB-MS3-s1, -MS1-s2, -MS1-s8, r8-18C5 and 
polyclonal α-AKAP17A (MBS711914) antibody for 30 min. All incubation steps were carried out at 
RT. Bound molecules were eluted in reducing SDS-PAGE loading buffer for 10 min at RT and 
analyzed by Western blotting (2.5.4).  
2.5.3.4 Immunoprecipitation of HEK-derived MAPK7, CRIP2 and CSRP2 
To verify reactivity of Ab-Ip2 to MAPK7, CRIP2 and CSRP2, commercially available HEK-derived 
proteins (all Origene) were applied to immunoprecipitation experiments.  
rAb-Ip2 and control antibodies r8-18C5 and rAb-MS3-s1 were covalently coupled to Protein G 
beads as described above and then incubated with 2 µg of MAPK7. Beads were washed six 
times with PBS-T and eluted in 200 µl 1x SDS-loading dye for 10 min at 95 °C.  
For immunoprecipitation of CRIP2 and CSRP2, Protein G beads were blocked in synthetic buffer 
in PBS-T with 0.5 mM DTT for 1 h at RT. Simultaneously, 2 µg of purified CRIP2 or CSRP2 
protein were incubated with 8 µg of antibodies Ab-Ip2, rOCB-MS3-s1, and r8-18C5 in synthetic 
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buffer in PBS with 0.3 mM DTT for 30 min at RT. After complex-formation, 30 µl of Protein G 
beads were added to each of the antibody-antigen solutions and incubated for 10 min at RT with 
shaking. The supernatant was discarded and beads washed five times with 100 µl of PBS-T with 
0.5 mM DTT. Complexes were eluted from the bead matrix by incubation with 1x SDS-loading 
dye for 10 min at 95 °C. Eluates were analyzed by SDS-PAGE and Western blotting. 
2.5.4 Western Blot 
Low amounts of defined proteins may be specifically detected by Western blotting. This method 
was used to analyze eluate fractions from immunoprecipitation experiments. In case of antibodies 
that recognize linear epitopes, antibody-antigen-recognition can be directly detected by Western 
blotting. 
Proteins separated by SDS-PAGE were electrotransferred to polyvinylidene fluoride (PVDF, GE 
Healthcare) membranes in a semi-dry manner for 3 h at 35 mA per membrane. Membranes were 
blocked in 5 % milk powder in PBS-T by incubation at RT for 1 h or overnight at 4 °C to prevent 
unspecific binding. Primary antibodies were diluted in 5 % milk powder in PBS-T and diluted as 
stated in Table 2-13. Membranes were incubated with primary antibodies at RT for 1 h with 
shaking and then washed off using PBS-T three times for 5 min. HRP-coupled secondary 
antibodies were also diluted in 5 % milk powder in PBS-T as stated in Table 2-14 and incubated 
with shaking at RT for 1 h. The washing procedure described above was repeated.  
Enhanced chemiluminescence (ECL)-substrate solution to detect antibody reactivity is prepared 
freshly by mixing 10 ml of ECL A with 100 µl of ECL B and 3.1 µl 30 % hydrogen peroxide. The 
membrane was covered with ECL-substrate solution for 1 min and signals were then captured on 
radiographic films and visualized using the OPTIMAX x-ray developer. Signals were also directly 
detected using digital imaging systems “Odyssey Fc” and “ImageQuant LAS4000”. Exposure 
times varied from seconds to maximally 20 min, depending on the signal strength.  
A modification of the described Western blotting technique is dot blots. In this case the sample is 
directly spotted onto a nitrocellulose membrane, where the target protein is immobilized in a 
denatured state. After complete drying, the membrane is treated as described above for classical 
Western blots.  
To exemplarily verify the capability of r8-18C5 to bind its antigen, 1 µg and 0.5 µg of recombinant 
human MOG (HEK293-derived, provided by D. Jenne) as well as sample buffer without protein 
were spotted. After drying, the membrane was blocked with synthetic block in PBS-T for 1 h at 
RT. r8-18C5 antibody was added at a final concentration of 1 µg/ml in blocking buffer and 
incubated for 1 h at RT. The primary antibody was washed off and HRP-coupled anti-V5 antibody 
was added and incubated for 1 h at RT. This was followed by developing the membrane using 
ECL, as described above.  
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For additional validation experiments with r8-18C5, human MOG (HEK293-derived, provided by 
E. Meinl) and candidate antigens FAM20B (in-vitro translation, Abnova) and CHD2 (CHO-derived, 
R&D) were used. 0.5 µg of each of the proteins was loaded to a SDS-gel and transferred to a 
PVDF-membrane. To detect reactivity to linear epitopes on these candidate antigens, 1.5 µg/ml 
of r8-18C5 in 5 % milk powder in PBS-T were used as primary antibody.  
2.5.5 Enzyme-linked immunosorbent Assay (ELISA) 
For ELISA, the target protein is directly coated to the assay plate. In sandwich-ELISAs, an 
antigen specific capture antibody is coated. The capture antibody immobilizes the antigen of 
interest and allows thorough washing throughout the procedure. In both cases, binding of the 
tested sample to the target antigen is detected by adding a detection antibody coupled to 
horseradish peroxidase (HRP). The subsequently added 3,3′,5,5′-Tetramethylbenzidin (TMB) 
substrate is oxidized by HRP thereby creating a blue-colored product. The reaction is stopped by 
adding sulfuric acid which quenches the reaction and turns oxidized TMB into a yellow-colored 
product that is read out at 450 nm wavelength. Measuring the absorbance at 540 nm allows 
correction of the measurements for uneven background signal. TMB substrate solution 
(eBioscience, San Diego, CA, USA) was used according to the manufacturer’s statement.  
2.5.5.1 ELISA for Reactivity to MKNK1 
Based on Protoarray findings, MKNK1 was identified as candidate antigen for rOCB-MS2-s5. To 
validate this result, an ELISA using commercial HEK-derived MKNK1 (amsbio) was established. 
scFv-MS2-s5 and Fab-fragments of control antibodies were used in this experiment. This accounts 
for the different binding characteristics of scFv-Fragment and full length antibodies due to the 
different number of antigen binding sites. 
a) Validation 
MKNK1 was directly coated to Costar half-area assay plates at a concentration of 16 µg/ml in 
PBS at 4 °C overnight. All other dilution and washing steps were carried out using 0.5 % BSA in 
PBS. Unless stated otherwise, further incubation was carried out at 37 °C. The plate was washed 
once with 1 % BSA in PBS and subsequently incubated in this blocking buffer for 2 h. Monoclonal 
OCB-derived Fab-fragments, scFv-MS2-s5 (section 2.3.2.2) and the commercial polyclonal 
antibody PA5-13951 were added at concentrations ranging from 0.5 µg/ml to 150 µg/ml and 
incubated for 40 min. After washing off excess antibody, HRP-coupled detection antibodies to 
human IgG H- and L-chains, rabbit IgG Fc-region and V5-tag were added and incubated for 
20 min. The final washing steps were done using PBS-T. Procedures of TMB substrate reaction, 
OD measurements and data analysis have been adopted as described in section 2.5.5. 
Developing time for the TMB reaction in this experimental setup is 4-5 min at RT.  
b) Patient Screening 
To screen patient CSF for reactivity to MKNK1, the above described MKNK1-ELISA was 
employed. Each of the samples was employed at 25 µl per well of undiluted CSF. Positive 
Materials and Methods 
44 
controls PA5-13951 and scFv-MS2-s5 were applied in concentrations of 100 µg/ml and 50 µg/ml 
respectively. 
In total, 28 CSF samples were screened for MKNK1-reactivity. The main focus of this screening 
approach was CSF samples of other MS patients (20 samples). For control reasons, non-
inflammatory neurological disorders (NIND, 8 samples) were screened in parallel. The NIND 
cohort consists generally of neurological symptoms with unclear etiology such as tension 
headache. The respective clinical findings of these patient samples are listed in Table 2-1.  
2.5.5.2 ELISA for Reactivity to FAM84A 
Reactivity of rOCB-MS1-s2 to FAM84A, as suggested by the Protoarray data, was further 
confirmed by ELISA. The assay described in the following section was also applied to screen 
CSF samples of a larger patient cohort and to examine more closely the epitope recognized by 
rOCB-MS1-s2 by analyzing alanine-mutants. 
a) Validation 
Costar half-area assay plates were coated with a final concentration of 10 µg/ml α-V5 capture 
antibody in PBS at 4 °C overnight. Plates were washed once and then incubated with 2 % bovine 
serum albumin (BSA) in PBS-T at 37 °C for 2 h. All dilution and washing steps were carried out 
with 0.5 % BSA in PBS-T. Unless stated otherwise, further incubation was carried out at 37 °C. 
FAM84A purified from E. coli (see Section 2.3.2) was diluted to a final concentration of 16 µg/ml, 
added to the blocked assay plate and incubated for 30 min. Recombinant FAM84A is bound by 
the capture antibody via its C-terminal V5-tag sequence (GKPIPNPLLGLDST). This sequence not 
only allows strong attachment of the target protein to the plate surface, but also adds an extra 
purification step to the experimental setup. Unbound impurities and excess FAM84A is washed 
off the plate and OCB-derived monoclonal antibodies are added at concentrations ranging from 
5 µg/ml to 2 mg/ml. Besides rOCB-MS1-s2, that had recognized FAM84A on the Protoarray, 
rOCB-MS3-s1, rOCB-MS1-s8 and r8-18C5 were used to control for unspecific isotype reactivity. 
The commercial monoclonal antibody to human FAM84A (ab58330) served as positive control at 
concentrations ranging from 2.5 ng/ml to 330 ng/ml. Monoclonal antibodies and the positive 
control were incubated for 40 min. Recombinant monoclonal antibodies bound to FAM84A were 
detected using HRP-coupled polyclonal rabbit α-human IgG at 1:100 000 dilution. The 
commercial α-FAM84A antibody was detected by HRP-coupled rabbit α-mouse diluted 1:5000. 
Detection antibodies were incubated for 20 min. After thorough washing of the plate and a final 
washing step with pure PBS, 25 µl of TMB substrate solution (eBioscience) were added and 
incubated at RT for 15-20 min. Following incubation time, the reaction was stopped by addition of 
13 µl of 1 M H2SO4 solution.  
The signal intensity was read out using the Victor2 1420 Multilabel Counter at 450 nm. 
Additionally, the OD at 540 nm was determined to account for optical imperfections. The OD 
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values at 540 nm were subtracted from those at 450 nm using Microsoft Excel and the corrected 
values were further analyzed using Prism Graphpad software.  
b) Patient screening 
To determine if other MS patients have antibodies reactive to FAM84A, the above described 
ELISA was applied to matching CSF and serum samples of a larger patient cohort. In total, 66 
samples were measured in a blinded manner. rOCB-MS1-s8 is derived from an antibody species 
expanded in the CNS of a MS patient. Thus, the main focus of this screening approach was CSF 
samples of other MS patients (20 samples). Additionally, samples from patients with other 
neurological disorders were employed for control purposes, these included neuroborreliosis (NB, 
13 samples), other inflammatory disorders (OID, 7 samples), cranial nerve palsies (CNP, 
9 samples) and non-inflammatory neurological disorders (NIND, 17 samples). CNP samples 
contained facialis paresis and cranial palsies and the NIND cohort consists generally of 
neurological symptoms with unclear etiology such as tension headache. Overall, the groups 
represent acute inflammatory settings (NB and OID) and chronic or non-inflammatory settings 
(MS, CNP and NIND). The clinical findings of these patient samples are listed in Table 2-1. 
The above described monoclonal OCB-derived antibodies as well as the original CSF sample of 
patient MS1 were run in parallel to the unknown samples as controls. rOCB were used at a final 
concentration of 50 µg/ml, the positive control antibody ab58330 was used at 10 µg/ml. CSF 
samples were applied without dilution, irrespective of their a priori unknown protein or IgG-
concentration. The matching serum samples were diluted 1:400 in PBS to lower the IgG-content 
to levels comparable to CSF IgG-concentrations. All other experimental details were retained. For 
a total of four CSF samples the matching serum sample was not available. 
c) Screening of mutated FAM84A 
In order to obtain a closer insight into the epitope that is recognized by rOCB-MS1-s2, FAM84A-
mutants were expressed and applied to the above described FAM84A validation assay (section 
2.5.5.1). Mutants were applied to the assay at a final concentration of 16 µg/ml. In contrast, only a 
reduced number of different monoclonal antibodies, namely rOCB-MS1-s2, r8-18C5 and the 
commercial α-FAM84A, were used in this setting.  
2.5.5.3 ELISA for Reactivity to GABAAR α1-subunit 
Costar half-area assay plates were coated with the refolded extracellular domain of the GABAAR 
α1-subunit (section 2.3.3). Final concentration of the GABAAR-fragment was 15 µg/ml. The 
protein was allowed to attach to the assay plate for 2 h at 37 °C. All following dilution and 
washing steps were carried out using 0.5 % BSA in PBS. Unless stated otherwise, incubation 
was carried out at 37 °C. The plate was washed once with 1 % BSA in PBS and then blocked in 
the same buffer for 1 h. rAb-Ip2, one MS-OCB-derived control (rOCB-MS3-s1) and r8-18C5, 
along with the positive control anti-V5 antibody, were applied at a final concentration of 50 µg/ml 
and incubated for 1 h. Unbound antibody was washed off thoroughly. HRP-coupled antibodies to 
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human and rabbit IgG H- and L-chains at concentrations of 1:50 000 and 1:10 000 were used as 
secondary antibodies respectively. Secondary antibodies were incubated for 20 min and excess 
was washed off. A final washing step with pure PBS was included. Reactivity was detected using 
TMB chemistry as described above (section 2.5.5) and the results analyzed using Graphpad 
Prism software as described (section 2.1.9). Developing time for the TMB reaction in this 
experimental setup was 20-30 min at RT. 
2.5.6 Immunofluorescence 
To test whether OCB-derived antibodies recognized target antigens in a cellular setting, 
HEK293E-cells were stained with OCB-derived antibodies and appropriate controls. HEK293E-
cells endogenously express the candidate antigens FAM84A and AKAP17A. Cells transfected 
with the individual candidate antigens were stained in parallel.  
Antigen-transfected and non-transfected HEK293E-cells were washed in PBS once. 1 x 105 cells 
were allowed to settle for 1 h at RT on poly-L-Lysin coated slides. Cells were again washed once 
with PBS and fixed in ice-cold ethanol with 5 % acetic acid for 10 min. Fixed cells were washed 
twice in PBS and permeabilized with PBS-T for 20 min. Unspecific binding sites were blocked 
with 2 % BSA in PBS-T for 1 h. rOCBs were added at 5 µg/ml final concentration. Positive control 
antibodies PA5-30705 and ab56425 were diluted 1:400, MBS711914 was diluted 1:100. After 
incubation for 1 h at RT, cells were washed three times in PBS-T. AlexaFluor594-coupled 
secondary antibodies A11005 to mouse IgG and A11037 to rabbit IgG were diluted 1:1000. The 
DyLight488-coupled secondary antibody 109-485-088 to human IgG was diluted 1:400. 
Secondary antibodies were incubated for 1 h. All antibodies were diluted in 1 % BSA in PBS-T. 
Cells were washed as described above with DAPI present in the final washing step. Stainings 
were analyzed using AxioVert 200M fluorescence microscope and MetaMorph software. For each 
of the antigens, the exposure times were kept constant for the different conditions. 
2.6 Statistical Analysis  
For statistical analysis, Prism software (GraphPad Software, La Jolla, Ca, USA) was used. 
Student’s unpaired t-tests were used to identify statistical differences. All data is presented as 
mean ± standard deviation. p-values ≤0.1 were considered significant.  
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3 Results 
The present study aimed at the identification of target antigens of expanded antibody species 
from patients with inflammatory neurologic diseases. The antibodies used here derive from MS 
patients and one GABAAR-encephalitis case. Table 2-17 lists the rAbs used in this study and their 
source. 
An approach established by B. Obermeier (Figure 1-8, [100]) allows the identification of matching 
H- and L-chains. In this previous study, H- and L-chain pairs of a total of six MS-OCB-derived 
antibodies were cloned and expressed in form of Fab-fragments by B. Obermeier. Fab-fragments 
were applied in primary antigen search experiments [100, 102]. Due to a lack of consistency of 
results, the established Fab-fragments were re-cloned into full length IgG-constructs to be used in 
the study described here.  
Ab-Ip2 was characterized from CSF of the GABAAR-encephalitis patient Ip2 by E. Beltrán 
(unpublished data). Next generation sequencing of the B-cell repertoire identified a monoclonal 
expansion of this antibody.  
Here, the experimental findings leading to the unambiguous identification and validation of target 
antigens of OCB-derived antibodies from MS patients and two target structures of rAb-Ip2 from a 
GABAAR-encephalitis patient are described. To this end, candidate antigens were identified by 
protein microarrays and independent methods were used to confirm the antigen-antibody-
interaction. Further, the epitope recognized by one of the OCB-derived antibodies is explored in 
greater depth and the reactivity profile of a larger patient cohort towards this antigen is presented.  
3.1 Expression and Characterization of recombinant MS-OCB Antibodies  
The full length IgG1 H-chains were cloned into the pTT5-vector, co-transfected with L-chains into 
HEK293E-cells, and purified from the cell culture supernatant. MS-OCBs were expressed as 
divalent antibodies because two antigen binding sites may allow the formation of more stable 
complexes with the antigen compared to Fab-fragments. This may facilitate the identification of 
target antigens. The L-chain constructs are the same for Fab-fragments and full length antibodies. 
Full length antibodies were expressed in two formats, with and without V5-tag. All antibodies 
carried the His6-tag which was used for purification. 
3.1.1 Biochemical Analysis of recombinant full length Antibodies derived from MS-OCB 
All antibodies, except rOCB-MS2-s5 (see section 3.1.2), were expressed at sufficient levels, 
secreted to the medium and purified by affinity chromatography. Figure 3-1 shows the individual 
recombinantly expressed and purified V5-tagged OCB-antibodies separated by SDS-PAGE under 
reducing and non-reducing conditions. Disulfide bridges in between the two H-chains and the H- 
and L-chain pairs break under reducing conditions, thereby disintegrate the molecule into its 
components. Thus, SDS-PAGE run under reducing conditions shows two distinct bands for each 
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antibody representing the L-chains at 25 kDa and the H-chains at approximately 55 kDa. Loading 
the samples under non-reducing conditions preserves the heterodimeric molecule hence only a 
single protein band at around 160 kDa is present after Coomassie staining. No other proteins 
were detected, demonstrating sufficient purity of the recombinantly produced antibodies (Figure 
3-2A). The final yield of an expression preparation was 2-4 mg/l of purified antibody. 
 
Figure 3-1: Recombinant full length monoclonal antibodies derived from MS-OCBs. 
V5-tagged antibodies were expressed in HEK293E, purified by affinity chromatography, separated by SDS-PAGE 
under reducing (A) and non-reducing (B) conditions and stained with Coomassie Brilliant Blue. Antibodies treated 
with reducing agent show two protein bands at 25 and 55 kDa, representing disassembled heavy and light chains 
(A). Antibodies under non-reducing conditions are visualized as a single band at approximately 160 kDa (B). The 
preparations show no additional bands.  
 
Western blotting to human IgG H- and L-chains confirmed the identity of the protein bands 
(Figure 3-2B). The secondary structure of the full length rAbs was determined using CD-
spectroscopy. The CD-measurements corresponded to the expected large proportion of β-sheets, 
representing more than 40 % of the protein’s secondary structure. Low levels of α-helical 
structures were detected within the limits of error. Approximately 20 % of the protein consist of 
turns, whereas the remainder is disordered stretches of AAs (Figure 3-2C and D). These results 
agree with antibody secondary structures described in the literature [139]. Mass spectrometry 
allowed the detection of unique peptides that unambiguously demonstrated the presence of the 
two distinct chains of a specific rAb (Figure 3-2E). These analyses were done in parallel for all full 
length rAbs. Figure 3-2 shows exemplary data from the humanized r8-18C5 antibody.  
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Figure 3-2: Detailed biochemical analysis of the humanized r8-18C5 antibody.  
Western blotting of reduced (A) and non-reduced (B) samples of the r8-18C5 antibody demonstrated that all 
protein bands detected in Coomassie staining represent a human IgG-molecule or either of the individual chains 
(A and B). The CD-spectrum revealed a high content of β-sheets, some turns and disordered stretches, and only 
marginal amounts of α-helical structures. The IgG1-molecule is made up of Ig-domains that mainly consist of β-
sheets interconnected by turns or disordered sequences (C). The correct assembly of the heterodimer was 
demonstrated by mass spectrometry. Green triangles indicate peptides derived from the light chain and blue 
triangles indicate heavy chain derived peptides (D) The illustration is modified from [101].  
 
3.1.2 Single chain variable Fragment of rOCB-MS2-s5  
rOCB-MS2-s5 could be purified from the cell culture supernatant in the same quality described for 
the other OCB-derived antibodies, but only in very low amounts. Pooling of 1.5 l total expression 
volume yielded approximately 15 µg (0.01 mg/l) of purified antibody. For comparison, the yields 
for the other MS-OCB antibodies are 2 – 4 mg recombinant protein per l of culture.  
The pooled antibody preparation was analyzed by SDS-PAGE under non-reducing conditions to 
ensure that H- and L-chains have assembled to a heterodimer (data not shown). Due to low 
yields, the full length rOCB-MS2-s5 was not analyzed in depth. The recovered amounts of 
antibody secreted by HEK293E cells were sufficient for screening for antigens using protein 
microarrays, but were not sufficient for subsequent validation studies. Due to the low expression 
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in the HEK-system, recombinant production of the rOCB-MS2-s5 in alternative expression 
systems was evaluated. 
Expression screenings in 58-, LTK-, CHO-, 3T3-cells and in vitro translation failed to produce 
sufficient amounts of rOCB-MS2-s5 in feasible culture volumes (data not shown). Therefore, the 
scFv-variant of the antibody was produced in E. coli BL21. The scFv-fragment was constructed 
and cloned into the pET19 vector and expressed in large amounts by this expression system.  
3.1.2.1 Refolding of the single chain variable Fragment of rOCB-MS2-s5 
The protein formed inclusion bodies (IBs) in E. coli BL21. The protein aggregates were purified in 
Tris buffer supplemented with low concentrations of urea and a detergent and then solubilized in 
high concentrations of guanidine hydrochloride, yielding 1-5 mg protein per gram wet weight 
bacterial pellet. To obtain natively folded protein, the solubilized protein is rapidly diluted in PBS, 
concentrated and dialyzed against PBS to remove residual denaturing agent. The refolding yield 
was approximately 70 µg/ml of soluble scFv. 
3.1.2.2 Biochemical Analysis of scFv-PT 
The scFv-MS2-s5 construct carried V5- and His6-tags but these were not used for affinity 
purification as the IB-preparation was of sufficient purity. The expected MW of approximately 
28 kDa and sufficient purity was verified by SDS-PAGE (Figure 3-3A). Western blotting confirmed 
that the protein band observed by Coomassie staining represents the recombinant protein with 
V5-tag.  
Folding of scFv-MS2-s5 into a native state was verified by CD-spectroscopy (Figure 3-3C and D). 
The secondary structure determined by CD-spectroscopy consists mainly of β-strands (40 %) 
with little contribution of α-helices (10 %). The other half of the protein contains approximately 
20 % of turns and 30 % disordered segments. Whereas the proportions of turns and disordered 
segments mirror the secondary structure of full length antibodies, the α-helix and β-strand 
proportions are shifted towards α-helices. This is represented by the more pronounced shoulder 
at 220-230 nm wavelength and a slight shift of the extremum that has been observed with single-
chain constructs before [139, 140]. The identity of the scFv was further demonstrated by detection 
of characteristic peptides by mass spectrometry (Figure 3-3E). 
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Figure 3-3: Characterization of scFv-MS2-s5.  
Size and purity of refolded scFv-MS2-s5 were determined by SDS-PAGE and Coomassie staining showing a 
strong band at 29 kDa that represents the scFv (A). Western Blot detection of the V5-tag revealed a band at the 
same size confirming the identity of the protein band (B). CD-spectroscopy revealed high percentages of β-sheets 
and disordered stretches in the refolded protein, as expected (C and D). The identity of the refolded protein was 
demonstrated by mass spectrometry that detected scFv-MS2-s5 specific peptides (E).  
 
3.1.3 Recognition of MOG by r8-18C5 
Functionality of the recombinant antibodies was verified using r8-18C5. Binding 8-18C5 produced 
in mouse hybridoma to MOG is well established and recombinant MOG-fragments were used in 
three individual experimental setups to ensure the rAbs’ capacity to recognize the antigen. 
The recombinant extracellular domain of human MOG, spotted onto a nitrocellulose membrane, 
was recognized by the humanized full length r8-18C5 (Figure 3-4A). The recombinant full length 
antibody had the capacity of binding the target antigen and carried the V5-tag, which was 
detectable by Western blotting. 
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Figure 3-4: Reactivity of r8-18C5 to recombinant human MOG-fragment.  
The extracellular domain of human MOG was spotted on a nitrocellulose membrane and detected by r8-18C5 and 
a secondary antibody to the V5-tag of the rAb. The antibody recognized its antigen in a dose-dependent manner 
(A). The soluble extracellular domain of MOG was bound by r8-18C5 in an immunoprecipitation experiment, while 
control antibodies did not show any reactivity (B). The extracellular domain of MOG present on the surface of 
TE671-cells was detected by r8-18C5 (blue) and the original mouse 8-18C5 (red). Non-transfected TE671-cells 
were not recognized (grey). Isotype controls rOCB-MS3-s1 and 349040 and secondary antibodies (A21455 and 
A21236) alone did not recognize MOG (grey) (C). Figure C is modified from [101]. 
 
Binding of r8-18C5 to natively folded MOG was demonstrated by immunoprecipitation of the 
soluble extracellular domain of MOG and FACS analysis with membrane-bound MOG on TE671 
cells. The extracellular domain of MOG produced in HEK293E cells was subjected to 
immunoprecipitation. Control antibodies rOCB-MS3-s1, rOCB-MS1-s8 and -s2 did not show any 
reactivity whereas r8-18C5 yielded a single band at the expected MW by Western blot detection 
(Figure 3-4B). TE671-cells, that carry the extracellular loop of MOG [138], were stained with r8-
18C5 (blue) and the original mouse IgG 8-18C5 (red), as expected both antibodies strongly 
reacted to the MOG-positive cells. Isotype controls and secondary antibodies did not show 
reactivity (Figure 3-4C). 
3.2 Identification of MS Candidate Antigens using Protein Microarrays 
Previous studies by B. Obermeier and J. Bruder tested for reactivity of MS-OCB derived Fab-
fragments to brain homogenate in 2D-Western blots, glycolipids, infectious agents and various 
proteins on microarrays [100, 102]. In this study, screening of protein microarrays to identify 
candidate antigens was repeated with full length antibodies. Chances of target antigen 
identification are enhanced by using full length antibodies due to increased avidity compared to 
Fab-fragments. Since array hybridization is known to often yield false positive or negative results, 
potential antigen candidates were later validated by independent experiments (see section 3.3 
below). 
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Commercial Protoarrays® (Invitrogen) were used that contain about 9 400 proteins. These 
protein microarrays were used as identification tool. Each of the MS-OCB-derived rAbs and r8-
18C5 were incubated with one protein microarray and detected by a secondary anti-V5-tag 
antibody. The secondary antibody was also tested independently in the absence of any primary 
antibody. Proteins were defined as candidate antigens only if duplicate signals were detected. 
Further, duplicates with mean signal 3x enriched compared to both the signal intensity of the 
negative control and the isotype control and 5x enriched to the specific background signal were 
considered.  
Analysis of the individual arrays yielded multiple candidate antigens for each of the monoclonal 
antibodies except for rOCB-MS3-s1 and rOCB-MS1-s9. The numbers of candidate antigens, the 
mean signal of the internal negative controls, as well as the mean signal of the specific array for 
each of the tested MS-OCB-derived antibodies are listed in Table 3-1. The secondary antibody 
alone and rOCB-MS3-s1 did not yield any duplicate signal as required for a candidate. Galectin 7 
was the only protein bound by rOCB-MS1-s9 according to the selection criteria. The low mean 
signal of internal negative controls indicates generally low unspecific reactivity of the antibodies to 
proteins on the array and efficient washing procedures. The mean array signal is calculated from 
all proteins on a particular array. This value is similar for all tested antibodies and further confirms 
similar background reactivity of the individual rAbs.  
Table 3-1: Protein Microarray Results from MS-OCB Antibodies. 
For each of the MS-OCB-antibodies, background signal corresponds to the arithmetic mean of all signals from 
internal negative controls. The second column gives the mean array signal that is calculated from all human 
protein features on the array. The right column gives the number of candidate antigens according to the selection 
criteria described in section 2.5.2. 
antibody Mean array signal internal 
negative controls [AU] 
mean array signal 
[AU] 
# of candidate 
antigens 
rOCB-MS3-s1 30 430 0 
rOCB-MS1-s8 34 542 8 
rOCB-MS1-s9 19 519 1 
rOCB-MS4 23 521 4 
rOCB-MS1-s2 24 518 9 
rOCB-MS2-s5 32 444 13 
r8-18C5 18 536 5 
Sec. Ab 19 323 0 
 
3.2.1 Recognition of Candidate Antigens by r8-18C5 
Hybridization of r8-18C5 to a microarray was used as a positive control for the assay and is 
depicted in Figure 3-5. The generated signals range from 0 to 65,635 AU and are represented by 
a color scale from black over red to white. The zoomed area (Figure 3-5B) comprises block 26 
with the MOG-protein. The position of the MOG duplicate (green box, C) and features 
representing internal array controls (red and white boxes) are highlighted in this illustration.  
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Figure 3-5: Exemplary Protein Microarray probed with r8-18C5.  
The left panel depicts the entire array, including all 48 subarrays (A). The green box highlights the subarray of 
block 26. The enlarged area features positive control signals at the corners that originate from the spotted 
fluorophore-coupled proteins (red boxes), a gradient of anti-human IgG antibody (upper white box) and a V5-
protein gradient (lower white box) (B). The final enlargement shows columns 21 and 22 in row 12 of block 26, the 
position of the MOG duplicate. The array is shown in PMT850 settings (C). The candidate antigens identified 
using r8-18C5 are listed (left column, D). Mean signal intensities of the duplicates, their respective secondary and 
isotype controls (middle columns) and the resulting enrichment factors (right column) are shown (D). 
 
r8-18C5 bound to five proteins on the microarray, four of these produced enrichment factors 
above 10, including MOG. Interestingly, two proteins on the protein microarray were recognized 
by this antibody that produced higher signals than MOG. The recombinant FAM20B and CHD2 
proteins and the extracellular domain of human MOG were tested for reactivity with r8-18C5 in an 
independent approach shown in Figure 3-6.  
It was shown earlier, that binding of 8-18C5 relies on a linear epitope of MOG [141] that is 
present in native and denatured conformations. Both may be detected by Western blotting and 
FACS analysis allows detection of natively folded MOG (compare to Figure 3-4). Thus, MOG and 
the two other candidates were used in a Western blotting experiment to determine whether the 
same linear epitope is recognized by r8-18C5. Human MOG was recognized by the antibody on 
the protein microarray as was the extracellular domain of the human MOG-protein in the Western 
blotting experiment. The two candidates each yielded bands at the expected MW of 44 kDa 
(FAM20B) and 81 kDa (CHD2) in SDS-PAGE (Figure 3-6A), but were not detected by r8-18C5 by 
Western blotting (Figure 3-6B). The only protein detectable with r8-18C5 in this experimental 
setup was the extracellular domain of MOG with an approximate MW of 21 kDa.  
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Figure 3-6: Independent Approach to validate Reactivity of r8-18C5 to FAM20B and CHD2.  
Commercially obtained FAM20B and CHD2 and the extracellular domain of human MOG each yielded a defined 
band at the expected MW on SDS-PAGE (A). Except the hMOG-fragment, none of the proteins were detectable 
with r8-18C5 in the Western blotting approach (B).  
 
Possibly, another epitope is recognized on these two candidate antigens that are only present in 
natively folded CHD2 and/or FAM20B. These findings underscored the need for validation studies 
on candidate antigens identified by protein microarrays. 
3.2.2 Reactivity Profiles of OCB-derived Antibodies on Protein Microarrays 
For all candidate antigens that conform to the selection criteria (section 2.5.2), enrichment 
compared to the isotype control was determined. Enrichment factors were assumed to correlate 
with the affinity of the antibody to the candidate antigen. Table 3-2 lists all antigens identified for 
MS-OCB-antibodies, including mean signal intensity, mean secondary antibody and isotype 
control signals, and the resulting enrichment factor.   
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Table 3-2: Candidate Antigens identified by Protein Microarrays using full length rAbs.  
All candidate antigens identified with MS-OCB antibodies are listed with the nomenclature used in the Protoarray. 
The mean signals of the MS-OCB antibody, secondary antibody and isotype control for the specified protein are 
given in AU. The enrichment factor compared to the isotype control is listed in the right column. Antigens 
employed in validation assays are highlighted in green, for details on the selection criteria see section 3.3.1.  
rAb protein 
mean 
signal [AU] 
sec. Ab 
signal [AU] 
isotype 
signal [AU] 
enriched to 
isotype 
MS1-
s8 
Family with sequence similarity 84, member A 
(FAM84A) 
65 446 71 163 402 
Alcohol dehydrogenase 5 (class III), chi 
polypeptide (ADH5) 10 652 22 136 
78 
EGF-like domain-containing protein 7 11 541 211 306 38 
NECAP endocytosis associated 1 (NECAP1) 4 499 103 140 32 
Stress-induced-phosphoprotein 1 (Hsp70/Hsp90-
organizing protein) (STIP1) 
3 464 50 156 22 
GTPase, IMAP family member 4 (GIMAP4) 3 898 114 374 10 
Betaine-homocysteine methyltransferase 2 
(BHMT2) 
5 299 48 704 8 
STIP1 homology and U box-containing protein 1 4 516 28 1 133 4 
MS1-
s2 
Splicing factor, arginine/serine-rich 17A 
(SFRS17A) 
46 830 74 458 102 
Alcohol dehydrogenase 5 (class III), chi 
polypeptide (ADH5) 
9 867 22 136 73 
Immunoglobulin lambda constant 1 (Mcg marker) 
(IGLC1) 
5 634 66 174 32 
cDNA clone MGC:31936 IMAGE:4765518, 
complete cds 
3 699 113 238 16 
Immunoglobulin lambda locus (IGL@) 2 618 166 299 9 
Ig lambda chain C regions 3 146 144 410 8 
Recombinant human CTLA-4/Fc 6 921 859 1 252 6 
Serine/threonine-protein kinase VRK2 4 940 231 816 6 
WD repeat domain 5B (WDR5B) 6 226 232 1 450 4 
MS1-
s9 
Lectin, galactoside-binding, soluble, 7 (galectin 7) 
(LGALS7)  
3 782 118 397 10 
MS2-
s5 
Cytochrome b5 reductase 3 (CYB5R3), transcript 
variant M 
65 423 177 127 515 
MAP kinase interacting serine/threonine kinase 1 
(MKNK1), transcript variant 1 
65 453 133 264 248 
EF-hand calcium binding domain 4A (EFCAB4A) 46 759 126 263 178 
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rAb protein 
mean 
signal [AU] 
sec. Ab 
signal [AU] 
isotype 
signal [AU] 
enriched to 
isotype 
Chromogranin B (secretogranin 1) (CHGB) 34 038 156 216 158 
MAP kinase-interacting serine/threonine-protein 
kinase 1 
65 438 228 530 123 
Regulatory factor X, 5 (influences HLA class II 
expression) (RFX5), transcript variant 1 
28 355 131 301 94 
MAP kinase-interacting serine/threonine-protein 
kinase 2 
21 412 66 298 72 
PDS5, regulator of cohesion maintenance, 
homolog A (S. cerevisiae) (SCC-112) 
28 348 203 497 57 
FCH domain only 1 (FCHO1)  12 660 117 226 56 
TCF3 fusion partner 14 801 325 732 20 
Melanoma antigen family B, 1 (MAGEB1), 
transcript variant 1 
52 313 409 4 111 13 
Melanoma antigen family H, 1 (MAGEH1) 15 161 2 459 2 829 5 
Twinfilin, actin-binding protein, homolog 1 
(Drosophila) (TWF1)  
14 203 1 371 3 573 4 
MS4 
Splicing factor 45 4 525 106 790 6 
STIP1 homology and U box-containing protein 1 6 008 28 1 133 5 
Cortactin (CTTN), transcript variant 2 9 588 118 2 200 4 
Chromatin modifying protein 6 (CHMP6) 9 418 1 846 2 628 4 
 
Each candidate antigen was only detected with one MS-OCB antibody except the “STIP 
homology and U-box containing protein 1” and the “alcohol dehydrogenase 5 chi polypeptide”, 
which were recognized by rOCB-MS1-s8 and -MS4 or -MS1-s2 respectively. Antibodies rOCB-
MS1-s9 and MS4 generated only enrichment factors of 10 or less. For comparison, the top hits 
produced by the other OCB-derived antibodies reached factors greater than 100. From the MS-
OCB-derived rAbs, rOCB-MS2-s5 recognized the largest number of candidate antigens.  
Common molecular patterns or functional similarities were not observed. Yet, about half of the 
candidate antigens are strictly intracellular. Some candidates are membrane associated and 
locate to various cell organelles, others may be found at multiple locations, or are secreted 
proteins. Besides various localizations, a wide range of biological functions and biochemical 
characteristics are represented by the candidates.  
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For detailed validation studies, candidate antigens were selected based on enrichment factor, 
reproducibility from Fab-fragment experiments and recurring protein families or motifs. The 
particular selection criteria for the individual candidate antigens are described in detail in section 
3.3.1. The proteins selected for validation studies are highlighted in green in Table 3-2.  
3.3 Validation of Candidate Antigens 
Two features of Protoarrays® may have a critical influence on antibody-antigen recognition and 
may cause false-positive or -negative results: First, all proteins coated on the ProtoArrays® are 
derived from insect cells. Although the insect cell system is capable of introducing 
posttranslational modifications (PTMs), those still differ from the human PTM patterns and 
potentially influence the antibody binding. To exclude reactivity to insect cell specific PTMs 
introduced by the expression system, validation experiments were done using recombinant 
protein produced in an expression system other than insect cells. Preferably, proteins expressed 
in HEK-cells were chosen as these resemble best the human protein that may be encountered by 
the OCB antibodies in vivo. Additionally, the E. coli BL21 prokaryotic system was used for 
recombinant expression. This system is not capable of introducing glycosylation, a major PTM 
that may influence the antigen recognition. Second, printing the proteins onto a solid phase can 
affect the protein’s secondary structure with unpredictable impact on antibody-reactivity. 
Consequently, besides recombinant protein derived from an alternative expression system, an 
independent validation method is required.  
Therefore, candidate antigens were independently validated by immunoprecipitation or in ELISA 
using protein produced in either HEK-cells or E. coli. To enable validation experiments, the 
candidate antigens were either cloned and recombinantly expressed or obtained commercially. 
3.3.1 Selection of Candidate Antigens from MS-OCB Antibodies 
Three candidate antigens were selected from the pool of candidate antigens identified by protein 
microarray for detailed validation. Candidates with enrichment factors above 100 were 
considered. To further confine the selection, previous identification of the candidate antigen with 
the Fab-fragment and recurring appearance of protein motifs and families was considered. Thus, 
validation studies were carried out with candidate antigens FAM84A, AKAP17A, and the MKNK-
family using rOCB-MS1-s8, rOCB-MS1-s2 and rscFv-MS2-s5 respectively. Figure 3-7 depicts 
duplicate signals (left panel) of each of the candidate antigens selected for validation along with 
the according secondary antibody controls (right panel). MKNK1, MKNK1_1 and FAM84A 
reached signal intensities at saturation (represented by white color). The signal produced by 
AKAP17A (SF17A)-recognition did not reach the maximum, but showed strong reactivity. MKNK2 
elicited only medium signal (represented by red color). In all cases, the secondary antibody 
control did not yield any signal with the selected candidate antigens. The following sections 
substantiate the selection of the candidate antigens for validation from the pool of candidates and 
outline their key characteristics.  
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Information on basic structural and functional features of the candidate antigens studied in detail 
in validation experiments was retrieved from the UniProt data base [142] and the Proteinatlas 
[143] and is summarized in Figure 3-7B. 
 
Figure 3-7: Details of Candidate Antigens identified by Protein Microarray Analysis.  
The illustration shows details from microarrays scanned with PMT850 setting (A). Protein name and ID from the 
UniProt database and a description of the proteins localization and function are given (B). Of note, MKNK1 and 
MKNK1_1 spotted on the array at different locations represent the same isoform of the protein, despite differential 
naming by the manufacturer. The figure is modified from [101]. 
 
Candidate Antigen MKNK1 
MAP kinase interacting kinase 1 (MKNK1) was recognized by rOCB-MS2-s5. Three out of 13 
candidates identified for this antibody belonged to the MKNK-families 1 and 2, providing strong 
evidence for actual reactivity of rOCB-MS2-s5. MKNK1 was selected for validation experiments. 
MKNK1 and MKNK1_1, that both reached signal intensities at saturation, represent the same 
protein. MKNK1 and MKNK2 are homologous proteins that share 51 % sequence identity. The 
two family members differ in their C-terminus and a central 41 AA-stretch that is absent in 
MKNK2 thus creating a 47 kDa large protein, while the MW of MKNK1 is 51 kDa (see Figure 3-8). 
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For MKNK1, data on protein expression levels is not available, but RNA data suggests 
expression of the protein in the majority of tissues. The candidate antigen recognized by rOCB-
MS2-s5 with the highest enrichment factor was cytochrome b5 reductase, transcript variant m 
(f=515, CYB5BR3). CYB5R3 was not selected as primary candidate of rOCB-MS2-s5 because 
the MKNK-family was highly overrepresented.  
Figure 3-8: Sequence Alignment of MKNK-isoforms.  
The three aligned MKNK-isoforms share high overall similarity. The N-terminal region of MKNK2 (upper row) is 
longer compared to MKNK1 (bottom row). MKNK2 is missing a 41-AA stretch that is found in MKNK1. White 
letters in red boxes represent residues identical in all three proteins. Homologous residues are depicted as red 
letters in white boxes. Letters without boxing indicate non-conservative exchanges or insertions/deletions in one 
of the sequences. Periods represent gaps.  
 
Candidate Antigen FAM84A 
Very high signal intensities (f=402) were recorded for reactivity of rOCB-MS1-s8 to “family with 
sequence similarity 84A-protein” (FAM84A). For comparison, the signals produced by other 
candidates of rOCB-MS1-s8 were at least five-fold less. Even though enrichment factors of 70-80 
were reached, these candidates were deferred.  
FAM84A is a 32 kDa protein that is localized in the cytoplasm.  
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Candidate Antigen AKAP17A 
AKAP17A, termed SF17A in the ProtoArray®, has consistently been identified with the full length 
antibody rOCB-MS1-s2 and the corresponding Fab-fragment. Additionally, this protein elicited by 
far the highest signal that was detected for rOCB-MS1-s2. AKAP17A is present on the array in its 
52 kDa isoform, i.e. isoform 3, which was selected for subsequent experiments. The protein is 
mainly found in nuclear speckles and a minor fraction of the protein is localized in the cytoplasm.  
3.3.2 Recognition of MKNK1 by rOCB-MS2-s5 
rOCB-MS2-s5 had shown strong reactivity to multiple MKNK-family members on the protein 
microarray. MKNK1-protein used for validation studies was recombinantly produced in HEK293-
cells (amsbio).  
3.3.2.1 Immunoprecipitation of MKNK1 
To verify that the OCB-derived antibody rOCB-MS2-s5 specifically binds to MKNK1, recombinant 
candidate antigen derived from HEK-cells was subjected to immunoprecipitation and subsequent 
Western blot analysis.  
 
 
Figure 3-9: Immunoprecipitation of MKNK1. 
Only rscFv-MS2-s5 and PA5-13951 specifically 
recognized MKNK1, while control antibodies did not 
yield signals. rscFv-MS2-s5 and the commercial PA5-
13951 to MKNK1 precipitated a single protein band at 
approximately 60 kDa with similar intensity to the 
loading control. The exemplary blot is representative of 
three individual experiments. The figure is modified 
from [101]. 
 
rscFv-MS2-s5 specifically precipitated MKNK1 which was detected by Western blotting as a 
single band at approximately 60 kDa MW. The positive control antibody PA5-13951 yielded a 
slightly stronger band with the same size. The expected molecular weight of MKNK1 is 51 kDa. 
The control Fab-fragments rFab-MS3-s1 and rFab8-18C5 did not yield any signal. 
3.3.2.2 ELISA of MKNK1 
Commercial MKNK1 was directly applied to an ELISA plate. In contrast to the other validation 
experiments described here, MKNK1 was validated using the scFv-fragment of rOCB-MS2-s5. 
Fab-fragments of other MS-OCB antibodies served as negative controls. Because the scFv-
fragment possesses only a single antigen binding site, Fab-fragments were used to mirror the 
binding characteristics of scFv-MS2-s5. 
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Figure 3-10: Titration of scFv-MS2-s5 Reactivity to MKNK1 by ELISA.  
scFv-MS2-s5 specifically recognized  recombinant MKNK1 in a dose dependent manner, while none of the control 
antibodies yielded signals above background. The commercial antibody PA5-13951 recognized MKNK1 with 
slightly higher affinity than the OCB-derived scFv-MS2-s5. Data represents four independent experiments. The 
figure is modified from [101]. 
 
ELISA on MKNK1 clearly confirmed that MKNK1 is recognized by scFv-MS2-s5 in a dose 
dependent manner, as illustrated in Figure 3-10. PA5-13951 recognized MKNK1 with slightly 
higher affinity. OCB-derived Fab-fragments as well as secondary antibodies to either human IgG 
H- and L-chains, rabbit IgG, or V5-tag alone showed background reactivity. After multiple freeze-
thaw cycles, MKNK was denatured and was no longer recognized by scFv-MS2-s5 (data not 
shown). Thus, scFv-MS2-s5 recognizes a conformational epitope of MKNK1.  
To test whether the reactivity can be detected in cells, HEK293E-cells, either transfected with 
MKNK1 or non-transfected, were stained with scFv-MS2-s5. scFv-MS2-s5 did not show any 
reactivity in neither transfected nor non-transfected cells (data not shown). Although MKNK1 is 
expressed in HEK293E-cells, the positive control antibody PA5-30705 only recognized 
transfected cells but not non-transfected cells. 
3.3.2.3 MKNK1-reactivity in a larger Patient Cohort 
To test whether other MS patients were reactive to MKNK1, CSF samples were screened for 
reactivity in the MKNK1-ELISA described above. Screening revealed no difference between the 
MS- and NIND-cohort. Both groups showed only background reactivity with single values slightly 
above the group mean (Figure 3-11).  
 
 
Figure 3-11: Screening of CSF Samples from 
MS and NIND patients for Reactivity to 
MKNK1. 
CSF samples from patients from MS- and 
NIND-cohorts were tested for reactivity to 
MKNK1 by ELISA. Reactivity of the MS-group 
was not different from the reactivity detected for 
NIND-samples. Individual samples had slightly 
increased reactivity in both groups.  
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3.3.3 Recognition of FAM84A by rOCB-MS1-s8 
Recombinant FAM84A was used in two formats: First, commercially obtained FAM84A produced 
in HEK293-cells was used for initial verification of reactivity with rOCB-MS1-s8. Attempts to 
express and purify this protein in HEK293E-cells did not yield sufficient amounts of secreted 
protein. FAM84A-transfected HEK293E-cells were used for further verification of rOCB-MS1-s8 
reactivity. Second, FAM84A was recombinantly expressed and purified from E. coli. Recombinant 
E. coli-derived protein was used in ELISA to verify the reactivity of rOCB-MS1-s8 to FAM84A and 
to test a larger patient cohort for such reactivity.  
3.3.3.1 Expression of recombinant FAM84A 
FAM84A was cloned into the pTT5 vector, carrying V5- and His6-tags and the same signal 
sequence applied for antibodies. Using standard expression conditions in HEK293E-cells, the 
protein was produced, but insufficiently secreted (data not shown).  
Therefore, the FAM84A-gene with tags was transferred to the pET33b(+)-vector for prokaryotic 
expression. The protein was soluble inside E. coli BL21 bacteria and purified by IMAC using its 
His6-tag. Expression yields were approximately 5 – 6 mg of natively folded protein per liter 
bacterial culture. The expected MW of the recombinant product was 32 kDa, the purified protein 
migrated at around 38 kDa on SDS-gels. Coomassie staining revealed the presence of one major 
band at 38 kDa and three additional bands at lower MWs (Figure 3-12A). Comparing Coomassie 
staining to Western blotting results demonstrated that all three protein bands at MW of 38 kDa, 35 
kDa and 32 kDa correspond to the FAM84A protein (Figure 3-12B). These bands result from 
proteolysis and represent an N-terminally truncated FAM84A-fragment as demonstrated by 
Edman-degradation (data not shown). The protein band at around 25 kDa seen in Coomassie 
staining, but not with Western blotting, may either be an unrelated contamination or a proteolytic 
FAM84A-product that is no longer detectable by anti-V5 Western blotting. The preparation was 
analyzed by CD-spectroscopy to determine the secondary structure. The spectrum reveals evenly 
distributed secondary structures with a slightly higher prevalence of β-sheets (Figure 3-12C and 
D), these data coincide with the predicted secondary structure (section 2.4.5).  
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Figure 3-12: Characterization of recombinant FAM84A purified from E. coli.  
Staining with Commassie brilliant blue of FAM84A separated by SDS-PAGE reveals the presence of three distinct 
bands at MW of 30-38 kDa. The uppermost band represents the majority of the sample’s protein content and 
corresponds to FAM84A. The recombinant protein has an expected MW of 32 kDa (A). Western blotting, 
detecting the C-terminal V5-tag of the protein revealed that all three bands with approximately the correct size are 
FAM84A (B). The conformational state of FAM84A was determined by circular dichroism spectroscopy. FAM84A 
is predicted to have α-helix, β-sheet and disordered regions as reflected by the CD-spectrum (C and D).  
 
3.3.3.2 Immunoprecipitation of FAM84A 
To verify that the OCB-derived antibody rOCB-MS1-s8 specifically binds to FAM84A, HEK 
derived FAM84A (amsbio) was subjected to immunoprecipitation and subsequent Western blot 
analysis.  
FAM84A was individually incubated with rOCB-MS1-s8, two other OCB-derived antibodies rOCB-
MS3-s1 and rOCB-MS1-s2, r8-18C5, and the monoclonal antibody ab58330 to FAM84A as 
positive control. As shown in Figure 3-13, rOCB-MS1-s8 is the only of the OCB-derived 
antibodies that bound detectable amounts of FAM84A, migrating at approximately 38 kDa. The 
other two OCB-derived antibodies and r8-18C5, which served as negative controls, did not 
 
Figure 3-13: Immunoprecipitation of FAM84A. 
rOCB-MS1-s8 and the commercial antibody ab58330 
to FAM84A recognized a protein band at 38 kDa. The 
expected MW of FAM84A was 31 kDa. Only rOCB-
MS1-s8 and the commercial anti-FAM84A antibodies 
specifically recognized FAM84A, while the control 
antibodies did not yield signals. Additional bands at 52 
kDa and 26 kDa correspond to H- and L-chains of the 
antibodies that are cross-reactive with the secondary 
antibody. The exemplary blot is representative of three 
individual experiments. The figure is modified from 
[101]. 
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precipitate the candidate antigen. ab58330 had precipitated FAM84A. Additional bands at 52 kDa 
and 26 kDa correspond to the H- and L-chains of the antibodies used for precipitation.  
3.3.3.3 Immunofluorescence Staining of FAM84A 
The reactivity of rOCB-MS1-s8 to FAM84A was further confirmed by immunofluorescence 
staining of HEK293E-cells. These cells endogenously express low levels of FAM84A [143], thus 
FAM84A transfected as well as non-transfected cells were stained.  
 
Figure 3-14: Immunfluorescence Staining of HEK293E-cells with rOCB-MS1-s8. 
FAM84A-transfected (A) and non-transfected (B) HEK293E-cells were stained with rOCB-MS1-s8 (green) and 
PA5-30705 (red) as positive control. Both rOCB-MS1-s8 and PA5-30705 stained transfected cells in perinuclear 
regions but did not yield any signal with non-transfected cells. Scale bar: 50 µm. 
 
As shown in Figure 3-14, rOCB-MS1-s8 and PA5-30705 both stained FAM84A transfected cells 
in perinuclear regions. Detected signals had higher intensity at their outer boundaries and were 
less intense in the center. Merging the channels revealed good overlap of signals. In contrast, 
non-transfected cells were neither recognized by rOCB-MS1-s8 nor by PA5-30705.  
3.3.3.4 ELISA of FAM84A 
An ELISA was developed to enable screening of biological material of a larger patient cohort for 
reactivity to FAM84A. FAM84A was bound to the assay plate in an oriented manner via its V5-
tag. The OCB-derived monoclonal antibodies were incubated with the target antigen and then 
detected using an HRP-coupled polyclonal antibody against human IgG.  
The ELISA confirmed the reactivity of rOCB-MS1-s8 to FAM84A and substantiated the results of 
the immunoprecipitation. rOCB-MS1-s8 recognized FAM84A in a dose-dependent manner and 
control antibodies showed signals on background level. At extreme IgG-concentrations, minor 
reactivity of the control antibodies was detected. The signal of the commercial antibody ab58330 
to FAM84A showed much stronger reactivity (Figure 3-15).  
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Figure 3-15: ELISA validating the Reactivity of rOCB-MS1-s8 to FAM84A.  
rOCB-MS1-s8 recognized FAM84A in a dose dependent manner as determined by ELISA. The commercial 
antibody ab58330 to FAM84A showed very high signals at low concentrations. Control antibodies yielded 
background signal and minor reactivity at extreme IgG-concentrations. The secondary antibody controls did not 
show any signal. Data represents four independent experiments. The figure is modified from [101]. 
 
Two proteolytic forms of FAM84A (see section 3.3.3.1) that occupy α-V5 binding sites but are not 
recognized by rOCB-MS1-s8 are present. The comparably lower signal from rOCB-MS1-s8 may 
in part be due to the reduced total number of molecules available for specific recognition. 
3.3.3.5 FAM84A-reactivity in a larger Patient Cohort 
Increased reactivity to FAM84A in serum and CSF has previously been described in the context 
of the autoimmune disease inflammatory bowel disease and multiple sclerosis [95, 144]. To 
determine whether other MS patients recognized FAM84A, the FAM84A-ELISA was employed to 
screen CSF and serum samples of larger patient cohorts including various controls. The 
individual samples were used in the ELISA without prior knowledge of their classification to one of 
the groups of neurologic disorders in study.  
a) CSF Samples 
A total of 65 CSF samples was analyzed representing multiple sclerosis (MS), neuroborreliosis 
(NB), other inflammatory diseases (OID), cranial nerve palsies (CNP) and non-inflammatory 
neurologic diseases (NIND) cases. Analysis revealed no difference in reactivity to FAM84A 
between CSF from MS patients compared to NIND-samples (Figure 3-16A). However, CSF of 
patient MS1, from which rOCB-MS1-s8 was derived, shows increased reactivity reaching the 
level of the monoclonal rAb used to validate the ELISA assay (compare to Figure 3-15). Samples 
of the CNP group were found to have slightly increased mean reactivity to FAM84A. In contrast, 
samples from patients with NB and OID showed significantly increased reactivity against FAM84A 
in comparison to NIND-samples. Besides increased mean reactivity of the samples from 
inflammatory conditions, these samples also showed higher variance within the group than the 
non-inflammatory CSF samples. These groups contain the samples producing highest signals, 
but also some with signals ranging around the control levels (Figure 3-16A). 
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Figure 3-16: Reactivity against FAM84A in CSF samples of Patient Cohorts by ELISA. 
CSF samples were applied without dilution to the FAM84A-ELISA. The mean reactivity in the MS-group was not 
different from the control NIND-group. However, CSF from MS1 (depicted as Δ), from which rOCB-MS1-s8 was 
cloned, did show increased reactivity. The NB- and OID-groups showed significantly increased reactivity to 
FAM84A compared to the NIND-group. CNP-samples had slightly increased reactivity compared to the NIND-
samples (A). To account for different IgG-concentrations, OD values were corrected for IgG-concentration. After 
corrections, the increased reactivity of MS1 was no longer present. Increased mean reactivity of the NB- and OID-
groups was also removed (B). ****=p≤0.0001, *=p≤0.1, and n.s. = not significant. Data are representative of two 
independent experiments. The figure is modified from [101].  
 
NB and OID are acute inflammatory diseases of the CNS. Therefore, IgG-concentrations in these 
samples are strongly increased as compared to NIND samples. IgG titers of MS-samples were 
moderately increased in comparison to NIND-samples. NIND- and CNP-samples showed normal 
IgG-concentrations. To test whether increased total IgG in the NB- and OID-samples account for 
the FAM84A-reactivity in the assay, OD-values were corrected for IgG-concentration (Figure 
3-16B). After correction, reactivity of NB- and OID-samples was no longer different from the other 
groups. Also, the reactivity of CSF of patient MS1 did not exceed the mean reactivity of the MS-
group. 
In summary, CSF samples from patients with infectious conditions showed reactivity to FAM84A 
whereas samples from MS patients did not show enhanced reactivity except the CSF of patient 
MS1. This effect is mainly due to increased IgG-levels in inflammatory samples. 
b) Serum Samples 
Matching serum samples were analyzed in parallel to CSF samples. Analysis did not reveal any 
significant difference between mean reactivity of the groups. In both the MS and NB cohort, two 
patient samples evidently exceeded the mean signal of the group, one in the MS-group being the 
MS1 sample (Figure 3-17A). NB and OID mean signals did not differ significantly from the other 
groups, in contrast to the findings with the respective CSF-samples.  
The IgG-titers from all patient serum samples were similar as compared to CSF samples. As 
above (Figure 3-16B), OD values were corrected for IgG-concentration of the sample (Figure 
3-17B). After corrections, two MS-samples and one NB-sample were still different from the 
respective group mean.  
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Figure 3-17: Reactivity against FAM84A in Serum Samples of Patient Cohorts by ELISA.  
Serum samples diluted 1:400 were applied to the FAM84A-ELISA. In the MS-group, two samples exhibited 
increased signal intensities. One of these is serum MS1 (depicted as Δ). Also, two samples in the NB-cohort and 
one in the OID-cohort showed increased reactivity. The mean reactivity to FAM84A was similar for all groups (A). 
After corrections for IgG-concentration, the same samples of the MS-group showed increased reactivity. From the 
NB-cohort, only one sample showed consistent reactivity independent of its IgG-concentration. The increased 
reactivity of one sample in the OID-group was no longer present. IgG-concentrations were comparable between 
the groups (B). Data are representative of two independent experiments. The figure is modified from [101]. 
 
3.3.4 Recognition of AKAP17A by rOCB-MS1-s2  
AKAP17A was cloned and recombinantly produced in the cytosol of HEK-cells. The recombinant 
protein was used for immunoprecipitations to verify the reactivity of rOCB-MS1-s2 to AKAP17A. 
3.3.4.1 Expression of recombinant AKAP17A 
The AKAP17A-coding sequence, including a secretory signal peptide and C-terminal His6-tag, 
was cloned into the pTT5 vector and expressed in HEK293E-cells. As observed before with 
FAM84A, the amount of secreted AKAP17A in the cell culture supernatant was only marginal 
(data not shown), despite fair expression in the cell pellet. Various other expression systems, 
including wheat germ extract and CHO-cells, were tested for AKAP17A production, but none of 
the systems secreted sufficient amounts of AKAP17A (data not shown). Thus, protein extraction 
from cell pellets was explored as an alternative approach.  
 
Figure 3-18: AKAP17A in HEK293E lysates.  
The crude lysate of AKAP17A-transfected HEK-cells 
contains large amounts of the recombinant target 
protein with a MW of 52 kDa. An additional band with 
comparable signal strength is observed at 40 kDa. 
Weak bands at 31 and 102 kDa are present as well. 
Additional bands may represent either proteolytic 
products or aggregates or derive from endogenous 
AKAP17A-variants.  
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AKAP17A-transfected HEK293E-cells were lysed using a high-salt buffer. The lysate contained a 
plethora of different proteins (data not shown), but also contained considerable amounts of 
AKAP17A as determined by Western blotting detection with a monoclonal antibody to AKAP17A 
(Figure 3-18). The originally transfected construct at approximately 52 kDa size was present 
along with a second, smaller fragment of around 40 kDa MW. This may represent a proteolytic 
product. Data reveals the presence of AKAP17A in the soluble fraction of crude HEK293E-cell 
lysate. AKAP17A is potentially associated with lipid structures because the protein is no longer 
detectable after ultracentrifugation (data not shown). AKAP17A was not detectable in non-
transfected cell lysates (data not shown). 
A variety of different detergents and high salt conditions were tested, but failed to identify suitable 
purification conditions (data not shown). Additional purification steps were therefore deferred and 
detailed characterization of the target protein was precluded by the insufficient purity of the 
preparation. Validation experiments were carried out using the crude HEK293E-cell lysate. 
3.3.4.2 Immunoprecipitation of AKAP17A 
Immunoprecipitation of AKAP17A from crude HEK293E-cell lysate validated the reactivity of 
rOCB-MS1-s2 identified in the protein microarray screening. The crude lysate was first pre-
cleared with uncoupled Protein G beads and then incubated with rAbs covalently coupled to 
Protein G beads. The eluted molecules were analyzed by Western blotting using the monoclonal 
MCA4225Z antibody to human AKAP17A.  
The immunoprecipitation experiment confirmed binding of rOCB-MS1-s2 to AKAP17A. Both, 
rOCB-MS1-s2 and MBS711914, a polyclonal antibody to AKAP17A, precipitated a band at 
52 kDa (Figure 3-19). In contrast to rOCB-MS3-s1 and r8-18C5, which did not show reactivity to 
AKAP17A, the rOCB-MS1-s8 unexpectedly recognized AKAP17A. Of note, this antibody was 
previously found to bind FAM84A (section 3.3.3.2). Additional bands at larger MW that were 
present in the loading control were not detected in the precipitates.  
 
Figure 3-19: Immunoprecipitation of AKAP17A. 
Recombinant AKAP17A was precipitated from crude 
HEK293-cell lysate by the positive control antibody 
MBS711914 and the OCB-derived antibodies rOCB-
MS1-s8 and rOCB-MS1-s2. The expected MW of 
AKAP17A is 52 kDa. Additional bands in the loading 
control were not detected in the precipitates. Other 
control antibodies rOCB-MS3-s1 and r8-18C5 did not 
show reactivity to AKAP17A.  
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3.3.4.3 Immunofluorescence Staining of AKAP17A 
To demonstrate that rOCB-MS1-s2 recognizes AKAP17A in cells as well, HEK293E-cells were 
stained. Since AKAP17A is expressed in these cells, however in low levels [143], antigen 
transfected and non-transfected cells were used.  
 
Figure 3-20: Immunfluorescence Staining of HEK293E-cells with rOCB-MS1-s2. 
AKAP17A-transfected (A) and non-transfected (B) HEK293E-cells were stained with rOCB-MS1-s2 (green) and 
MBS711914 (red) as positive control. Both rOCB-MS1-s2 and MBS711914 stained transfected cells in perinuclear 
regions, but did not yield any signal with non-transfected cells. See Figure 3-14 for scale bar. 
 
Immunofluorescence staining of AKAP17A transfected HEK293E-cells with rOCB-MS1-s2 and 
MBS711914 further confirmed AKAP17A as target antigen. rOCB-MS1-s2, like the positive 
control, stained perinuclear regions of transfected cells. In part of the stained cells, the signal was 
locally enriched. In contrast, neither of the antibodies yielded any signal in non-transfected cells 
even though HEK293E-cells endogenously express AKAP17A [143]. 
3.4 Cross-reactivity of rOCB-MS1-s8 to FAM84A and AKAP17A 
Validation studies for AKAP17A revealed that rOCB-MS1-s8, besides binding FAM84A, also 
recognized AKAP17A. The major hypothesis to explain this finding is that both antigens share a 
structural characteristic that allows rOCB-MS1-s8 to bind to both proteins. This may be a similar 
AA-sequence or a secondary structure that forms similar epitopes. Therefore, the AA-sequences 
of both target antigens AKAP17A and FAM84A were aligned to detect sequence stretches with 
high similarity and secondary structure predictions were analyzed to find structural characteristics 
that may cause the observed cross-reactivity. 
3.4.1 Identification of potentially cross-reactive Epitopes 
Global alignment of the two AA-sequences did not disclose highly similar regions, but local 
alignments of 20 AA-stretches of FAM84A to the complete AKAP17A sequence revealed two 
sections that are similar in the two proteins (Figure 3-21). 
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Figure 3-21: Potential Epitopes of AKAP17A and FAM84A for rOCB-MS1-s8 Recognition.  
AKAP17A AA370-391 (A) and AA305-323 (B) are shown in comparison to FAM84A AA182-203 and AA258-279 
respectively. The two AA-stretches were selected based on their high AA-sequence similarity. The AA370-391 
stretch in AKAP17A shares high homology with AA182-203 of FAM84A (A). Even higher homology is seen 
between the AA305-323 in AKAP17A and AA258-279 in FAM84A (B). Blue characters indicate positively charged 
AA. Red characters represent negatively charged residues. Identical residues are represented by a vertical line, 
colon depicts highly similar residues and periods weakly similar residues, dashes represent gaps. The figure is 
modified from [101].  
 
First, FAM84A AA182-203 comprises six AA that closely resemble AA370-391 of AKAP17A. 
There are four identical and two highly similar AA in close proximity surrounded by non-
homologous sequences (Figure 3-21A). This stretch carries hydrophobic AA interspersed with 
few charged ones. Second, FAM84A AA258-279 encompasses a ten AA-stretch with six identical 
and three highly similar residues to AKAP17A AA305-323 (Figure 3-21B). The FAM84A 
sequence, and even more so the corresponding AKAP17A sequence, is characterized by a 
sequence of charged AAs only interrupted by few hydrophobic residues. Such stretches of 
charged residues are frequently located on the surface of proteins in their native state, because 
this is thermodynamically favorable.  
 
Figure 3-22: Detail of Secondary Structure Predictions of FAM84A and AKAP17A.  
Secondary structure predictions revealed that the potentially cross-reactive epitope between FAM84A (A and B) 
and AKAP17A (C and D) is located to an α-helical structure (pink barrel) in both proteins. Two homologous 
candidate epitopes are depicted that encompass AA182-203 (A) and AA370-391 (C), and AA258-279 (B) and 
AA305-323 (D). For each AA-stretch, the secondary structure prediction is depicted on top of the AA-sequence. 
Charged AAs are color-coded: red letters indicate negatively charged residues, blue indicates positively charged 
residues.  
 
ELISA and Western blot experiments using FAM84A and AKAP17A showed that the epitopes are 
not recognized when denatured (data not shown). Therefore, a secondary structure is necessary 
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to form the epitope recognized by rOCB-MS1-s8. Hence, the highly similar AA-sequences 
identified above are not sufficient for rOCB-MS1-s8 to recognize both proteins, but the secondary 
structure plays a crucial role. Secondary structure predictions [134] revealed that the two 
corresponding sequence stretches, described above, are most probably embedded in α-helical 
structures in the respective protein’s native conformation (Figure 3-22). 
 
Figure 3-23: Helical Wheel Projections of FAM84A and AKAP17A Epitopes.  
Epitopes AA182-203 and AA258-279 of FAM84A (A and B) and the respective corresponding sequences of 
AKAP17A (C and D) are depicted. The projection approximates the arrangement of AAs in an α-helical structure. 
Hydrophobicity is color-coded and represented by shapes: blue pentagons are positively charged residues, red 
triangles represent negative charges. Hydrophobicity decreases from green to yellow. Hydrophobic residues that 
are depicted as diamonds. Circles represent hydrophobic AAs. Empty circles represent large neutral, hydrophilic 
residues. The corresponding sequences in A and C share a similar distribution of hydrophilic and hydrophobic 
residues. The helical wheels shown in B and D share higher similarity. Charged residues are concentrated at the 
bottom half of the wheel and are exactly matched by its counterpart.  
 
A full α-helical turn of 3.6 AAs translates into every third to fourth AA facing the same direction of 
the helix as illustrated in Figure 3-23. As a consequence, only some AAs of a sequence stretch 
may be involved in the binding reaction. Resulting from the high sequence similarity, AA-
distributions of AA258-279 and AA209-318 in the helix prediction are highly similar (Figure 3-23B 
and D). The similarity of the other candidate epitope (Figure 3-23A and C) is clearly lower, but still 
features regions with distinct similarity. In summary, sequence analysis and secondary structure 
predictions revealed two candidate epitopes that share similarity between the two antigens, are 
predicted to form similar secondary structures, and are probably located on the protein surface. 
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3.4.2 Mutant Screening of FAM84A with site directed AA-exchange 
To clarify whether these candidate epitopes are involved in antigen recognition by rOCB-MS1-s8, 
alanine mutants of FAM84A were produced. In each mutant, a single AA of the original FAM84A 
sequence is replaced with alanine. As depicted in Figure 3-21, three AAs were exchanged in 
candidate epitope AA182-203 and five AAs in candidate epitope AA258-279. All mutants were 
expressed in and purified from E. coli (data not shown) and subsequently analyzed for reactivity 
with rOCB-MS1-s8 using the FAM84A-ELISA.  
 
Figure 3-24: ELISA FAM84A-Mutant Screening.  
Individual AAs of the putative epitopes were exchanged to alanine. AA-exchanges at positions AA188, AA190, 
and AA191 in FAM84A did not change the antigen recognition by rOCB-MS1-s8. Substitutions at positions 
AA263, AA264, AA268, and AA271 considerably reduced binding of the antibody as compared to wild type 
FAM84A. Exchanging the glutamic acid at position AA267 did not influence the binding. The control r8-18C5 did 
not react with any of the mutants. Data is representative of four independent experiments. Error bars indicate 
standard deviation. The figure is modified from [101]. 
 
FAM84A-ELISA screening revealed that the candidate epitope AA182-203 does not influence the 
recognition by rOCB-MS1-s8, while some AAs of the AA258-279 candidate epitope did change 
the binding capacity of the antibody to its antigen. Alanine substitution at positions AA263, AA268 
and AA271 markedly reduced the reactivity detected by ELISA. Position AA264 may also play a 
role in antigen recognition in this case. None of the single alanine exchanges completely 
abolished the binding of rOCB-MS1-s8. The final preparation was free of contaminants detectable 
on SDS-PAGE. The positions of the mutations were selected based on homologous regions of 
the AKAP17A and FAM84A proteins. The secondary structure in this segment was predicted to 
form an α-helix and the helical wheel projection of the individual residues revealed that all 
mutated positions locate to the same side of the helix. As all of these residues are charged, it is 
conceivable that this side of the helix faces the solvent in the natively folded protein. AAs 
identified to be of relevance, locate to the same side of the helix (compare Figure 3-23) however 
AA267 also faces the same direction, but does not influence the interaction. Overall, the findings 
confirm the concept of a conformation dependent epitope located in an α-helical structure at 
AA258-279 in FAM84A that is targeted by the rOCB-MS1-s8 and shares strong homology with its 
counterpart in AKAP17A.   
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3.5 Antigen Recognition of the encephalitogenic rAb-Ip2 
In contrast to MS, where chronic inflammation is a hallmark of pathogenesis, there is a broad 
spectrum of CNS diseases with acute neuroinflammation.  
Analysis of CSF from patient Ip2, who had a severe form of acute encephalitis, revealed 
monoclonal expansion of a single antibody species. Using next generation sequencing of CSF B-
cells, E. Beltrán identified and cloned the expanded antibody species (unpublished data). The 
V(D)J-regions of the H- and L-chains of Ab-Ip2 were cloned into the pTT5 H- and L-chain 
cassette vectors and expressed in HEK293E-cells as full length IgG1-molecules.  
The recombinant antibody, termed rAb-Ip2, was biochemically analyzed as previously described 
for the OCB-derived antibodies (see section 3.1.1). The antibody formed a heterodimer that 
disintegrated upon treatment with a reducing agent and secondary structure proportions 
determined by CD-spectroscopy conform to the other rAbs.  
 
Figure 3-25: Characterization of rAb-Ip2. 
rAb-Ip2 separated by SDS-PAGE under reducing and non-reduicng conditions and Commassie brilliant blue 
staining. Two protein bands at 25 kDa and 57 kDa were detected under reducing conditions, confirming the 
disassembly of the heterodimer. Under non-reducing conditions, a single protein band at 160 kDa was detected 
corresponding to the full length antibody (A). Western blotting, detecting the H-chain C-terminal V5-tag confirmed 
these findings (A and B). The conformation of rAb-Ip2 was determined by circular dichroism spectroscopy. Large 
parts of antibodies fold into ß-sheet interconnected by turns and disordered segments as reflected by the CD-
spectrum (C and D).  
 
3.5.1 Recognition of the GABAARα1ex by rAb-Ip2 
It has been shown that CSF from patient Ip2 strongly reacts to the GABAAR α1-subunit [111]. 
Here, it was therefore tested whether rAb-Ip2 would also recognize the GABAAR α1-subunit. 
Since only the extracellular domain is accessible in intact cells, the extracellular domain of the 
GABAAR α1-subunit was cloned into the vector pET33b(+) and recombinantly expressed in E. coli 
BL21. The protein fragment formed IBs in the E. coli cytoplasm. These were purified and 
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solubilized in guanidine hydrochloride and yielded about 20 mg/g bacterial wet weight. Solubilized 
protein was refolded by rapid dilution in PBS. Attempts to subsequently concentrate the protein 
were not successful as the protein was lost due to aggregation or adsorption to the ultrafiltration 
membrane. Hence, the protein was used in the dilute solution of approximately 15 µg/ml. SDS-
PAGE analysis demonstrated a single band at the expected MW of 31 kDa. CD-spectroscopic 
analysis was not possible due to the low concentration of refolded protein in solution. 
GABAARα1ex-ELISA was employed to determine whether the isolated monoclonal rAb-Ip2 
recognizes the extracellular domain of the GABAAR α1-subunit. The assay revealed significantly 
higher reactivity of rAb-Ip2 to GABAARα1ex as compared to the MS-OCB-derived control 
antibody 1039-s1 and the humanized r8-18C5 (****=p≤0.0001). The C-terminal V5-tag of the 
GABAAR-fragment was used as positive control. Both secondary antibody controls alone did not 
yield any signal.  
 
Figure 3-26: Recombinant GABAARα1ex and its Recognition by Ab-Ip2 in ELISA.  
SDS-PAGE of the refolded extracellular domain of GABAAR α1-subunit yielded a single band at approximately 
28 kDa. The calculated MW of the GABAAR-fragment is 31 kDa (A). ELISA demonstrated binding of rAb-Ip2 to the 
extracellular domain of the GABAAR α1-subunit. rAb-Ip2 recognized the recombinant GABAAR-fragment, while 
MS-OCB-derived control and r8-18C5 did not show any reactivity (****=p≤0.0001, n=5). Reactivity did not differ 
from the positive control antibody that detected the V5-tag of the recombinant protein (B). 
 
3.5.2 Reactivity Profile of rAb-Ip2 on Protein Microarrays 
To assess the hypothesis that the encephalitis of patient Ip2 might have a paraneoplastic 
background, reactivity of rAb-Ip2 to other protein antigens was analyzed. To this end, rAb-Ip2 was 
applied to a protein microarray to identify potential peripheral cross-reactive antigens that might 
have induced an immune response to the GABAAR.  
The array revealed reactivity to a total of 17 antigen candidates. The mean signal of the internal 
negative controls (18 [AU]) was comparably low, while the mean array signal (736 [AU]) was 
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increased compared to the MS-OCB-derived rAbs. The candidate antigens are listed along with 
the mean signal intensity of rAb-Ip2 and the controls as well as the enrichment factor in Table 
3-3.  
Table 3-3: Candidate Antigens identified for Ab-Ip2 using Protein Microarrays.  
The mean signals of rAb-Ip2, secondary antibody and r8-18C5 (isotype control) for the specified protein are given 
in AU. The enrichment factor compared to the isotype control is listed in the right column. Antigens employed in 
validation assays are highlighted in green. Zinc-binding proteins are indicated by grey background. For details on 
the selection of these proteins see section 3.5.3. 
Ab Protein 
Mean signal 
[AU] 
Sec. Ab 
signal [AU] 
Isotype 
signal [AU] 
enriched to 
isotype 
 
Mitogen-activated protein kinase 7 (MAPK7), 
transcript variant 3 
12 406 140 546 22.7 
Isovaleryl-CoA dehydrogenase, mitochondrial 15 077 3 656 1 323 11.3 
Zinc-finger protein 207 (ZNF207), transcript 
variant 2 
6 149 452 602 10.2 
Cysteine- and glycine-rich protein 1 (CSRP1) 10 306 942 1 324 7.8 
Cysteine- and glycine-rich protein 2 (CSRP2) 49 741 7 145 8 908 5.6 
Putative E3 ubiquitin-protein ligase SH3RF2 7 806 352 1 501 5.2 
ATP-dependent RNA helicase DHX8 4°222 177 944 4.5 
STIP1 homology and U-box containing protein 1 4 982 28 1 133 4.4 
Outer dense fiber protein 3-like protein 2 5 118 264 1 259 4.1 
Sciellin (SCEL) 5 680 443 1 422 4 
Leukocyte receptor cluster (LRC) member 1 
(LENG1) 
3 721 175 966 3.9 
Cell cycle associated protein 1 (CAPRIN1), 
transcript variant 1 
6 271 261 1 683 3.7 
Cortactin (CTTN), transcript variant 2 7 799 118 2 200 3.5 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
(DDX17), transcript variant 2  
6 745 421 1 905 3.5 
Cystein-rich protein 2 (CRIP2) 14 160 2 073 4 158 3.4 
Serine/threonine kinase 40 (STK40) 5 121 3 211 1 508 3.4 
C-C motif chemokine 21 4 598 354 1 411 3.3 
 
Overall, the signal intensities of the candidate antigens measured in the isotype control (r8-18C5) 
treated array are increased compared to the MS-OCB-derived rAbs and this converts into low 
Ip2 
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enrichment factors. The cysteine- and glycine-rich protein 2 (CSRP2) was the only protein that 
elicited a very high signal approaching saturation. Due to the signal intensity of the isotype control 
the high signal did not translate into a high enrichment factor. The strongest enrichment was 
found for the mitogen-activated protein kinase 7 (MAPK7).  
The STIP 1 protein, which had previously been identified as candidate antigens for rOCB-MS1-s8 
and rOCB-MS4, was recognized by rAb-Ip2 at comparable levels. The pool of candidate antigens 
contains a total of six zinc-binding proteins, representing about one third of all candidates. Four of 
these carry a LIM-domain: CSRP1, CSRP2, CRIP1 and sciellin. The zinc-finger protein 207 and 
the putative E3 ubiquitin-protein ligase both are zinc-binding proteins but mediate this interaction 
via a different zinc-binding motif.  
Several subunits and transcript variants of GABAAR, including the GABAAR-α1-subunit, are 
present on the array. None of these showed enhanced reactivity with rAb-Ip2 even though the 
reactivity to the extracellular domain of the GABAAR-α1-subunit had previously been 
demonstrated by ELISA.  
3.5.3 Selected Antigen Candidates for rAb-Ip2 
From the list of candidate antigens identified for rAb-Ip2, two entities were selected for further 
validation. MAPK7 was selected because it had the highest enrichment factor. The LIM-domain 
proteins, especially CSRP-proteins, represented another focus, because multiple members of this 
gene family were identified as candidate antigens. CSRP2 elicited the highest signal intensity. 
CRIP2 and CSRP1 showed comparably lower signal intensities of about the level detected for 
MAPK7. Figure 3-27A depicts the signals for each of the candidate antigens selected for 
validation and the appropriate secondary antibody control spots. The protein name and UniProt-
ID and basic information on localization and function of the protein are summarized in Figure 
3-27B. 
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Figure 3-27: Details of the Protein Microarray developed with the Ab-Ip2.  
The most enriched signal compared to controls was found with MAPK7 (uppermost panel). Three closely related 
LIM-domain proteins were recognized by rAb-Ip2. Highest signal intensity was elicited by CSRP2, CRIP2 and 
CSRP1 showed slightly lower signal intensities reaching similar levels like the MAPK7 (left panel). The secondary 
antibody control did show some signal for CSRP2 but strongly reduced in comparison to the signal produced by 
rAb-Ip2. The other secondary antibody controls did not elicit increased background signals (right panel). 
Increasing brightness of red represents stronger signals with strongest signals being depicted in white (A). Protein 
name and Uniprot-ID as well as localization and functional information of candidate antigens selected for 
validation (B). 
 
Candidate Antigen MAPK7 
Mitogen-activated protein kinase 7 (MAPK7) is a ubiquitously expressed protein that plays a role 
in cell survival, proliferation and differentiation in response to extracellular stimuli through 
transcriptional regulation. It is therefore also named extracellular signal regulated kinase 5. The 
88 kDa protein localizes to the cytoplasm or nucleus, depending on its functional state.  
Candidate Antigen LIM-proteins 
CSRP2 is a 21 kDa protein that contains two zinc-binding LIM-domains. It is expressed in most 
cells and localizes to the cytoplasm or the nucleus. CSRP1 is highly similar to CSRP2 with ≈80 % 
sequence identity (Figure 3-28) and localizes to intracellular regions. The exact function of these 
proteins is not understood. Both proteins contain about 15 % of glycine and 8 % cysteine 
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residues which are essential for the zinc-binding activity. CSRP2 was selected for validation since 
this protein gave the highest array signals and shares fundamental similarity with CSRP1. 
 
Figure 3-28: Sequence Alignment of Ab-Ip2 Candidate Antigens with LIM-domain.  
The CRIP2-protein (upper row) shares similarities with both CSRP2 and CSRP1 (middle and bottom row), in 
particular the zinc-coordinating cysteine- and histidine-residues are conserved. The residues that form the LIM-
domains and coordinate Zn2+-ions are marked by arrows. AAs in between the zinc-binding LIM-domains show 
lesser conservation. The two CSRP-proteins share high homology even in the non-conserved regions. See 
legend Figure 3-8 for explanations of symbols. 
 
CRIP2 also contains two zinc-binding LIM-domains, but only shares 34-39 % sequence identity 
with the CSRP-proteins (Figure 3-28). This protein is 208 AAs in length and has a slightly higher 
MW of 23 kDa as compared to the CSRPs. CRIP2 was selected for further validation as well. All 
three LIM-domain proteins carry a positive net charge due to the high number of lysine residues.  
3.5.4 Recognition of CSRP2 by rAb-Ip2 
The LIM-domain protein CSRP2 is strongly expressed in HEK293E cells, CSRP1 and MAPK7 are 
expressed at medium levels, and the expression of CRIP1 is not detectable in this cell line [143]. 
Therefore, non-transfected HEK293E-cells were stained with rAb-Ip2 for initial validation of 
reactivity. rAb-Ip2 stained perinuclear regions, while r8-18C5 and the secondary antibody did not 
yield any signal (Figure 3-29). The staining pattern corresponds to the expected cytoplasmic or 
nuclear localization of the proteins but does not allow conclusions on the identity of the stained 
structure.  
 
Figure 3-29: Immunofluorescence Staining of non-transfected HEK293E-cells.  
Ab-Ip2 stained perinuclear regions in HEK293E cells (red). r8-18C5 and the secondary antibody did not show 
staining. Cell nuclei are depicted in blue. Pictures by courtesy of E. Beltrán. 
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Reactivity of rAb-Ip2 towards MAPK7, CSRP2 and CRIP1 was therefore analyzed in 
immunoprecipitation experiments with purified recombinant protein produced in HEK293-cells. 
Besides rAb-Ip2, the OCB-derived rOCB-MS3-s1 and r8-18C5 were used as controls. rAb-Ip2 
precipitated CSRP2, while the other antibodies only showed background reactivity at the 
expected MW of 21 kDa. An additional band at 50 kDa was detected with rAb-Ip2 (Figure 3-30). 
Recognition of CSRP2 by rAb-Ip2 was lost upon repeated freeze-thaw cycles or prolonged 
storage of the recombinant protein at -80 °C (data not shown). The other LIM-domain protein, 
CRIP2, and MAPK7 did not show any reactivity in the immunoprecipitation assays.  
 
 
Figure 3-30: Immunoprecipitation of MAPK7 
and two LIM-domain Proteins by rAb-Ip2  
rAb-Ip2 precipitated recombinant CSPR2, yielding 
a band at 25 kDa, while the control antibodies 
rOCB-MS3-s1 and r8-18C5 showed background 
signal at this MW. An additional band at 48 kDa 
was detected for rAb-Ip2, but none of the control 
antibodies. Arrows indicate the position of gel 
slices cut for mass spectrometric analysis. Slices 
were cut from all three CSRP2-
immunoprecipitations. The candidate antigens 
MAPK7 and CRIP2 did not elicit any specific 
reactivity in the immunoprecipitation assay. The 
blot is representative of two independent 
experiments.  
 
CSRP2-precipitates were additionally analyzed by mass spectrometry. Six slices from each 
CSRP2-immunoprecipitation (rAb-MS3-s1, r8-18C5 and rAb-Ip2) were cut at the appropriate 
region between 20-25 kDa from the Coomassie-stained SDS-PAGE gel (see Figure 3-30) and the 
proteins were in-gel digested with trypsin. Mass spectrometric analysis revealed the presence of 
CSRP2-specific peptides in three of the six slices taken from the rAb-Ip2 loaded lane. None of the 
slices cut from the control antibody lanes carried CSRP2-specific peptides. The unspecific 
background at 25 kDa in control antibody lanes, detected by Western blotting, is attributable to 
the antibody light chains that dissociate during the elution process, since this band was also 
observed in control assays that omitted the CSRP2 completely (data not shown). 
Figure 3-31 shows an enlargement of the spectra obtained with the three rAbs. Exemplarily, the 
1099.5 peak is depicted that corresponds to the CGDSVYAAEK-peptide (carbamidomethylated 
cysteine) which is solely detected with rAb-Ip2. Because the antibody L-chain migrates at similar 
MW, non-CSRP2-specific peaks are detected as well.  
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Figure 3-31: Detail from mass spectrometric Analysis of CSRP2 Immunoprecipitation. 
The 1099.5 mass corresponds to the CSRP2-specific peptide sequence CGDSVYAAEK (carbamidomethylated 
cysteine) and was only detected in slices taken from the lane loaded with rAb-Ip2-eluate. Other strong signals not 
attributable to CSRP2, for example the peak at 1124.5 in rOCB-MS3-s1, correspond to antibody L-chain peptides. 
CSRP2-specific peptides were not found in lanes loaded with eluates from rOCB-MS3-s1 and r8-18C5. 
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4 Discussion 
This study aimed at identifying the target antigens of OCB-antibodies from patients with 
neurologic diseases. In the first project target antigens of OCB-antibodies from patients with MS 
were identified. The OCB-antibodies had previously been identified using a newly developed 
strategy by B. Obermeier. This technique allows differentiating distinct expanded antibody 
species from the polyclonal background of IgG and from other OCBs in CSF samples. H- and L-
chains were matched by combining proteome analysis and sequencing of the IgG-transcriptome 
(see Figure 1-8) [100]. This method allowed for the first time to characterize and recombinantly 
produce distinct OCB antibodies. As all previous studies that investigated target molecules of 
OCBs could not link the target antigens to distinct expanded antibody species (see section 1.2.3). 
Here, three target antigens of distinct OCB-antibodies were identified that showed a common 
pattern: all three are intracellular proteins, not specific for CNS-tissue.  
The second project focused on the expanded antibody species from CSF of a patient with 
GABAAR-encephalitis. CSF from this patient was found to react to the GABAAR α1-subunit and 
presumably causes neurologic symptoms [111]. Deep sequencing of the CSF IgG-repertoire 
revealed antibody rAb-Ip2 as an expanded species. The pathogenesis of GABAAR-encephalitis in 
this patient is unknown, but neurologic symptoms might possibly been caused by a cross-
reactivity of an antibody to GABAAR and an unknown tumor antigen. Here, binding to the 
GABAAR α1-subunit was confirmed and a potential systemic target antigen of rAb-Ip2, that might 
have initiated such a paraneoplastic process, was identified. 
4.1 Recombinantly expressed rAbs  
In previous experiments, OCB-derived Fab-fragments were used for antigen searches but these 
did not yield conclusive results [100, 102]. Here, full length antibodies were recombinantly 
expressed which mirror the natural structure and avidity of antibodies. The presence of two 
antigen binding sites can stabilize complexes and may allow identification of low affinity 
interactions.  
A total of eight antibodies were expressed as full length IgG1-molecules in HEK293E-cells. Six of 
the antibodies derived from MS-OCBs, one derived from the GABAAR-encephalitis patient Ip2 
and one antibody represented the humanized MOG-specific r8-18C5, serving as a control. All 
antibodies were produced as heterodimers and all but rOCB-MS2-s5 yielded fair amounts of 
protein. The final preparations were of sufficient purity as demonstrated by Coomassie staining of 
SDS-gels. The identity of each of the antibodies was confirmed by Western blotting and mass 
spectrometry. CD-spectroscopy demonstrated that approximately 40 % of the protein had a β-
sheet conformation and marginal amounts α-helical structures were detected. These findings 
correlate well with CD-spectra and x-ray diffraction studies on other antibodies [145].  
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Expression yields of the full length rOCB-MS2-s5 from HEK cell supernatant were approximately 
100-fold lower than expected from the other rAbs. The marginal amounts of purified antibody 
allowed screening for antigen candidates with protein microarrays but no subsequent validation 
experiments. Thus, this antibody was cloned and expressed as scFv in E. coli. Detailed 
biochemical analysis of the corresponding scFv-fragment of rOCB-MS2-s5 confirmed that the 
scFv matches the quality of the full length antibodies regarding purity and conformation and thus 
was suited for validation experiments. 
4.1.1 Recognition of native and denatured Forms of MOG by r8-18C5 
The general capability of the full length antibodies expressed in HEK293E-cells to bind their 
target antigen was shown exemplarily for r8-18C5. The reactivity of the original mouse 8-18C5 
antibody to MOG is well established [127]. Reactivity of r8-18C5 to MOG was demonstrated in 
three setups: dot blot, immunoprecipitation and flow cytometry. For dot blotting, the target protein 
in applied to a nitrocellulose membrane, which often results in conformational changes and 
denaturation of the protein. In immunoprecipitation experiments and flow cytometric analysis 
using living cells, MOG is present in its native conformation. All three experimental setups 
showed specific recognition of MOG by r8-18C5. The interaction of r8-18C5 and MOG is 
insensitive to the conformational status of the target antigen. 
These experiments also demonstrated that none of the MS-OCB-derived antibodies rOCB-MS1-
s2, rOCB-MS1-s8, and rOCB-MS3-s1 recognized the extracellular domain of MOG, although 
components of the myelin sheath such as MOG [146], MAG [147], and MBP [148] are suspected 
MS-antigens [149] and it was suggested that OCB would recognize myelin antigens [96]. 
Additionally, these proteins play a prominent role in animal models of the disease [150] and are 
CNS-specific target structures that may be accessible to antibodies.  
4.2 Proof of Concept - Neuroborreliosis 
In a parallel project, CSF from NB patients was used in a study by M. Senel to demonstrate that 
OCB-antibodies in NB represent disease-related antibodies. NB is an inflammatory disease of the 
CNS caused by borrelia-infection [151]. NB patients have OCBs and show strong reactivity to 
whole borrelia-lysates in later disease stages, suggestive of anti-borrelia specificity of the 
expanded antibodies in CSF [152, 153]. Using the method to isolate and characterize OCB-
antibodies, rOCB-NB1-s13 was identified. rOCB-NB1-s13 was cloned, recombinantly expressed 
and employed in clinical routine tests for reactivity against borrelia. These experiments revealed 
increased reactivity of rOCB-NB1-s13 to whole borrelia lysates and identified protein “p21”, 
representing a 21 kDa-fragment of BBK53 [154] from B. burgdorferi, as target antigen (M. Senel, 
[101]). Reactivity of OCB-antibodies from CSF of patients with CNS-infections to borrelia is long 
known [155]. Therefore, these findings confirmed that the OCB-derived rOCB-NB1-s13 is 
involved in the patient’s immune reaction against the causative agent and that the method to 
identify and clone distinct OCB-antibodies indeed yields functionally relevant antibodies.  
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4.3 Identification and Validation of Candidate Antigens of MS-OCBs 
Despite intensive antigen searches, specific factors that initiate and promote MS pathology 
remain elusive. Besides components of the myelin sheath, numerous other antigens have been 
proposed, including viral and bacterial components [89, 156-159] as well as self-structures like 
DNA, intracellular proteins [74, 160], and lipids [86, 87, 94]. These previous studies used either 
unfractionated CSF samples of MS patients or antibodies derived from single CSF B-cells. Both 
approaches suffer major shortcomings: using full CSF for screening purposes is complicated by 
the low IgG-concentration in the samples and signals may be superimposed by the high 
polyspecific background of antibodies. In contrast, single cell derived antibodies do not 
necessarily represent a distinct OCB-antibody, but may represent polyclonal background 
antibodies in CSF [98]. 
To identify candidate antigens of OCB-derived antibodies rOCB-MS1-s2, -MS1-s8, -MS1-s9, -
MS3-s1 and -MS4, B. Obermeier and J. Bruder applied the corresponding Fab-fragments to 
different screening assays. Clinical routine tests were used to test for reactivity against viruses, 
including Epstein-Barr, measles and herpes simplex, chlamydia and intracellular components like 
nuclear and neutrophil cytoplasmic factors. Further, reactivity against DNA, insulin, lipids and 
human brain homogenates was tested. However, these experiments yielded negative or 
inconclusive results [100, 102].  
J. Bruder used protein microarrays to screen a larger panel of protein antigens. Experiments 
using Fab-fragments identified candidate antigens, which had not been verified so far [102]. In the 
present study, full length rAbs were used on protein microarrays. Full length rAbs have two 
antigen binding sites, thus higher avidity for the antigen as compared to the Fab-fragment and 
therefore increase the chances of identifying candidate antigens.  
4.3.1 Protoarray Screening as Tool for Antigen Identification 
Protein microarrays are a tool to rapidly screen for reactivity of a monoclonal antibody to a large 
number of candidate antigens [161, 162]. Different microarrays have previously been used by 
others to analyze the antigen specificity of antibodies from full serum [163] or CSF samples [82, 
164, 165] of MS patients. Here, Protoarrays® were used to assess the reactivity of OCB-derived 
antibodies to protein antigens. A protein binding profile of each of the antibodies was created and 
the field of potential antigens narrowed down. 
More than 9 000 proteins are spotted in duplicates on the Protoarrays®. According to the 
manufacturer, all proteins are expressed in insect cells and present in their native conformation. 
This approach enables parallel testing of a variety of proteins representing distinct structural and 
functional properties on a lab scale. Further, the array displays sufficient amounts of compounds 
that may be beneath the detection limit on the cellular- or tissue-level or difficult to access. r8-
18C5 was used as positive control since its cognate antigen (MOG) is also spotted on the array.  
Discussion 
 
85 
The use of protein microarrays has several shortcomings: First, as all proteins are expressed in 
an insect cell system, they may differ from their human original in their posttranslational 
modifications (PTMs) and thus the accessibility of epitopes [166]. Second, the coating process 
may influence individual proteins differently. While most proteins keep their conformation during 
coating, a number of others may lose their natively folded state. Antibody-antigen complexes that 
rely on conformational epitopes will not be formed. Conversely, denatured proteins may exhibit 
structures that may not appear naturally, generating misleading results [167]. All proteins 
underwent purification but the purity of the particular entity is not known. Thus, it is possible that 
reactivity measured at a distinct spot is not directed at the coated protein, but at some co-purified 
contaminant. Therefore validation of the results using an independent method and candidate 
antigens produced in another expression system is imperative. To this end, candidate antigens 
produced in either HEK293-cells or E. coli were subjected to validation studies using independent 
experimental setups.  
4.3.1.1 Fab-fragments versus full length OCB Antibodies on Protein Microarrays 
The overall reactivity profiles of the OCB-derived full length antibodies were compared to the 
results of the corresponding Fab-fragments.  
Identification of target antigens depends on the stability of the antibody-antigen-complex, which is 
a function of the antibody’s affinity. It may be assumed that somatic hypermutation (SHM) 
introduced during the maturation process confer considerable affinity to these antibodies, 
however, it is not known a priori. Increasing the number of binding sites, i.e. avidity, stabilizes 
complexes and may therefore improve the screening for candidate antigens. 
The mean array signal is comparable in Fab- and full length antibody-probed microarrays. The 
mean signal of the internal negative controls is clearly reduced in the full length antibody 
experiment compared to the Fab-probed arrays. This may in part be explained by the differential 
experimental setup. Because Fabs have a single antigen binding site and bind weaker to their 
target, the total amount of Fab-fragments had to be increased and the washing procedure 
minimized. Further, a secondary antibody to human IgG (H+L) was used, which might also 
recognize some epitopes on the array. In contrast, the antibody-probed arrays were developed 
using the V5-tag/anti-V5-system that is recommended for this assay, because it is much more 
specific. This may explain the clear reduction of internal negative control signals when using the 
full length antibodies.  
Comparison of the Fab and full length data further revealed a considerable increase in enrichment 
factors. Using Fab-fragments a total of 34 antigen candidates was identified, six of these (≈18 %) 
showed signals that exceeded their corresponding controls by a factor of ten or more [102]. In 
contrast, using the respective full length antibodies, approximately half (13 out of 27) of all 
candidate antigens had enrichment factors larger than ten. This observation clearly underscores 
the benefit of the full length antibodies in this experiment as it indicates a better signal to noise 
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ratio. Generally, lot-to-lot differences may also account for minor changes in the identified 
reactivity profile.  
From a functional point of view, both experiments yielded proteins classified as kinases, 
GTPases, transcription and regulatory factors. Thus, the vast part of candidate proteins localizes 
to intracellular compartments. 
Apart from that, the overlap of results from the two protein microarray analyses using Fab-
fragments and full length antibodies is small. The only candidate antigen consistently recognized 
in both approaches is AKAP17A. This may be attributed to the improved discrimination of signals 
from background reactivity due to higher avidity of full length antibodies. This is also reflected by 
considerably increased enrichment factors.  
Except FAM84A, which has been associated with MS in another study [95], none of the identified 
candidate antigens had previously been linked to MS. Overall, for validation experiments, 
candidate antigens identified with full length antibodies were selected. 
4.3.1.2 r8-18C5 recognizes MOG on Protein Microarrays 
A signal of intermediate intensity was detected on protein microarrays upon hybridization of r8-
18C5 to MOG. The signal doubled as compared to the signal detected with Fab-8-18C5. 
Surprisingly, the analysis revealed that two other proteins were recognized, producing higher 
signal intensities than MOG. Fab-8-18C5 had bound multiple antigens in the previous microarray 
[102] as well. Possibly, the avidity of the full length antibody may allow complexation of antigens 
recognized with weak affinity that may be missed when Fab-fragments are used. Two proteins, 
FAM20B and CHD2 that were identified by protein microarray hybridization were subjected to 
Western blotting experiments to verify reactivity of r8-18C5. In both cases validation failed. 
Therefore, no linear epitopes are recognized by r8-18C5 on those two proteins although r8-18C5 
does recognize linear MOG epitopes. However, reactivity to a conformational epitope is not 
excluded by this experiment. Whether a conformational epitope is recognized and the molecular 
basis for this remains unclear. A previous study found 8-18C5 to recognize bovine butyrophilin 
[168], indicating the cross-reactive potential of this antibody. The corresponding human 
butyrophilin was present on the microarray, but was not recognized by r8-18C5. It is not clear 
whether this is due to the human sequence or the protein’s conformation on the array. 
This finding highlights that array data represent guidelines that help to confine potential antigens. 
For ultimate proof, candidate antigens must be validated by independent techniques.  
4.3.2 Validation of Antigens recognized by MS-OCB Antibodies  
Protein microarrays were used as an antigen identification tool and provided an overview of 
protein candidate antigens recognized by MS-OCB antibodies. Selected antigens were validated 
in independent experiments.  
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For three OCB-derived antibodies, target antigens were identified and confirmed. rOCB-MS2-s5 
recognized MKNK1, antibodies rOCB-MS1-s8 and rOCB-MS1-s2 bound FAM84A and AKAP17A 
respectively. Three other antibodies did recognize protein antigens on microarrays with low signal 
intensities and therefore were not followed up on (Table 3-2). MS3-s1 did not recognize any of 
the proteins present on the microarray. 
4.3.2.1 rOCB-MS2-s5 recognizes MKNK1  
rOCB-MS2-s5 represents the monoclonally expanded antibody species from CSF of a newly 
diagnosed MS patient. This antibody is particularly interesting because it was present from the 
time of first clinical signs of the disease, it was the only expanded antibody species in the sample 
and the patient had an acute exacerbation at the time of sampling. Therefore, this antibody may 
hold clues for a target structure that plays a role very early in disease development and that may 
relate to disease severity.  
rOCB-MS2-s5 recognized three different members of the MKNK-family on the protein microarray, 
putting a strong focus on this candidate antigen family. mRNA coding for MKNK1 is detectable in 
all human tissues. Primary data on protein expression is only available for MKNK2 and suggests 
ubiquitous expression of the protein and its nuclear localization (Proteinatlas, [143]). Although all 
family members are strictly intracellular, the individual isoforms may differ in their precise 
localization [169]. By phosphorylation of the eukaryotic translation initiation factor 4E (EIF4E), 
MKNK-proteins regulate protein translation [170]. MKNK-proteins are part of ERK- and p38 MAP-
kinase pathways that allow integration of external stimuli and adaption to those in terms of 
proliferation, survival or production of certain factors. Thus, members of the MKNK-family may 
exert a broad influence on cellular systems [169]. Due to their regulatory function in gene 
expression, they have been associated with tumor development [171].  
Reactivity of scFv-MS2-s5 to MKNK1 was initially validated by immunoprecipitation. Dose 
dependent binding of scFv-MS2-s5 to MKNK1 was further confirmed by ELISA. Recognition of 
MKNK1 by scFv-MS2-s5 was conformation dependent, because reactivity was lost upon repeated 
freeze-thaw cycles. 
Subsequent screening of a small cohort of MS and NIND patients did not show increased 
reactivity to MKNK1 by other MS patients. Thus, MKNK1 appears to be a private antigen to 
patient MS2. Testing of the original CSF sample was not possible because the existing sample 
had been used to identify rOCB-MS-s5 and was therefore depleted of IgG-molecules. 
4.3.2.2 rOCB-MS1-s8 recognizes FAM84A  
rOCB-MS1-s8 yielded the highest signal with FAM84A. FAM84A is a 32 kDa protein with only 
limited data available on its function. It is localized beneath the plasma membrane at regions 
where cells do not contact neighboring cells and has been associated with increased 
invasiveness of colon cancer [172]. FAM84A has so far been found to be expressed in a variety 
Discussion 
88 
of tissues, including central nervous system tissues and exhibits enhanced staining in striated 
muscle, respiratory epithelium and the exocrine pancreas (Proteinatlas, [143]). The general 
function of FAM84A in the various tissues remains elusive. 
Immunoprecipitation of FAM84A unambiguously confirmed the specific reactivity of rOCB-MS1-
s8. Like the MKNK-family, this protein is an intracellular protein with a number of cysteine 
residues and therefore sensitive to oxidation. This may explain the gradual loss of reactivity of 
rOCB-MS1-s8 to purified FAM84A over time.  
rOCB-MS1-s8 also recognized FAM84A in mildly fixed antigen-transfected HEK293E-cells. This 
finding further confirms reactivity of rOCB-MS1-s8 to FAM84A. Non-transfected cells that 
endogenously express low levels of FAM84A were not recognized by the antibody. This may be 
due to the low expression rate of this protein that may not suffice to detect immunofluorescence 
staining. This is also in agreement with the fact that previous experiments staining brain tissue 
and 2D Western blots [100, 102] failed to demonstrate a distinct staining pattern.  
FAM84A-reactivity of unfractionated CSF samples from MS patients and serum from 
inflammatory bowel disease (IBD) patients has previously been found in other antigen search 
studies using Protoarrays® [95, 144]. In the MS study, from a total of seven CSF samples, three 
showed clearly increased reactivity and three others showed reactivity around the cut-off value. 
Although the overall FAM84A-reactivity did not reach statistical significance, the data suggest 
enhanced FAM84A-reactivity in a subset of MS patients [95]. Therefore, an ELISA was 
established that allows rapid screening of larger patient cohorts for reactivity against FAM84A. 
Additionally, this assay required a minimal sample volume of 25 µl. This is a major advantage 
when using scarce patient material such as CSF. The use of unfractionated patient materials 
requires a highly specific technique to minimize background reactivity. The FAM84A preparation 
used for these experiments was of sufficient purity, as judged from SDS-PAGE. The specificity 
was further enhanced by coating anti-V5 antibody that specifically retains the recombinant E. coli 
protein and simultaneously prevents aggregation of FAM84A due to interactions with the 
hydrophobic assay plate surface. The findings of the protein microarray and the 
immunoprecipitation of FAM84A were confirmed with FAM84A-ELISA. rOCB-MS1-s8 specifically 
recognized FAM84A.  
To clarify to what extend FAM84A is a target antigen in other MS patients, CSF and serum 
samples from different patient cohorts were tested using FAM84A-ELISA. From the MS-cohort, 
MS1, the patient from whom rOCB-MS1-s8 was isolated, was the only patient showing clearly 
increased CSF-reactivity to FAM84A. The finding suggests that FAM84A is a private antigen to 
this patient and other MS patients in this cohort do not share increased sensitivity to this protein.  
In contrast, NB and OID CSF samples showed high reactivity to FAM84A. This may indicate that 
this protein is a preferred target in excessive humoral immune reactions. Infections initiate 
inflammatory processes that involve the production of antibodies at high titers. The IgG-
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concentration in normal CSF is approximately 42 mg/l [173]. In this experiment, samples of the 
MS-, CNP- and NIND-cohort had normal to slightly increased IgG concentrations, but individual 
samples in NB- and OID-cohorts reached up to 1 300 mg/l. Within each of the groups, the IgG-
concentrations were rather homogeneous.  
After correcting for IgG-concentration, none of the CSF-samples from the NB- and OID-cohorts 
showed increased signal intensity. Similarly, the reactivity of the CSF sample of patient MS1 is 
eliminated by adjustments for IgG-concentration. This may indicate that the detection limit of the 
assay is not sufficient to detect FAM84A reactivity in CSF. Improving the assay sensitivity may 
help to clarify the reactivity of patient samples to FAM84A. Parallel reactivity in CSF and serum 
may be explained by related clones inside the CNS and the periphery that produce antibodies 
[68, 174].  
The results are in accordance with two previous studies that analyzed the reactivity of patient 
material to FAM84A. Previously mentioned work by Querol et al. found a slight increase in CSF-
reactivity to FAM84A in three out of seven MS patients [95]. This study focused on identifying 
antigens that discriminate MS patients from inflammatory and non-inflammatory controls, and 
FAM84A did not qualify. Here, only MS1 showed slightly increased reactivity to this protein. 
Accordingly, FAM84A is a private antigen to patient MS1. 
Experiments by Vermeulen et al. revealed enhanced seroreactivity to FAM84A in IBD patients 
[144]. IBD is an immune-mediated disease that is characterized by chronic inflammation of the 
gastro-intestinal tract [175]. The disease has a higher prevalence in MS patients as in the general 
population [176] and may share etiological characteristics with MS [177]. Approximately 20 % of 
IBD patients had significantly higher seroreactivity to FAM84A than gastrointestinal controls [144]. 
This is in accordance with our findings that acute inflammatory reactions, e. g. viral or bacterial 
infections of the CNS, manifest high reactivity to FAM84A in CSF. FAM84A may be a highly 
immunogenic protein that rapidly elicits humoral responses, once available to the immune 
system. The general reactivity in serum was not increased in the individual cohorts, but in a small 
number of samples from the MS-, NB-, and OID-groups the signal was above the average.  
4.3.2.3 rOCB-MS1-s2 recognizes AKAP17A  
The A-kinase anchoring protein 17A (AKAP17A) was selected for validation because this 
candidate antigen had previously been detected in the Fab-fragment protein microarray and had 
the highest enrichment factor of rOCB-MS1-s2 candidates. AKAP17A is also known as “splicing 
factor 17A”. AKAP17A forms complexes with proteinkinase A targeting it to splicing factor 
compartments in nuclear speckles [178]. Additionally, minor amounts of this protein localize to the 
cytoplasm [179]. AKAP17A also interacts with a number of other factors involved in pre-mRNA 
splicing, controlling splice site selection [179]. AKAP17A is ubiquitously transcribed which is in 
line with its universal function [178]. The protein has an overall positive charge with arginine being 
highly overrepresented. Due to the positive charges, the protein is well suited to interact non-
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specifically with negatively charged molecules such as DNA or phospholipid bilayers. The 
observation that the per se soluble AKAP17A is lost upon high speed centrifugation of crude 
lysate may suggest that the protein associates with lipid-vesicles.  
Immunocytochemistry using rOCB-MS1-s2 on AKAP17A-transfected HEK293E-cells revealed a 
perinuclear staining pattern. In contrast, non-transfected cells that endogenously express low 
levels of AKAP17A did not yield any signal. Thus, AKAP17A was confirmed as target antigen of 
rOCB-MS1-s2 by immunocytochemistry when present at high concentrations. This is in 
agreement with previous attempts to stain brain tissue and 2D-Western blots, that did not identify 
a specific staining pattern or antigen [100, 102]. The low endogenous expression levels of 
AKAP17A seem not to be sufficient for detection with these screening methods. 
Membrane association of AKAP17A and the fact that it is an anchoring protein that binds to many 
other proteins make purification difficult. Different expression and purification strategies were 
found not to be effective. Thus, the method of choice to verify the binding of rOCB-MS1-s2 to this 
candidate antigen was immunoprecipitation from crude HEK-cell lysate in combination with 
Western blot detection. This allows the identification of a target protein in the presence of a 
variety of impurities. Additionally, immunoprecipitation is performed in solution, thus the antigen is 
accessible from all sides.  
4.3.2.4 Cross-reactivity of rOCB-MS1-s8 
AKAP17A was also recognized by rOCB-MS1-s8 in immunoprecipitation experiments. This 
antibody had previously been shown to recognize FAM84A, but had not displayed enhanced 
reactivity to AKAP17A in the protein microarrays. These seemingly contradictory findings may be 
explained by the differential experimental setup. Most probably, the epitope of AKAP17A 
recognized by rOCB-MS1-s8 is either not present on the protein microarray or not accessible to 
the antibody. This may be due to differential posttranslational modifications, (partial) misfolding or 
the protein’s preferential orientation on microarrays.  
To identify the molecular basis of the cross-reactivity, FAM84A-ELISA was applied to alanine-
mutants of FAM84A. ELISA-technique allows handling a large number of parallel experiments, 
thus this method was chosen for the required screening experiments. The fact that AKAP17A 
could not be sufficiently purified precluded the use of an AKAP17A-ELISA, because OCB-derived 
antibodies may recognize co-purified contaminants. Therefore, the existing FAM84A-ELISA was 
employed to test rOCB-MS1-s8 for reactivity with FAM84A-mutants. 
Mutations in the AA258-279 stretch resulted in differential recognition of FAM84A by rOCB-MS1-
s8. This epitope is characterized by a high number of charged residues that locate to the same 
side of an α-helix. It is conceivable that this side of the helix faces the solvent in the natively 
folded protein. Interestingly, the AA exchange at position 267 to alanine did not change the 
binding although this position seems to be located in the center of the epitope. 
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In conclusion, the results revealed the α-helical structure of the AA-region 258-271 of FAM84A as 
epitope targeted by rOCB-MS1-s8. A homologous structure is present in the AA-region 305-323 
of AKAP17A. The results suggest that the reactivity of rOCB-MS1-s8 to both FAM84A and 
AKAP17A may be due to the presence of this homologous sequence stretch that adopts a similar 
α-helical secondary structure. This finding does not exclude that rOCB-MS1-s8 also may bind to 
proteins other than those described here.  
Identification of multiple antigens for a single monoclonal antibody is not surprising. 
Polyspecificity is defined as reactivity to LPS, DNA and insulin and is most pronounced in the 
naïve IgM-antibody repertoire [12]. Such classical polyreactivity was not observed with the OCB-
derived antibodies studied here [102]. However, reactivity to multiple unrelated antigens is also 
found in affinity-matured IgG- and IgA-molecules [180]. Multispecificity of a monoclonal antibody 
may be attributed to distinct physical and chemical interactions that can be mediated by the 
binding pocket (Figure 1-5) [9]. Multispecific antibodies were shown to bind to numerous 
molecules in late apoptotic cells, activate complement and enhance phagocytosis of cell debris by 
macrophages [27].  
Multispecificity of antibodies has been related to autoimmunity. It has been described in systemic 
lupus erythematosus (SLE). In the 1980s, Lafer et al. demonstrated that monoclonal antibodies 
derived from spleen cells of unimmunized MRL/1 mice, an animal model of SLE, reacted to DNA, 
the hallmark of SLE, but also recognized cardiolipin and phospholipids. They attributed this 
finding to the reactivity of such antibodies to the phosphate ester bonds in the different target 
structures [181]. This may, in part, explain the tremendous number of autoantigens described for 
this disease. Defective early maturation checkpoints may play a role [182], but the driving force 
behind the antibody production remains elusive [18].  
4.3.3 Intracellular Proteins are Targets of expanded Antibody Species from MS-CSF 
This study characterized three antigens of individual, unambiguously identified MS-OCB-
antibodies. All are intracellular proteins that are ubiquitously transcribed and expressed in various 
tissues, including the CNS. One of these targets is recognized by a monoclonally expanded 
antibody species present in an early disease stage and may be particularly interesting with regard 
to early events in disease manifestation.  
The array does not cover all human proteins, thus the possibility remains that the rAbs 
additionally recognize other molecules that were not identified in this study. A common pattern in 
their function could not be identified. Ubiquitous, intracellular proteins as targets of OCB-
antibodies will not seem plausible at first, because these molecules reside inside cells, hidden 
from the immune system. Yet, a number of intracellular proteins were previously found to be 
specifically targeted by antibodies from MS samples, these include tubulin [183], transketolase 
[74] and GAPDH [160]. These antigens were identified using unfractionated serum and CSF, thus 
it is not clear whether this reactivity may be attributed to OCB-antibodies.  
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In an approach using antibodies derived from single CNS-resident B-cells from autopsy material, 
Willis et al. found expanded clones that virtually all recognized an intracellular structure, as 
demonstrated by intracellular flow cytometry. The same staining profiles were found with control 
antibodies from tumor tissue and inclusion body myositis [184], arguing against a primary 
pathogenic role of OCBs in MS. Another study based on single cell derived antibodies from MS-
CSF found reactivity to areas of myelin degradation but rarely in healthy CNS-tissue [96]. Thus, 
these OCBs recognized structures, which were only accessible after tissue destruction. Similarly, 
Owens and Bennett et al. found that single cell derived antibodies weakly stained nucleic and 
cytoplasmic granules in brain tissue [97]. These findings, in accordance with the present data, 
support a role for intracellular molecules as target structures of OCB-antibodies.  
In autoimmune-mediated connective tissue diseases like SLE [185] and systemic sclerosis [186], 
intracellular proteins are a major group of target antigens. In this context, different hypotheses 
were proposed to explain the origin of autoreactive antibodies against intracellular proteins. First, 
general dysregulation of the immune system may cause the production of irrelevant Igs, thereby 
creating autoimmunity [187]. The antibodies studied here, however, seem to have undergone 
antigen-driven affinity-maturation, demonstrated by extensive somatic hypermutation. This argues 
against random antibody expression. Second, antibodies raised in a previous immune response 
may be cross-reactive with an intracellular molecule by so called molecular mimicry [88]. 
However, if molecular mimicry induced cross-reactive antibodies, one might expect highly similar 
structures to be targeted. At least the antigens identified here do not share major properties 
except their intracellular localization. Third, apoptotic processes may deliberate intracellular 
molecules that had previously been hidden from the immune system. These newly appearing 
antigens then elicit an immune reaction, including the production of antibodies. This phenomenon 
has been described in apoptotic cells in breast cancer patients [188] and systemic autoimmune 
diseases [189, 190]. This concept also provides a potential functional role of these expanded 
antibody species in CSF of MS patients.  
4.4 Potential Origins and Functions of OCB Antibodies in MS 
The function and role of OCBs in MS etiology and pathogenesis is not understood. Although 
OCBs are thought to contribute to demyelination [191, 192] in a subgroup of patients, proof of a 
pathogenetic role of OCB-antibodies in MS is still lacking. OCB antibodies in MS may not 
recognize a causative agent but byproducts of a primary immune reaction or irrelevant structures 
[193].  
OCB-antibodies carry somatic hypermutations and are of the IgG isotype, thus have obviously 
undergone an antigen-driven maturation process. The mere expansion of antibodies that show 
characteristic signs of antigen-experience points to a targeted humoral immune reaction in the 
CNS. Further, evidence of sustained intrathecal antibody production [68, 92] suggests a role of 
these antibodies in MS. 
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A number of early studies detected antibodies directed at MOG or other myelin antigens in MS 
patients [96, 146, 194]. In accordance with recent literature that suggests only minor reactivity to 
myelin in MS [149, 195] these classical MS antigens were not recognized by the six OCB-derived 
rAbs in this study. In general, a pathogenic role of OCBs, i.e. binding and inducing destruction of 
myelin and perpetuating a harmful immunologic response, does not seem to be the major 
function. OCB patterns remain stable over time [66]. However, affected patients live for years 
experiencing relapses and phases of remission. In contrast, conditions where pathogenic 
autoantibodies are present, mainly monophasic, fulminant disease courses are observed such as 
in paraneoplastic encephalitides [196].  
The presence of affinity-matured and expanded antibody species [68, 69] indicates an underlying 
antigen-driven process and their persistence suggests a recurring stimulus that sustain the 
antibody production. Such a stimulus may be provided by a foreign invader or by a cryptic self-
antigen. The concept of molecular mimicry describes the potential of an immune response initially 
targeted at foreign molecule to simultaneously recognize homologous self-structures [197]. This 
may be one way how pathogens may trigger autoimmunity and a number of autoimmune 
diseases are suspected to be associated with distinct infections [198]. Despite extensive research 
on infectious agents associated to MS pathology, conclusive data is lacking so far [199]. 
However, OCB-derived antibodies studied here did not react with commonly MS-associated viral 
(EBV, measles, rubella, varicella zoster) and bacterial (chlamydia) invaders [100, 101].  
The release or presentation of intracellular components, originating from apoptotic processes, 
could be an alternative mechanism to induce autoreactive antibodies [200]. Antibodies may be 
formed in response to large amounts of cell debris that may occur naturally or due to a primary 
pathogenic condition inside the CNS. In this situation, antibodies may opsonize cellular debris 
including all types of molecules: DNA, lipids and intracellular proteins. This may simplify 
endocytosis by macrophages, help to clear the site of damage, and potentially enhances recovery 
processes. Such a process has been shown for SLE and may play a role in other autoimmune 
diseases [200, 201]. Interestingly, Willis et al. found reactivity to intracellular structures in virtually 
all expanded MS derived B-cell clones, control antibodies derived from tumors, and inclusion 
body myositis [184]. This finding may support the concept of expanded antibody species targeting 
a variety of intracellular molecules possibly in order to enhance clearance of excessive cell debris 
in a variety of conditions. In general, it is well accepted that the specificity of antibodies in MS 
ranges widely, possibly reflecting part of the heterogeneity of the disease [91, 202]. A role in cell 
debris removal may not only have implications on the origin of the expanded antibodies, but may 
also represent a function of OCB-antibodies. In early years of immunological research, the 
potential role of expanded antibodies in cell debris removal was proposed by Grabar. He 
hypothesized that antibodies may not only have a functional role in defense against foreign 
substances, but also may represent a physiological mechanism that allows “cleaning up” of 
cellular debris [203].  
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As discussed earlier, numerous studies have identified a wide variety of MS-antigens [91]. Based 
on three distinct OCB-derived antibodies, the present results support previous studies that failed 
to identify a single molecule that drives pathogenesis and/or disease progression to be targeted 
by OCB-antibodies. The three antigens studied here point to a rather heterogeneous humoral 
response in individual MS patients [91] and may suggest that the expanded antibodies possibly 
do not recognize a causative agent, but rather cryptic self-structures. This mechanism could help 
to efficiently remove cellular debris from the tissue after an initial insult. In the 1980s, 
macrophages present in MS lesions were found to take up cellular debris via an antibody-
mediated endocytic process [191, 204]. This finding was associated with destructive 
demyelination, but may also entail beneficial clearance processes [205]. This is further supported 
by the fact that all rAbs described in this study derive from complement-fixing IgG1-molecules 
[100]. Antibodies of the IgG1-isotype are found in all OCB-positive MS patients and are the 
predominant Ig-subclass in OCBs [206, 207]. Opsonization of cell debris may be an important 
process to ensure rapid clearance of damaged cells to avoid more unspecific immunologic 
activation. This potential function would conform with the unchanged antibody profiles throughout 
the different disease states and has been associated with beneficial effects, like improved 
remyelination of damaged areas [208, 209].  
 
 
4.5 Identification and Validation of a systemic Antigen of rAb-Ip2 
Although identical in regard of biochemical characteristics, the functional role of OCBs may differ. 
Three general modes of action could be differentiated: First, OCBs recognize infectious agents in 
infectious disorders. Thus, OCBs in NB recognize borrelia [153] and thereby help clearing the 
infection. Second, antibodies could help clearing cell debris produced by primary immune 
responses. This potential function of OCBs in MS, as proposed here, was previously shown to 
play a role in SLE [201]. Third, a number diseases is associated with clearly pathogenic 
antibodies such as NMDAR- [36] or AMPAR-encephalitis [105]. These pathogenic antibodies are 
found in serum and CSF and recognize a CNS-specific structure such as neuronal cell surface 
structures and synaptic receptors [196]. The functional difference of MS-OCBs and 
encephalitogenic antibodies is reflected by distinct disease courses. MS is usually characterized 
by a relapsing-remitting disease course [210] whereas encephalitis cases often display an acute, 
monophasic course [196]. 
4.5.1 rAb-Ip2 recognizes the extracellular Domain of the GABAAR α1-subunit 
Unfractionated CSF and serum of patient Ip2 was used to first describe a severe form of 
encephalitis as GABAAR-encephalitis [111]. Reactivity to the GABAAR α1-subunit was confirmed 
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in both serum and CSF of this patient by immunoprecipitation and immunostaining of rat brain 
[111].  
So far, pathology of the GABAAR-encephalitis remains to be elucidated. Here, patient Ip2 was 
studied who had severe encephalitis with seizures and psychic symptoms. Despite intensive 
search, an infectious cause was not identified [111]. A potential mechanism that was previously 
found to be involved in GABABR-encephalitis and similar conditions is an underlying 
paraneoplastic syndrome [211]. For most GABAAR-encephalitis patients, an autoimmune process 
is assumed and patients presenting GABAAR-encephalitis symptoms and a coexisting thymoma 
have been described [121]. The identification of a cross-reactive protein may be supportive of a 
paraneoplastic background in GABAAR-encephalitis. 
Since rAb-Ip2 represents the only expanded antibody species in the sample (E. Beltrán, 
unpublished data), it was hypothesized that it may be involved in GABAAR recognition. This 
hypothesis was confirmed here, as rAb-Ip2 recognized the extracellular domain of the GABAAR 
α1-subunit in an ELISA. Furthermore, application of rAb-Ip2 to hippocampal neuronal cultures 
[111] resulted in a staining pattern highly similar to the pattern observed with the unfractionated 
CSF sample (J. Dalmau, E. Beltrán, personal communication). These findings provide evidence 
for a pathologic role of rAb-Ip2 in patient Ip2.  
Despite the fact that a number of GABA-receptor subunits were present on the Protoarray®, none 
of these were recognized by rAb-Ip2. The reason presumably is misfolding of the protein and 
resulting loss of conformational epitopes. Recombinant production and purification of membrane-
associated proteins is difficult, as the insertion of hydrophobic residues into the membrane is 
crucial for overall folding. In the absence of a lipid-bilayer, the residues forming the 
transmembrane domain of the GABAAR α1-subunit will not be able to fold into their native 
conformation. This will interfere with the overall folding of the protein and thereby impede the 
conformation-sensitive antibody-antigen binding.  
4.5.2 rAb-Ip2 recognizes CSRP2  
To identify potential cross-reactive candidate antigens, rAb-Ip2 reactivity was analyzed on protein 
microarrays. In the protein microarray, rAb-Ip2 recognized a total of six different zinc-binding 
proteins (Table 3-3) and the majority the zinc-binding candidate antigens mediated this interaction 
via LIM-domains. rAb-Ip2 recognized three different LIM-domain proteins. The strongest overall 
signal was detected with CSRP2. The related proteins CSRP1 and CRIP2 showed lesser 
reactivity. The LIM-domain characterizes a distinct zinc-binding motif that makes up a large part 
of these LIM-domain proteins. LIM-domains serve as platform for protein-protein-interactions 
[212]. LIM-proteins are thought to mediate the organization of transcriptional protein-complexes 
[213] and thereby regulate gene expression [214]. In accordance with this, LIM-only proteins, 
which are closely related to CSRP2, have been associated with a variety of malignancies [215]. 
The highest enrichment factor was found with MAPK7, but immunoprecipitation of HEK-derived 
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MAPK7 did not confirm the protein microarray results. These findings may suggest the 
involvement of a paraneoplastic background of the encephalitis in patient Ip2.  
Interestingly, GABAAR function is regulated by a zinc-binding site, which is located to an N-
terminal cysteine-loop of the α-subunit [120]. Common zinc-coordinating residues Cys, His, Glu 
and Asp [216] are thought to form the binding site [120]. In contrast, in all LIM-domain proteins, 
zinc-ions are bound by the consensus LIM-motif [217]. The two distinct zinc-binding motifs are 
illustrated in Figure 4-1. 
 
 
 
Figure 4-1: Comparison of Zn2+-binding Motifs in CSRP2 and the GABAAR α-subunit.  
The upper row depicts the LIM-domain consensus sequence found in CSRP2. CSRP2 carries an N-terminal 
(AA10-61) and a C-terminal (AA119-170) LIM-domain. Regulatory zinc-binding in the GABAAR α-subunit may be 
mediated by negatively charged AA in a cysteine-loop (lower row). Binding of zinc ions may also involve residues 
of neighboring subunits. Residues are color-coded: cysteine: orange, boxed, histdine: blue, negatively charged 
AA: red, black: any other AA.  
The LIM-domain coordinates zinc mainly with cysteine-residues, whereas negatively charged 
residues play a crucial role in zinc binding by GABAAR. As the primary sequence of the motifs is 
quite distinct, structural analysis is needed to clarify whether the cross-reactivity of rAb-Ip2 to 
GABAAR and CSRP2 relates to the zinc-binding site.  
Figure 4-2 highlights the localization of (potential) zinc-binding residues in a GABAA-receptor 
subunit and in CSRP2. The zinc binding site of the GABAAR appears to be located in the 
extracellular domain facing the extracellular space. This location may be accessible to antibodies 
in tissue. Thus, the zinc-binding sites in CSRP2 and GABAAR may present a potential common 
structural feature that could form the basis for cross-reactivity of rAb-Ip2 and a potential 
paraneoplastic background. Co-crystallization of rAb-Ip2 with GABAAR and CSRP2 may elucidate 
the target epitope. 
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Figure 4-2: Ribbon-diagram of a GABAAR-pentamer, single Subunit, and CSRP2 C-terminus.  
Comparison of putative zinc-binding sites in a GABAAR β3-pentamere (A), a single subunit (B, both 4COF) and 
the C-terminal part of CSRP2 (C, 1QLI) are depicted. Putative zinc-binding residues are highlighted in green. 
CSRP2 is depicted with zinc ions (grey spheres). In both proteins, zinc-binding residues are located to beta-sheet 
secondary structures and in flexible loops. From this model, both putative zinc-binding sites appear to be localized 
on the protein’s surface and may be accessible for antibodies. Note that the structural information depicted here is 
deduced from GABAAR β3-subunit and corresponding residues of the α1-subunit are highlighted as zinc-binding. 
The illustrations of 4COF and 1QLI are modified from [114] and [218] respectively. 
 
Immunofluorescence staining of non-transfected HEK293E-cells, which endogenously express 
high levels of CSRP2, medium levels of CSRP1 and CRIP2, but not GABAAR, yielded signals in 
perinuclear regions (Figure 3-29). This is in accordance with the expected intracellular localization 
of the LIM-domain proteins [219, 220]. These results further substantiate the reactivity of rAb-Ip2 
with CSRP2. Whether rAb-Ip2 recognizes CSRP2 in vivo remains to be formally demonstrated.  
In patient Ip2 no tumor could be detected [111]. As neurologic symptoms regularly occur prior to 
cancer diagnosis [108] and underlying malignancies may be small [34], a paraneoplastic etiology 
is conceivable. In such a scenario, rAb-Ip2 would have been raised in a primary immune 
response against CSRP2 (peripheral tumor antigen), which may be exposed due to effective 
tumor destruction, and was cross-reactive to GABAAR (CNS-specific antigen). The cross-
reactivity may be mediated by the structurally similar zinc-binding sites of the two antigens. This 
finding may suggest the presence of a malignancy that initiated the production of rAb-Ip2.  
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4.6 Future Prospects 
a) MS-OCBs 
In this study, three ubiquitous intracellular proteins were identified as targets of OCB antibodies 
from MS patients. The target antigens presented here suggest that MS-OCBs represent a highly 
variable and seemingly patient-specific population of expanded antibodies. To confirm that a 
majority of OCBs recognizes ubiquitous, intracellular proteins, a larger number of distinct OCB-
derived antibodies should be analyzed. Recognition of ubiquitous intracellular proteins by OCB-
antibodies points to a rather non-pathogenic role of OCBs. In MS, most patients present with a 
relapsing-remitting disease course. However, in case of an expanded antibody targeting a CNS-
specific, accessible antigen, the disease course is probably expected to be monophasic and 
fulminant as has been observed with paraneoplastic encephalitides for example. One potential 
functional role of OCB-antibodies, in agreement with the present data, may be opsonization of 
cellular debris to facilitate phagocytic clearance processes. To strengthen this hypothesis, it is 
important to clarify whether the antigens described here are also targeted in vivo and to 
characterize more OCB-antibodies.  
Importantly, the antigens presented here are clearly not exclusive and each of the antibodies 
holds the potential to recognize multiple other related or un-related structures. Therefore, 
infectious agents may be reconsidered. Suspected causative pathogens may play a role as a 
trigger of disease [221] possibly through induction of autoreactivity. Full length OCB-derived 
antibodies were not yet analyzed with regard to infectious agents and potential cross-reactivity 
cannot be excluded.  
Analyzing potential changes of OCB reactivity during the disease course could elucidate whether 
the reactivity spectrum is as stable as OCB-patterns are. To this end, OCB-antibody specificities 
from patients in distinct disease states, i.e. relapses vs. remission could be compared. Similarly, 
profiling the antigen-specificity in longitudinal follow-up CSF-samples of a patient could hold 
information. However, these samples are sparse because lumbar punctures are generally only 
done at the time of diagnosis.  
Genetic factors play a role in MS etiology [222], thus the risk to develop the disease is increased 
if family members are affected. Monitoring of relatives of MS patients offers the opportunity to 
diagnose the disease in very early stages, even before clinical signs are detectable. Studies of 
MS-discordant monozygotic twins showed that non-MS diagnosed twins occasionally present 
signs of MS, such as clinically-silent lesions in MRI-scans or OCBs (E. Beltran, K. Held, 
unpublished data). Identifying the specificity of OCB-antibodies from such incipient MS patients 
may promote the understanding of early pathogenetic processes in the disease. 
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b) GABAAR-encephalitis 
rAb-Ip2 was found to recognize the GABAAR α1-subunit and to cross-react with a ubiquitously 
expressed antigen, CSRP2 and related LIM-domain proteins. The number of GABAAR-
encephalitis cases, which may be caused by a paraneoplastic syndrome is extremely small [111, 
223]. Identification of the cross-reactive CSRP2 protein provides a hint for a systemic antigen to 
play a role, but direct evidence of a malignancy in patient Ip2 is not available. To this end, studies 
on CSF and serum samples of other patients are necessary. So far, few patients with GABAAR-
encephalitis and co-existing thymoma are described [121]. CSRP2-reactivity in CSF and/or serum 
of these patients could be assessed to test whether this cross-reactivity is specific for patient Ip2 
or a common feature in GABAAR-encephalitis. Implementation of an ELISA to screen patient 
samples would allow rapid identification of CSRP2-reactivity in other GABAAR-encephalitis 
patients using minimal amounts of CSF. Identification of a malignancy that may cause a 
neurologic syndrome could help to improve diagnosis and treatment of the disorder. Removal of 
malignant tissue has proven effective in other paraneoplastic syndromes [211] and in most cases 
tumors are only diagnosed after the onset of neurologic symptoms [34]. Knowledge on associated 
tumors could help diagnosing patients early.  
Functionally, Petit-Pedrol et al. showed that CSF from patient Ip2 downregulates synaptical 
GABAAR, thereby impeding inhibitory signals [111]. This finding could account for seizures and 
psychic symptoms that may be caused by disturbed synaptic activity. Thus, electrophysiological 
experiments using rAb-Ip2 could clarify whether this antibody causes changes in synaptical 
expression of GABAAR and thereby may induce pathologic symptoms. 
The occurrence of paraneoplastic syndromes had been ascribed to ectopic expression of 
neuronal antigens in tumor-tissue that are targeted by the immune response [108]. However, 
pathogenic antibodies may also derive from anti-tumor responses to non-CNS-antigens that are 
cross-reactive with CNS-tissue. In this case, the antibody’s cross-reactivity may be based on the 
recognition of either structurally similar or distinct epitopes on different proteins. rAb-Ip2 
recognized multiple proteins containing LIM-domains and other zinc-binding proteins on the 
protein microarray, suggesting that zinc-binding motifs may play a role for cross-reactivity. 
Understanding the molecular basis for the cross-reactivity of CSRP2 and the GABAAR 1-subunit 
would offer mechanistic insights and allow predictions on other proteins that potentially cross-
react. As discussed earlier, crystallization experiments could elucidate whether the zinc-binding 
sites of GABAAR and CSRP2 are epitopes of rAb-Ip2. Crystals of antibody-antigen-complexes will 
be analyzed by x-ray diffraction and allow for identification of molecular structures involved in 
recognition by rAb-Ip2.  
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Appendix 
Vector Maps 
 
 
Vector map of pCR2.1-TOPO. 
This vector was used intermediate steps during 
molecular cloning. Abbreviations: Plac: promoter 
of the lacZ-gene, lacZα: α-galactosidase (α-
fragment)-gene,  f1 ori: f1 phage origin of 
replication, pUC ori: origin of replication for 
bacterial plasmid propagation. The illustration is 
taken from the “TOPO®TA Cloning” handbook 
(Invitrogen). 
 
 
 
Vector map of pET-19b.  
This vector was used for recombinant expression 
of the scFv-MS2-s5 in E. coli. Abbreviations: lacI: 
lac inhibitor, ori: origin of replication, Ap: ampicillin 
resistance gene, rbs: ribosomal binding site. The 
illustration is taken from the Novagen datasheet. 
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Vector map of pET-33b(+).  
This vector was used for recombinant expression 
of FAM84A, FAM84A-mutants, and GABAARα1ex 
in E. coli. Abbreviations: lacI: lac inhibitor, ori: 
origin of replication, Kan: kanamycin resistance 
gene, f1 ori: f1 phage origin of replication, rbs: 
ribosomal binding site. The illustration is taken 
from the Novagen datasheet. 
 
 
Vector map of pTT5.  
This vector was used to recombinantly express 
full length antibodies and the AKAP17A-protein in 
HEK293E-cells. Abbreviations: hCMV: Promotor 
of the human Cytomegalovirus, TPL: Tripartite 
leader sequence of the Adenovirus, SD: Splice 
donor, SA: splice acceptor, MCS: multiple cloning 
site, pA: polyadenylation site, EBV oriP: origin of 
replication from the Epstein-Barr-Virus, pMB1 ori: 
origin of replication for bacterial propagation, bla: 
β-lactamase gene conferes ampicillin resistence. 
The illustration is taken from [224]. 
 
 
Amino Acid Sequences 
Full length Antibodies 
Each antibody heavy chain was cloned with and without V5-tag, it is therefore depicted as grey 
letters. 
rAb- Sequence 
MS3-
s1 
H-chain 
QVQLQESGPRLVKPSEALSLTCIVSGGSINSNTYYWDWLRQPPGKGLEWIGSISYSGGTYYNPSLKNRVTMSVDTSNNQFSLK
LSSVTAADTAVYYCARHTPRQAYYNILTSSQDYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP
ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
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L-chain 
DIVMTQSPLSLPVTPGEAASISCRSSQSLLHSSGNNYLDWYLQKPGQPPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRV
EAEDVGVYYCMQALETPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
MS1-
s8 
H-chain 
QVQLVQSGGGLVQPGESVRLSCAVSGFSSTTYWMSWVRQAPGKGLEWVANINQDGRQEYYVDSVKGRFTISRDNAENSLYLQM
NSLRAEDTAVYYCARRTYDFWSGSSLAFDVWGQGTMVIVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
DIQMTQSPVTLSASVGDRVTITCRASQSVSSYLNWYQQKPGEAPKLLIYAASRLHSGVPSRFSGSGSGTHFTLTVTSLLPEDF
ATYYCQQSYSNPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
MS1-
s9 
H-chain 
QVQLVQSGGGLVQPGGPLRLSCAASGFTFTNYEMNWVRQAPGKGLEWVSYISISGRTIYYADSVKGRFTISRDNARNSLYLQM
NSLRAEDTAVYYCARELSHWDGMIVVDSDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
EIVMTQSPATLSVSPGERATLSCRASQNVSSNLAWYQQKPGQVPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDF
AVYYCQQYNDWPRTFGRGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
MS4 
H-chain 
QVQLQESGPGLVKPSQTLSLTCTVSGGSITSGSYYWSWVRQSAGKGLEWIGRISATGSTNYNPSLWSRVTISVDTSKNQFSLK
LTSVTAADTAVYYCARHSSYSDSSYLPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
DIQMTQSPVTLSASVGDRVSITCRASQGISNYLAWYQQKPGKVPKLLIYAASTLKSGVPSRFSGSGSGTDFTLTITSLQPEDV
ATYYCQKYYSTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
MS1-
s2 
H-chain 
QVQLVQSGGGLVHPGGSLRLSCATSGFTFNSYNMNWVRQAPGKGLEWLAYINSDSSTTYYADSVKGRFTISRDDARRSLDLQM
NSLRAEDTAVYYCARLSGYDWYSDESVLYHDYWGQGTLVTVSSTSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
SYELTQPPSVSVSPGQTARITCSGDGLPKKYAYWYQQKSGQAPVLVIYQNTARPSGIPERFSGSTSGNTAALIISGTQAVDEA
DYYCQAWDGSTVVFGRGTKLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
r8-
18C5 
H-chain 
QVQLQQSGAELMKPGASVEISCKATGYTFSSFWIEWVKQRPGHGLEWIGEILPGRGRTNYNEKFKGKATFTAETSSNTAYMQL
SSLTSEDSAVYYCATGNTMVNMPYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
DIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFTGSGSGTDFTLTISS
VQAEDLAVYYCQNDHSYPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
MS2-
s5 
H-chain 
QVQLVQSGGGVVQPGRSLRLSCEGAGFTFSSYVVHWVRQTPDKGLEWVALISYDGNNRDYADAVKGRFIISRDNSKNTVYLEM
HSLRSEDTSIYYCARGLSWVDLLYTVDWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS
NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
DIQMTQSPSSLSASVGDRVTIPCRASQDISNYLNWYQQKPGKAPKLLIYDTSNLETGVPSRFTGSGSGTEFTLTISSLQPEDI
AIYYCQQYDSLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
Ip2 
H-chain 
EVQLVESGGGLVKPGGSLRLSCAASGFTSSFYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQM
SSLRADDTAVYYCARVGIMEWSDPRFVDEKYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
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PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS
FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGKPIPNPLLGLDSTHHHHHH 
L-chain 
EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFILTISRLEPED
FAVYYCQQYGSSLYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
 
Single chain variable Fragment of rOCB-MS2-s5 
Ab- Sequence 
scFv-
MS2-
s5 
MGQLVQSGGGVVQPGRSLRLSCEGAGFTFSSYVVHWVRQTPDKGLEWVALISYDGNNRDYADAVKGRFIISRDNSKNTV
YLEMHSLRSEDTAIYYCARGLSWVDLLYTVDWFDPWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDR
VTIPCRASQDISNYLNWYQQKPGKAPKLLIYDTSNLETGVPSRFTGSGSGTEFTLTISSLQPEDIAIYYCQQYDSLPLT
FGGGTKVEIKGKPIPNPLLGLDSTHHHHHH 
 
Candidate Antigens 
Antibody Sequence 
MKNK1 
MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGEGAYAKVQGAVSLQNGKEYAVKII
EKQAGHSRSRVFREVETLYQCQGNKNILELIEFFEDDTRFYLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDF
LHTKDKVSLCHLGWSAMAPSGLTAAPTSLGSSDPPTSASQVAGTTGIAHRDLKPENILCESPEKVSPVKICDFDLGSGMK
LNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCDLWSLGVVLYIMLSGYPPFVGHCGADCGWDRGEVCRVC
QNKLFESIQEGKYEFPDKDWAHISSEAKDLISKLLVRDAKQRLSAAQVLQHPWVQGQAPEKGLPTPQVLQRNSSTMDLTL
FAAEAIALNRQLSQHEENELAEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRGEDRSPPTALTRTRPLEQKLISEED
LAANDILDYKDDDDKV 
FAM84A
wt 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQLV
LNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQGE
IRQDSLYEAGAANVGRVVNSWYRYRPLVAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQPPQ
QQYYLKVHLGENKVHTARFHSLEDLIREKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
AKAP17
A 
NSTMKHLWFFLLLVAAPRWVLSMAAATIVHDTSEAVELCPAYGLYLKPITKMTISVALPQLKQPGKSISNWEVMERLKGM
VQNHQFSTLRISKSTMDFIRFEGEVENKSLVKSFLACLDGKTIKLSGFSDILKVRAAEFKIDFPTRHDWDSFFRDAKDMN
ETLPGERPDTIHLEGLPCKWFALKESGSEKPSEDVLVKVFEKFGEIRNVDIPMLDSYREEMTGRNFHTFSFGGHLNFEAY
VQYREYMGFIQAMSALRGMKLMYKGEDGKAVACNIKVSFDSTKHLSDASIKKRQLERQKLQELEQQREEQKRREKEAEER
QRAEERKQKELEELERERKREEKLRKREQKQRDRELRRNQKKLEKLQAEEQKQLQEKIKLEERKLLLAQRNLQSIRLIAE
LLSRAKVPGGSLCSRQPRPGCPQCPPLKCGRRHGAVSPPAAAVATKPALMPRMTAPSREGVALVCRSRGKPIPNPLLGLD
STHHHHHH 
FAM20B 
YPYDVPDYANLDTSAANREDQRAFHRMMTGLRVELAPKLDHTLQSPWEIAAQWVVPREVYPEETPELGAVMHAMATKKII
KADVGYKGTQLKALLILEGGQKVVFKPKRYSRDHVVEGEPYAGYDRHNAEVAAFHLDRILGFHRAPLVVGRFVNLRTEIK
PVATEQLLSTFLTVGNNTCFYGKCYYCRETEPACADGDIMEGSVTLWLPDVWPLQKHRHPWGRTYREGKLARWEYDESYC
DAVKKTSPYDSGPRLLDIIDTAVFDYLIGNADRHHYESFQDDEGASMLILLDNAKSFGNPSLDERSILAPLYQCCIIRVS
TWNRLNYLKNGVLKSALKSAMAHDPISPVLSDPHLDAVDQRLLSVLATVKQCTDQFGMDTVLVEDRMPLSHL 
CHD2 
MMRNKDKSQEEDSSLHSNASSHSASEEASGSDSGSQSESEQGSDPGSGHGSESNSSSESSESQSESESESAGSKSQPVLP
EAKEKPASKKERIADVKKMWEEYPDVYGVRRSNRSRQEPSRFNIKEEASSGSESGSPKRRGQRQLKKQEKWKQEPSEDEQ
EQGTSAESEPEQKKVKARRPVPRRTVPKPRVKKQPKTQRGKRKKQDSSDEDDDDDEAPKRQTRRRAAKNVSYKEDDDFET
DSDDLIEMTGEGVDEQQDNSETIEKVLDSRLGKKGATGASTTVYAIEANGDPSGDFDTEKDEGEIQYLIKWKGWSYIHST
WESEESLQQQKVKGLKKLENFKKKEDEIKQWLGKVSPEDVEYFNCQQELASELNKQYQIVERVIAVKTSKSTLGQTDFPA
HSRKPAPSNEPEYLCKWMGLPYSECSWEDEALIGKKFQNCIDSFHSRNNSKTIPTRECKALKQRPRFVALKKQPAYLGGE
NLELRDYQLEGLNWLAHSWCK 
MAPK7 
MAEPLKEEDGEDGSAEPPGPVKAEPAHTAASVAAKNLALLKARSFDVTFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQ
VAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVR
YFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYT
QAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQA
LSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGIRQQIR
FQPSLQPVASEPGCPDVEMPSPWAPSGDCAMESPPPAPPPCPGPAPDTIDLTLQPPPPVSEPAPPKKDGAISDNTKAALK
AALLKSLRSRLRDGPSAPLEAPEPRKPVTAQERQREREEKRRRRQERAKEREKRRQERERKERGAGASGGPSTDPLAGLV
LSDNDRSLLERWTRMARPAAPALTSVPAPAPAPTPTPTPVQPTSPPPGPVAQPTGPQPQSAGSTSGPVPQPACPPPGPAP
HPTGPPGPIPVPAPPQIATSTSLLAAQSLVPPPGLPGSSTPGVLPYFPPGLPPPDAGGAPQSSMSESPDVNLVTQQLSKS
QVEDPLPPVFSGTPKGSGAGYGVGFDLEEFLNQSFDMGVADGPQDGQADSASLSASLLADWLEGHGMNPADIESLQREIQ
MDSPMLLADLPDLQDPTRTRPLEQKLISEEDLAANDILDYKDDDDKV 
CRIP2 
MASKCPKCDKTVYFAEKVSSLGKDWHKFCLKCERCSKTLTPGGHAEHDGKPFCHKPCYATLFGPKGVNIGGAGSYIYEKP
LAEGPQVTGPIEVPAARAEERKASGPPKGPSRASSVTTFTGEPNTCPRCSKKVYFAEKVTSLGKDWHRPCLRCERCGKTL
TPGGHAEHDGQPYCHKPCYGILFGPKGVNTGAVGSYIYDRDPEGKVQPTRTRPLEQKLISEEDLAANDILDYKDDDDKV 
CSRP2 
MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSTTVAIHDEEIYCKSCYGKKYGPKGYGYGQGAGTL
NMDRGERLGIKPESVQPHRPTTNPNTSKFAQKYGGAEKCSRCGDSVYAAEKIIGAGKPWHKNCFRCAKCGKSLESTTLTE
KEGEIYCKGCYAKNFGPKGFGYGQGAGALVHAQTRTRPLEQKLISEEDLAANDILDYKDDDDKV 
GABAAR
α1ex 
MGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPGLGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFK
GPMTVLRLNNLMASKIRTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHACPLKFG
SYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVMTTHFHLKRKIGGSGGGKPIPNPLLG
LDSTHHHHHH 
hMOG 
METDTLLLWVLLLWVPGSTGDAAGGSGQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNG
KDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPGSGMGMGMGM
MGLNDIFEAQKIEWHESGGSGHHHHHHS 
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FAM84A-Mutants 
Mutant Sequence 
188VA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLAAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEDLIREKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
190EA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAALVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEDLIREKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
191LA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAEAVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEDLIREKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
263EA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLADLIREKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
264DA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEALIREKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
267RA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEDLIAEKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
268EA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEDLIRAKRRIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
271RA 
MGNQLDRITHLNYSELPTGDPSGIEKDELRVGVAYFFSDDEEDLDERGQPDKFGVKAPPGCTPCPESPSRHHHHLLHQL
VLNETQFSAFRGQECIFSKVSGGPQGADLSVYAVTALPALCEPGDLLELLWLQHAPEPPAPAPHWAVYVGGGQIIHLHQ
GEIRQDSLYEAGAANVGRVVNSWYRYRPLVAELVVQNACGHLGLKSEEICWTNSESFAAWCRFGKREFKAGGEVPAGTQ
PPQQQYYLKVHLGENKVHTARFHSLEDLIREKRAIDASGRLRVLQELADLVDDKEGKPIPNPLLGLDSQHHHHHH 
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List of Abbreviations 
A alanine 
AA amino acid 
ADCC antibody-dependent cell-
mediated cytotoxicity 
ADH5 alcohol dehydrogenase 5, chi 
polypeptide  
AID activation-induced cytidine 
deaminase 
AKAP17A A-kinase anchoring protein 
17A 
AMPAR α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid 
receptor  
APC antigen-presenting cell 
AU arbitrary unit 
BCR B-cell receptor 
BS3 bis(sulfosuccinimidyl)suberate 
BSA bovine serum albumine 
CASPR2 contactin-associated protein-
like 2 
CD circular dichroism 
cDNA complementary 
desoxyribonucleic acid 
CDR complementary-determining 
region 
CHD2 Chromodomain helicase DNA 
binding protein 2 
CHO chinese hamster ovary 
CNP cranial nerve palsies 
CNS central nervous system 
CRIP2 cystein-rich protein 2 
CSF cerebrospinal fluid 
CSRP2 Cystein and serine rich 
protein 2 
C-terminal carboxy-terminal 
CV coulmn volume 
CYB5R3 Cytochrome b5 reductase 3 
D aspartic acid 
Da Dalton 
DNA desoxyribonucleic acid 
dNTP desoxynucleosid triphosphate 
DTT dithiothreitol 
E glutamic acid 
E. coli Escherichia coli 
EAE experimental autoimmune 
encephalitis 
ECL enhanced 
chemiluminescence 
 
ELISA enzyme-linked 
immunosorbent assay 
 
 
Fab antigen-binding fragment 
FAM20B Family with sequence 
similarity 20 B 
FAM84A Family with sequence 
similarity 84 A 
for forward 
g gravitational force 
GABAAR γ-aminobutyric acid-A 
receptor  
 
GABAARα1 
ex 
extracellular domain of γ-
aminobutyric acid-A receptor 
α1-subunit 
GABABR γ-aminobutyric acid-B 
receptor  
GAPDH glyceraldehyd-3-phosphate 
dehydrogenase 
GC germinal centre 
h hours 
H-chain heavy chain 
HEK human embryonic kidney cell 
HIV human immunodeficiency 
virus 
HRP horseradish peroxidase 
IB inclusion body 
IBD inflammatory bowel disease 
IEF isoelectric focusing 
Ig immunoglobulin 
IgA immunoglobulin subclass A, 
D, G ,E, M 
IMAC immobilized metal affinity 
chromatography 
IPTG isopropyl-thio-β-galactoside  
L leucine 
LB Luria-Broth 
L-chain light-chain 
LGI1 leucine-rich glioma 
inactivated protein 1 
LPS lipopolysccharide 
M molar 
MAG myelin-associated 
glycoprotein 
MALDI matrix-assisted 
laser/desorption/ionization  
MAPK7 mitogen-activated protein 
kinase 7 
MBP myelin basic protein 
MKNK1 MAP-kinase interacting 
kinase 1 
ml milliliter 
MOG myelin oligodendrocyte 
glycoprotein 
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mRNA messenger ribonucleic acid 
MRZ measles-varizella-zoster 
MS multiple sclerosis 
MW molecular weight 
NB neuroborreliosis 
NIND non-inflammatory neurologic 
disorder 
NMDAR N-methyl-D-aspartate 
receptor 
NMO neorumyelitis optica 
N-terminal amino-terminal 
OCB oligoclonal band 
OD optical density 
OID  other inflammatory disorder 
p probability 
PBMC peripheral blood mononuclear 
cell 
PBS phosphate-buffered saline 
PBS-T phosphate-buffered saline 
with tween 
PCR polymerase chain reaction 
PEI polyethylen imine 
PLP proteolipid protein 
PMSF phenylmethanesulfonyl 
fluoride  
PMT photomultiplier-tube 
PTM posttranslational modification 
PVDF polyvinylidene fluoride  
R arginine 
rAb recombinant antibody 
rev reverse 
RT room temperature 
scFv 
single chain variable 
Fragment 
SD standard deviation 
SDS sodium dodecyl sulfate 
SDS-
PAGE 
sodium dodecyl sulfate 
polyacrylamid gel 
electrophoresis 
SLE 
systemic lupus 
erythematosus  
STUB1 
STIP homology and U-box 
containing protein 1 
Taq thermus aquaticus 
TBE tris-boric acid-EDTA buffer 
TMB 3,3′,5,5′-Tetramethylbenzidin  
TOF time-of-flight 
Tris 
tris(hydroxymethyl)-
aminomethan 
UV ultraviolet light 
V valine 
V(D)J 
variable (diversity) junctional 
gene segments 
v/v volume per volume 
w/v weight per volume 
WB Western blot 
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